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1.1.1 Pregnancy complications with fetal growth restriction 
Definition and types of fetal growth restriction 
The fetal growth restriction diseases are divided into two large groups, one termed 
“intra-uterine growth restriction (IUGR)” and the other “small for gestational age 
(SGA)” 1. IUGR is defined as a condition in which the fetus does not reach its 
genetically given growth potential, resulting in low birth weight. The newborns are 
below the 10th percentile in weight for their estimated gestational age 2-5. This is true 
also for the other group of newly born babies with birth weights below the 10th 
percentile referred to as SGA. The majority of SGA neonates by genetic constitution 
grow in utero in accordance with their percentiles 2,3,5,6. The gestational age of IUGR 
and SGA pregnancies has been found to range from 24 – 36 and 37 – 41 weeks 
respectively 7, whiles normal pregnancies on average last 39 – 41 weeks 8. 
Depending upon the gestational age (after application of a cut-off of 32 weeks) when 
growth restriction is diagnosed, IUGR can be classified as early onset or late onset 9. 
Early onset IUGR occurs before 32 weeks gestation representing about 20 - 30 % of 
all IUGR cases. It is distinguished by severe systemic cardiovascular adaption in 
utero due to chronic hypoxia resulting from significant disruption to placental 
perfusion 10,11. Fetuses from early onset are prone to be born preterm, hence have a 
higher risk of morbidity or mortality 12. Late onset IUGR occurs more frequent (about 
80 % of IUGR occurrences) and starts after 32 weeks gestation. This late onset 
IUGR is usually associated with a milder placental insufficiency and a lower degree of 
hemodynamic fetal variation. Fetuses within this category are at a greater risk of 
rapid deterioration, leading to intrauterine fetal death although the dysfunction of the 
placenta is not considered severe 10,13.  
 
Epidemiology, Prevalence, and Sequelae of IUGR 
Low birth weight is defined as newborns with birth weight of less than 2500 g 
irrespective of the gestational age 14. This measure includes infants affected by SGA 
and IUGR. Low birth weight rate affects approximately 16% of all neonates in 
developing countries, which is about six times higher than in developed countries 15. 
IUGR complicates about 5 - 10 % of all pregnancies 16,17. It is estimated that IUGR 
affects about 3 - 8 % and 24 % of all neonates in developed 18 and developing 15 
countries respectively. However, incidence of IUGR in neonates is about 3 - 7 % of 
the total population 19. 
IUGR is a major cause of perinatal morbidity and mortality 2,20,21, such as birth 
asphyxia, meconium aspiration, neonatal hypoglycemia, hypothermia and intrauterine 
fetal death 20,22,23. Besides its contribution to perinatal morbidity and mortality, several 
epidemiologic studies have shown that IUGR contributes to neurodevelopmental 
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delay or functioning 24-26 and also increases the infant’s risk of cardiovascular and 
metabolic diseases 27-33 later in adulthood.  
 
Etiology, Pathogenicity, and Symptoms of IUGR 
Pregnant women who abuse drugs, drink alcohol, smoke, or have heart disease, high 
blood pressure, sickle cell anemia, kidney disease, infections, etc., are most probable 
to have their fetuses affected by IUGR. However, combination of other factors also 
contribute to IUGR. Hence, the causes of IUGR can be categorized into maternal, 
fetal or placental 2,5,34-36. The maternal causes result from pregnancy-associated 
hypertensive disease 37,38, autoimmune diseases 2,39,40, substance abuse 38,41-44 and 
teratogen exposure 45-48. Fetal causes result from multiple gestations 49, infections 
50,51 and genetic and structural disorders 52,53. Placental dysfunction accounts for the 
majority of IUGR cases 21,54-57.  
The pathogenesis of IUGR unfortunately has not been clearly defined but it is 
believed that the primary pathophysiological mechanisms underlying the maternal, 
fetal or placental conditions 2,5,34-36, although different, play decisive roles usually 
ending in an eventual prevalent result: suboptimal uterine-placental perfusion and 
restricted fetal nutrition leading to development of IUGR 2,21,58. 
The key symptom of IUGR is a small for gestational age fetus which is initially 
identified by measuring the fundal height after 20 weeks during antenatal care. 
Normal pregnancies grow at 1 cm / week hence, any fundal height that is 3 cm or 
more behind weeks of pregnancy suggests IUGR. Further clinical assessments such 
as ultrasound investigations are required to confirm the diagnosis 59,60. It is imperative 
in most countries, that pregnant women attend hospitals / clinics regularly because 
during antenatal care, close surveillance can best identify pregnancy-related 
complications. Identification of pregnant women who are at risk and referring them to 
specialists early will reduce perinatal morbidity and mortality 61,62. 
 
Clinical diagnostic methods for IUGR detection 
Currently, ultrasound biometry is the “gold standard” for assessing fetal growth 
restriction. Biparietal diameter, head circumference, abdominal circumference and 
femur length are the four biometric measurements most commonly used. The 
percentiles established for each of these parameters are then combined to generate 
an estimated fetal weight 2,6,63,64. When the estimated fetal weight is below the 10th 
percentile for gestational age, additional ultrasonographic examinations such as 
amniotic fluid index (oligohydramnios) 2,65-67 and Doppler velocimetry (measurement 
of absent or reversed end-diastolic flow in the umbilical artery) 2,68,69 are used to 
monitor fetuses during antenatal in the second or third trimester. The absent or 
reversed end-diastolic flow in the umbilical artery has been associated with an 
increased risk of IUGR and perinatal mortality 70,71. Though antenatal monitoring with 
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the umbilical artery Doppler velocimetry has led to about 30 % reduction of perinatal 
mortality in high-risk pregnancies 72, up to about 80 % of IUGR fetuses remained 
undetected until delivery 23.  
Another difficulty is that, SGA fetuses (constitutionally small) may not be distinct 
during antenatal Doppler velocimetry examinations resulting in a diagnostic challenge 
of differentiating SGA pregnancies from IUGR pregnancies by clinical means 2,73. 
Clinical screening of risk assessments during antenatal using the ultrasound biometry 
approach is known to have low sensitivity 35 and is unable to predict the pathological 
conditions of pregnancy before their clinical manifestation 74. 
 
Blood-based diagnostic tests for assaying pregnancy complications and 
neonatal diseases 
Biomarkers which are biomolecules found in serum, plasma or tissues and serve as 
measurable indicators of specific physiological conditions to determine the presence 
or absence of a disease state 75,76, have found critical roles in clinical applications 
such as screening, diagnosis, and prognosis of diseases 75,77,78. 
In the clinics, dried blood spots, have been used in risk assessments of neonates by 
the analysis of phenylalanine for the detection of phenylketonuria in newborns using 
bacterial inhibition test 79. Glucose test strips are used to determine the blood 
glucose levels of pregnant women based on simple blood tests in the diagnosis of 
gestational diabetes mellitus 80-82 and immunoanalytical assays e.g. enzyme linked 
immune-sorbent assays (ELISAs), are used in the diagnosis of preeclampsia by the 
analysis of either placental growth factor (PlGF) concentrations 83,84 and/or the ratio 
of maternal soluble fms-like tyrosine kinase-1, (sFlt1) to PlGF, (sFlt1/PlGF) 85-87. 
Screening assays of pregnant women based on simple blood tests to detect 
biomarkers indicative of placental insufficiency has become an attractive method for 
identifying high-risk pregnancies 35. Maternal PlGF is reported to be associated with 
placental dysfunction and fetal growth restriction 88,89. Hence, measurements of 
maternal PlGF concentrations have been included in pregnancy management when 
there was suspected cases of fetal growth restriction and showed beneficial outcome 
when the obstetrician’s decision was guided by those results 35,90. However, low PlGF 
concentrations which were associated with lower perinatal mortality and birth weight 
<3rd centile, appeared to lead to earlier delivery with more neonatal respiratory 
morbidity 91. 
The ratio of sFlt1/PlGF has found useful application in the prediction of fetal growth 
restriction outcome 92-94 and in conjunction with either Doppler ultrasound or 
ultrasound biometry there is an improvement in the prediction 95,96. Despite the 
progress made in the use of these assays in the prediction of fetal growth restriction 
outcome, the analytical methods employed in these studies are not able to 
distinguish IUGR fetuses from that of SGA before time of birth 97,98.  
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Therapy for IUGR 
Currently, there is no specific treatment for pregnant women diagnosed with IUGR 
but the assessment of fetal health and timely delivery are the main concerns for 
management of IUGR 2,3. The well-being of an IUGR fetus is monitored by using 
umbilical artery Doppler velocimetry to examine the fetus’ umbilical blood flow and 
serial ultrasonographic measurements to measure the growth of the fetus 2,3. Under 
some rather rare circumstances, medications may be administered to assist the 
growth of the fetus 2. 
At current, there is no specific criteria that determines the optimal timing of delivery of 
an IUGR fetus. Hence, signs of fetal deterioration, detected from the monitoring 
process, determines the time of delivery 2,3. 
 
 
1.1.2 Application of proteomics methods in prenatal screening 
Identification / discovery of biomarkers  
Several body fluids such as amniotic fluid, cervical vaginal fluid, umbilical cord blood 
and maternal blood have been used in the process of discovery of biomarkers for 
pregnancy complications 74,99,100. Amniotic fluid is closely related to the fetus and 
could be a suitable source for discovery of biomarkers associated with pregnancy 
complications but sampling is not easily accessible and depends on an invasive 
method such as amniocentesis 74,99,100. Maternal blood is a much preferred source for 
discovery of biomarkers because of easy accessibility as little invasive methods can 
be applied for sampling 74,99,100.  
In the analyses of multifaceted pregnancy-related pathophysiological disorders, such 
as hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome, 
preeclampsia and IUGR, analytical methods that can deal with the complexity of the 
biological samples are needed 101. The emergence of proteomics-based technologies 
such as two-dimensional gel electrophoresis (2-DE), liquid chromatography multiple-
reaction-monitoring mass spectrometry (LC-MRM/MS) and matrix assisted laser 
desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) which are 
capable of identifying and characterizing biomolecules of various body fluids in 
normal and diseased states has contributed immensely to the discovery and/or 
identification of biomarkers associated with pregnancy-related complications 
74,76,102,103. 
 
Global Proteomics and Targeted Proteomics Research Approaches 
Proteomic approaches make it possible for precise classification of proteins in 
multifaceted biological organisms, by offering significant information on the state of 
biological systems 104. Based on the goal of a research study, proteomic approaches 
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can be categorized into two main groups: global approaches and targeted 
approaches 105. 
Global proteomics approaches are applied in discovery / identification projects as a 
profiling tool to identify many undefined sets of modified proteins and the proteome 
profiles are compare to different physiological or pathological states 104. This is called 
the “data-driven” research approach. Global proteomic approaches are grouped into 
gel based methods, i.e. two-dimensional gel electrophoresis (2-DE) separation of 
proteins, e.g. from biological fluids, based on their molecular masses and isoelectric 
points, is followed by mass spectrometry based analytics. Generally, MALDI-ToF-MS 
and liquid chromatography – electrospray ionization - mass spectrometry (LC-ESI-
MS) methods have been developed in combination with gel-based high resolution 
protein separation methods. The limitations of 2-DE include poor gel-to-gel variability, 
low reproducibility, substantial time required for the analysis and the difficulty to 
automate the process. Due to these reasons, the method is usually preferred for the 
preliminary stage of biomarker discovery and has not been directly transferred into 
clinical applications 74,76,100. The LC-ESI-MS based analysis strategy is further divided 
into two: isotope-labeling and label-free approaches 104. Most of label-free LC-MS 
approaches employed in the identification of proteome signatures use the so-called 
“shotgun” technique, in which the pre-separated proteins are enzymatically digested 
before the generated peptides are subjected to LC-ESI-MS analysis 106-109. 
The targeted proteomics approach is used for quantitation of a smaller number of 
defined sets of proteins and is applied in “hypothesis-driven” research studies 110. 
Liquid chromatography multiple-reaction-monitoring mass spectrometry (LC-MRM-
MS) is a mass spectrometry-based method which is used for quantitation of proteins 
based on selection and fragmentation of a targeted peptide ions with detection of 
specific fragment ions, compared to added isotopically labelled synthetic peptides 
which serve as internal standards 111-113. Even though MRM-MS based quantitation is 
normally used for clinical validation of potential biomarkers 111,114,115, MRM-MS 
assays can also be applied in the discovery of biomarkers 111. The application of 
MRM-MS for analyses of maternal serum identified a putative proteomic biomarkers 
for trisomy 21 116 and a potential biomarker associated with early spontaneous 
preterm birth (early SPTB) 117. While MRM-MS has shown to be accurate, specific 
and reproducible 111, assay of clinical samples require a prolonged LC separation 
time 118, which will likely prolong the duration of sample analyses in clinical 
applications. Hence, LC-MRM-MS analyses of clinical samples require the installation 
of highly specialized laboratories run by trained specialists. 
Both, global and targeted proteomics approaches have contributed immensely to the 
identification of proteome signatures for characterizing complications associated with 
pregnancies on the molecular level. 2-DE approaches have revealed putative plasma 
biomarkers of gestational diabetes mellitus when maternal plasma from women with 
normal pregnancies were compared with those who had developed gestational 
diabetes mellitus 119. Proteome studies of umbilical cord blood using 2-DE identified 
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protein markers potentially responsible for IUGR associated complications 120,121 and 
also analyses of maternal plasma with 2-DE identified proteome signatures for 
HELLP-syndrome 122,123. 
 
Affinity proteomics screening / diagnosis of pregnancy complications 
MALDI-ToF-MS is a rather simple, rapid and now even automated analytical 
technique which is suitable for the detection of a broad spectrum of biomolecules, 
such as peptides and proteins from clinically obtained body fluids 124,125. The major 
bottle-neck for analyses of body fluids using MALDI-ToF-MS is a sample preparation 
procedure that will purify the complex body fluids and additionally enrich the peptides 
or proteins of interest 126. To overcome these limitations, magnetic beads with 
hydrophobic surfaces have been found valuable for purification and enrichment of 
peptides or proteins of interest prior to MALDI-ToF-MS profiling of body fluids. Serum 
protein profiling for the analysis of peptides or proteins using magnetic bead 
fractionation in combination with MALDI-ToF-MS has aided in the identification of 
potential biomarkers for diseases due to its ease of operation, sensitivity, good 
reproducibility and robustness 127-129.  
Proteome profiles of maternal blood serum obtained by MALDI-ToF-MS identified 
biomarkers that differentiated pre-eclampsia patients from those of healthy controls 
130. Mass spectrometric proteome profiling of umbilical cord blood serum identified 
proteome signatures that differentiated neonates that were born after pregnancies 
had been complicated by IUGR from those who had been small for gestational age 
and / or normal (control) individuals 131,132. Proteome profiling of maternal blood 
serum identified proteome signatures that differentiated pregnancies carrying IUGR 
fetuses from those carrying normal (control) fetuses 133. The identification of these 
proteome signatures using MALDI-ToF-MS will contribute to the understanding of the 
underlying pathological conditions and the clinical diagnosis of multifactorial 
pregnancy disorders leading to an improved maternal healthcare. 
 
Translation of affinity proteomics to the clinics 
IUGR is a worldwide clinical problem 134 and the use of ultrasound for serial 
assessment of growth in all pregnancies is not practicable even in developed 
countries 60. Blood tests are cost effective and favorable sources implemented even 
in developing countries for clinical analyses 135,136. 
Over the past years, our group has researched into the application of mass 
spectrometric profiling methods as a possible screening or diagnostic tool for 
pregnancy complications. A protein profiling method for analysis of plasma samples 
from HELLP patients and from healthy women prior to and after delivery without 
fractionation of the plasma samples 123 that used a cryodetector mass spectrometer 
137 was developed. Though there was no sample fractionation prior to analyses, the 
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mass spectrometric profiling analysis displayed high molecular mass proteins with 
significant differences in ion intensities between post-HELLP (control) samples and 
HELLP patients which were detected using the cryodetector MS equipment. The 
most conspicuous difference in the spectra between most of the HELLP cases and 
those from the same persons after delivery post-HELLP (control) was the presence 
or absence of an ion signal at 11.8 kDa which was assigned to serum amyloid A 
(SAA). The cryodetector MS-based screening technique permits a rapid and reliable 
differentiation of HELLP patients from healthy women. The role of SAA for 
identification of HELLP and separation from preecclampsia has later been confirmed 
by ELISA-based investigations 138. 
Furthermore, a MALDI-ToF-MS method was developed to analyze serum proteins of 
pregnant women with severe early-onset preeclampsia and those of control 
individuals 130. Here, reversed-phase coated magnetic beads were used for the 
fractionation of serum proteins. The fractionation produced serum proteins suitable 
for MALDI-ToF-MS profiling without the need for additional work-up. In order to 
differentiate between preeclampsia and control groups by accurately assigning 
protein ion signals to either, a variety of distinctive signatures signals which could be 
used for the characterization of a sample were examined. Three best group of 
differentiating singly charged protein ion signals regarded as a ‘‘signature for 
preeclampsia’’, i.e. transthyretin and its derivatives, were selected because they 
carried sufficient information to form the rules that enabled accurate sorting of 
individual spectra. A multiparametric analysis was performed by bringing the ion 
signal areas within each spectrum into context with each other. The ‘‘signature for 
preeclampsia’’, i.e. transthyretin and derivatives, differentiated pregnant women with 
severe early-onset preeclampsia from control individuals. 
The probable diagnostic value and clinical practicality of the established affinity-
based MALDI-TOF-MS method capable of distinguishing preeclampsia patients from 
controls 130 was assessed in a multicenter setting 139. The MALDI-ToF-MS serum 
profiling with center-wise standardization presents a rapid and robust method to 
categorize preeclampsia. 
Carrying the research studies further, the established affinity MALDI-ToF-MS profiling 
method previously proven successful in a multiparametric characterization of blood 
serum samples from preeclampsia pregnant women 130 was utilized in the analysis of 
umbilical cord blood serum samples belonging to either IUGR or normal (control) 
neonates by subjecting the umbilical cord blood serum samples to fractionation by 
affinity chromatography using a bead system with hydrophobic interaction capabilities 
and the prepared protein mixtures were then analyzed by MALDI-ToF-MS 132. The 
best differentiating ion signals were identified as belonging to apolipoprotein C-III 
protein species, i.e. apoC-III0, apoC-III1, and apoC-III2, which were collectively 
assigned as “IUGR proteome signature”. This proteome signature was used for the 
multiparametic analysis upon which IUGR neonates were successfully separated 
from control neonates. 
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Encouraged by the results obtained from the analyses of umbilical cord blood serum 
by affinity MALDI-ToF-MS profiling 132, the method was further used to analyze 
different umbilical cord blood serum samples from IUGR, SGA, and control infants 
131. The established proteome signature (apolipoprotein C-III protein species) was 
able to differentiated IUGR infants from SGA and control infants at time of birth 131. 
In an effort to aid the screening of pregnant women for the early detection of 
pregnancy-related complications such as IUGR via affinity mass spectrometry, 
molecular profiling of maternal peripheral blood was anticipated to play a vital in the 
monitoring the health conditions of fetuses. To develop such a minimally invasive 
assay, the established affinity MALDI-ToF-MS profiling method for the analyses of 
blood proteins of pregnant women with preeclampsia 130,139 and umbilical cord blood 
proteins from IUGR and SGA infants 131,132 was applied to analyze peripheral blood 
serum samples from pregnant women carrying IUGR fetuses or normal (control) 
fetuses after affinity fractionation with magnetic beads 133. The peripheral maternal 
blood serum used 133 was obtained from respective maternal counterparts of the 
infants from the previous study of fetal cord blood proteome profiling 132. The best 
differentiating protein ion signals from the maternal serum were apolipoprotein C-II 
and apolipoprotein C-III protein species (previously identified in fetal cord blood 
proteome profiling). Together they constituted the “maternal IUGR proteome 
signature” and were used for relative quantitation analysis. The “maternal IUGR 
proteome signature” differentiated IUGR pregnancies from control with high 
confidence. 
Hence, with the emergence of MALDI-ToF-MS in clinical applications 131-133, in future, 
the screening and diagnosis of IUGR during pregnancy may be based on blood 
protein assays using MALDI-ToF-MS in combination with clinical assessments such 
as determination of fundal height 60 in the absence of ultrasound data. These 
approaches may have the potential to improve screening and diagnostic accuracy in 




1.2 Aim of the study 
Currently, differentiating between IUGR fetuses and SGA fetuses in the clinics 
remains a challenge which shall be overcome by blood-based analyses which are 
capable of determining the individual´s proteome signature(s). Therefore, the 
objectives of this thesis were (i) to profile blood samples from pregnant women using 
the affinity mass spectrometric method to identify proteome signature(s) that can 
differentiate IUGR pregnancies from SGA and/or normal pregnancies (ii) to broaden 
the spectrum for the identification and quantification of proteome signature(s) for 
IUGR using a multiplexing serological assay based on liquid chromatography–
multiple-reaction-monitoring mass spectrometry, (LC-MRM-MS) and (iii) to develop a 
workflow that will circumvent the necessity of the “cold-chain”, but still keep proteins 
intact during transportation of serum samples from the clinics to the mass 
spectrometry laboratory for in-depth analysis. 
First, within this thesis, a targeted multiplexing mass spectrometric method was 
employed for identification and quantification of protein(s) capable of differentiating 
pregnancies affected with IUGR from normal pregnancies. 
Second and foremost within this thesis, relative protein abundances of maternal 
blood serum were analyzed using affinity proteomics, i.e. MALDI-ToF-MS profiling of 
fractionated serum proteins. Changes in serum protein composition in relation to 
gestational age lead to the development of a “three value regime” for classification of 
patient cohorts, separating IUGR cases from both, SGA and control individuals. 
Third, within this thesis, an analytical procedure was developed where intact proteins 
from maternal blood serum samples were stored on filter membranes at room 
temperature (“dried serum spot”). Resolubilization steps for elution were developed 
and made compatible with analysis by MALDI-ToF-MS. The developed analytical 
procedure was compared with the conventional procedure which included “freeze-
thaw cycles” for storing, shipping, and preparation of serum protein solutions for 
analysis. In summary, maternal blood serum samples from the clinics could be stored 
on a “storage discs” and shipped by regular mail or courier to the mass spectrometry 
laboratory, thereby reducing costs of transportation and storage.  
The user friendly linear MALDI-ToF-MS analysis of intact proteins has reached a 
state of maturation that is ready to be employed in profiling of the relative 
abundances of serum proteins of interest, termed the IUGR proteome signature. This 
affinity – mass spectrometry procedure shall in greater length help to improve risk 






1.3.1 Quantification of apolipoproteins in maternal serum 
In the analyses of clinically obtained biological fluids, pre-analytical factors such as 
sample collection and sample storage are significant stages because they have the 
tendency to affect accuracy and reproducibility. Due to the delicate nature of peptides 
/ proteins present in biological fluids, a sample storage system which will avoid 
freezing temperatures and still preserve peptides / proteins is an ideal one. 
Lyophylization is a process of removal of water (drying) from biological samples 
without the application of heat. It is usually applied to samples that contain proteins 
and/or peptides that are sensitive to heat. The dried proteins and/or peptides can be 
stored for a longer period of time without the need for applying freezing temperatures. 
Lyophylization helps with sample stability and easy handling during transportation 
from one laboratory to the other. 
In this thesis, we developed two different sample work-up protocols from maternal 
blood serum form pregnant women diagnosed to be carrying IUGR fetuses and those 
carrying normal fetuses. The sample work-ups were analyzed using liquid 
chromatography – multiple-reaction-monitoring – mass spectrometry (LC-MRM-MS). 
For the first sample work-up, the maternal serum proteins were reduced, alkylated 
and digested to obtain the native (NAT) peptides. Synthesized stable isotope-labeled 
(SIS) peptides obtained in the dried form (lyophilized to dryness and shipped to the 
lab), were re-solubilized and added to the NAT peptides. The peptide mixtures (both 
NAT and SIS) were desalted and lyophilized to dryness. The dried peptide mixtures 
(both NAT and SIS) were then re-solubilized and the final solution was labeled as 
MS1 prior to analysis. For the second sample work-up, the maternal serum proteins 
were obtained in the dried form (lyophilized to dryness and shipped to the lab). 
Afterwards, it was re-solubilized, reduced, alkylated and digested to obtain the NAT 
peptides. SIS peptides, already in solution, were added and the peptide mixtures 
(both NAT and SIS) were desalted. The final solution was labeled as MS2 prior to 
analysis. 
There was no significant difference between the results obtained for sample work-up 
MS1 (peptide level) and sample work-up MS2 (intact protein level) indicating that 
serum proteins samples can be shipped at both the processed peptide level and the 
intact protein level without loss of quality. 
The apolipoprotein B100 levels were found to decrease in pregnant women whose 
fetuses were complicated by IUGR compared to pregnant women with healthy 




1.3.2 Application of three value regimes: below – in between – above cut-offs to 
maternal blood serum samples 
The complexity and abundance of maternal blood protein compositions change in 
relation to advancing gestational age. For any blood protein-based analytical method 
to find suitable application in pregnant women, this information plays a critical role. 
In this thesis, we investigated peripheral blood serum protein abundance differences 
from 45 Caucasian pregnant women using our developed affinity - MALDI-ToF-MS 
serum proteome profiling method. Of the Caucasian pregnant women whose serum 
samples were used for the study, 15 were clinically diagnosed to carry normal 
fetuses; referred to as the Control (CTRL) group, another 15 were clinically 
diagnosed to carry SGA fetuses, and the third group of 15 were clinically diagnosed 
to carry IUGR fetuses. The CTRL group consisted of women with unsuspicious 
pregnancies who delivered healthy babies after normal gestational periods, ca. 39.6 
(± 0.7) weeks of gestation. The IUGR group delivered after ca. 30.5 (± 1.3) weeks, 
and the SGA group delivered after ca. 38.1 (± 0.7) weeks of gestation. The CTRL 
group was chosen to match with the IUGR and the SGA groups only at the 
gestational age at blood sampling, which took place at ca. 31.0 (± 1.5) weeks. The 
duration between blood sampling and delivery for the CTRL, SGA and IUGR groups 
were around 71, 50, and 6 days, respectively. From the results of our training set, 
“best cut-off” values were determined using the Youden index (Jmax) analysis 
procedure. 
Previously, our group had established cut-off values for CTRL and IUGR cohorts but 
because in that earlier study 133 the CTRL group consisted of pregnant women who 
delivered preterm, ca. 32.8 (± 2.6) weeks of gestation for various reasons (premature 
rupture of the membrane, spontaneous onset of labor, vaginal bleeding), these cut-
off values were considered not suitable for this study. To optimize our procedure of 
assigning a specific mass spectrum to either of the groups, we generated a new set 
of cut-off values and combined both sets of “cut-off” values to generate a three value 
regimes (below – in between – above cut-offs). Application of our novel three value 
regimes cut-off successfully differentiated IUGR from CTRL / SGA with high 
confidence. For more information on application of three value regimes: below – in 
between – above cut-offs to maternal blood serum samples see Chapter 1.4.2. 
 
1.3.3 Analysis of intact proteins from “dried serum spot” 
Mass spectrometry-based proteome profiling provides a formidable technique to 
diagnose pregnancy-related diseases like IUGR due to its ability to characterize 
individual serum samples based on multifaceted proteome signatures from pregnant 
women. Nonetheless, transferring of biological fluids from the clinic to the mass 
spectrometry laboratory remains a challenge due to high cost of shipping and 
storage. In order to advance the use of mass spectrometry in clinical applications, 
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there is the demand to bridge the distance between the clinic and the mass 
spectrometry laboratory. 
In this thesis, we developed a novel work-up procedure for the resolubilization and 
elution of intact proteins from maternal sera stored on NoviplexTM cards (referred to 
as “dried serum spots”) prior to analysis with the mass spectrometer. 
Maternal serum samples from pregnant donors diagnosed to carrying normal fetuses 
referred to as control (CTRL) and patients diagnosed to be carrying IUGR fetuses 
obtained from the clinics were deposited on the ‘‘serum storage discs’’ that were 
mounted on the base sheets of NoviplexTM cards. Serum was allowed to dry at 
ambient temperature in a clean box and “dried serum spots” were stored at room 
temperature for up to three days. The “dried serum spots” were then shipped by 
courier at room temperature to the mass spectrometry laboratory. The dried serum 
proteins were resolubilized and eluted using our novel work-up procedure. Another 
set of serum samples from the same donors and patients were shipped to mass 
spectrometry laboratory on dry ice and a conventional work-up procedure was used 
(freezing of serum at the clinics, shipping of samples in the frozen state, and thawing 
of serum in the laboratory) prior to analysis. 
The eluted intact proteins from the “dried serum spots” using our novel work-up 
procedure and that from fresh frozen and thawed serum using the conventional work-
up procedure were analyzed using our affinity - MALDI-ToF-MS serum proteome 
profiling method and the obtained mass spectra were compared to each other. The 
resulting proteome profiles of intact serum proteins from the ‘‘dried serum spots’’ 
using our novel work-up procedures were found to be of comparable quality as the 
ones which were obtained from the same serum using conventional work-up 
procedures. 
Application of our developed multiparametric analysis to proteins of interest 
differentiated IUGR serum samples from the control serum samples upon both, the 
novel work-up and the conventional work-up series. Our novel procedure avoids the 
conventional freeze / thaw cycle, paving the way for potential mass spectrometric 
analysis of other diseases using intact proteins eluted from “dried serum”. For more 






1.4.1 Maternal Apolipoprotein B100 Serum Levels are Diminished in 
Pregnancies with Intrauterine Growth Restriction and Differentiate from 
Controls 
Purpose: Intrauterine growth restriction, a major cause of fetal morbidity and 
mortality, is defined as a condition in which the fetus does not reach its genetically 
given growth potential. Screening for intrauterine growth restriction biomarkers in the 
mother’s blood would be of great help for optimal pregnancy management and timing 
of delivery as well as for identifying fetuses requiring further surveillance during their 
infancies. 
Experimental Design: A multiplexing serological assay based on liquid 
chromatography–multiple-reaction-monitoring mass spectrometry is applied for 
distinguishing serum samples of pregnant women. 
Results: Assessment of concentrations of apolipoproteins and of proteins that 
belong to the lipid transport system is performed with maternal serum samples, 
consuming only 10 μL of serum per multiplex assay from each patient. Of all 
investigated proteins the serum concentrations of apolipoprotein B100 shows the 
greatest power for discriminating intrauterine growth restriction from control samples, 
reaching areas under curves above 0.85 in receiver-operator-characteristics 
analyses. 
Conclusions: These results indicate the potential of liquid chromatography-multiple-
reaction-monitoring mass spectrometry to become of clinical importance in the future 
for intrauterine growth restriction risk assessment based on maternal apolipoprotein 
B100 serum levels. 
For detailed information on apolipoproteins levels in maternal serum using LC-
MRM/MS see Chapter 2.1 
 
1.4.2 Precision Diagnostics by Affinity - Mass Spectrometry: A Novel Approach 
for Fetal Growth Restriction Screening During Pregnancy 
Fetal growth restriction (FGR) affects about 3 to 8% of pregnancies leading to higher 
perinatal mortality and morbidity. Current strategies for detecting fetal growth 
impairment are based on ultrasound inspection. However, antenatal detection rates 
are insufficient and critical in countries with substandard care. To overcome 
difficulties with detection and to better discriminate between high risk FGR and low 
risk small for gestational age (SGA) fetuses we here investigated suitability of risk 
assessment based on analysis of a recently developed proteome profile derived from 
maternal serum in different study groups. Maternal serum, collected at around 31 
weeks of gestation was analyzed in 30 FGR, 15 SGA, and 30 control (CTRL) 
pregnant women who delivered between 31 and 40 weeks of gestation. From the 75 
pregnant women of this study, 2 were excluded because of deficient raw data and 2 
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patients could not be grouped due to indeterminate results. Consistency between 
proteome profile and sonography results was obtained for 59 patients (26 true 
positive and 33 true negative). Of the by proteome profiling 12 contrarious grouped 
individuals, 3 were false negative and 9 were false positive cases with respect to 
ultrasound data. Both, true positive and false positive grouping transfer the 
respective patients to closer surveillance and thorough pregnancy management. 
Accuracy of the test is considered high with an area-under-curve value of 0.88 in 
receiver-operator-characteristics analysis. Proteome profiling by affinity – mass 
spectrometry during pregnancy provides a reliable method for risk assessment of 
impaired development in fetuses and consumes just minute volumes of maternal 
peripheral blood. Additive to clinical testing proteome profiling by affinity – mass 
spectrometry may improve risk assessment, referring pregnant women to specialists 
early, thereby improving perinatal outcome. 
For detailed information on Precision Diagnostics using Affinity - Mass Spectrometry 
see Chapter 2.2 
 
1.4.3 Comparison of blood serum protein analysis by MALDI-MS from either 
conventional frozen samples or storage disc-deposited samples: A study with 
human serum from pregnant donors and from patients with intrauterine growth 
restriction 
Mass spectrometric profiling of intact serum proteins, i.e. determination of relative 
protein abundance differences, was performed using two different serum sample 
preparation methods: one with frozen and thawed serum, the other with at room 
temperature deposited and dried serum. Since in a typical clinical setting freezing of 
serum is difficult to achieve, sampling at room temperature is preferred and can be 
met when using the NoviplexTM card system. Once deposited and dried, serum 
proteins can be stored and shipped at room temperature. After resolubilization of 
serum proteins from ‘‘dried serum spots’’, mass spectra of high quality have been 
recorded comparable to those that were obtained using fresh-frozen and 
subsequently thawed serum samples. Differentiation between patients with 
intrauterine growth restriction and control individuals was achievable, independent 
from the sample work-up procedure. Having at hand a reliable and robust method for 
serum storage and shipment which works at room temperature bridges the gap 
between the clinics and the protein analysis laboratory. Our novel serum handling 
protocol reduces costs for both, storage and shipping, and ultimately enables clinical 
risk assessment based on mass spectrometric determination of intact protein 
abundance profiles. 
For detailed information on comparison of blood serum protein analysis by MALDI-





Screening for biomarkers associated with diseases during pregnancy is a significant 
phase of clinical diagnosis due to its impact on clinical decision making in improving 
maternal healthcare 140. Currently in the clinics, screening of pregnancy-related 
complication like preeclampsia depends on immunoassays e.g. ELISA, which is 
based on an antigen-antibody reactions 83-87. The antibody has the ability to react 
with other antigens (with similar configurations) present in biological fluids other than 
the specific antigen to which it was raised, leading to cross-reactivity 141. Due to 
interferences, these diagnostic techniques quite often produce false positive and 
false negative results 124,125,141.  
The challenges associated with classical immunoassay diagnostic methods are 
gradually being overcome by the development of powerful analytical techniques such 
as MALDI-ToF-MS which directly identifies biomolecules in biological fluids by means 
of their mass-to-charge (m/z) ratios with high accuracy 124,125,142. 
Likewise, in the area of clinical microbiology, conventional techniques employed in 
the detection microorganisms are costly, complicated and time consuming 143,144. 
MALDI-ToF-MS has contributed tremendously to overcoming these limitations by the 
identification of microorganisms based on their protein profiles with accuracy and 
consistency 145-148. Upon this successful application, MALDI-ToF-MS has been 
approved by the U.S. Food and Drug Administration leading to its acceptance and 
usage in many clinical microbiology laboratories 149 and in some cases, complements 
the conventional detection techniques 146. 
MALDI-ToF-MS has the tendency to probe multiple biomolecules concurrently, 
leading to the possibility of uncovering “several protein marker” candidates 75,119,150. It 
is believed that differentiating a polygenic disease from a healthy one by means of a 
single marker proteins may not be suitable but the ‘several protein marker’ 
candidates, so-called “proteome signatures” might be more appropriate with the 
capability of stratification of patients 109 and essentially contribute to the specificity 
and sensitivity of clinical applications 75,119,150. Similarly, the “proteome signatures” 
might contribute to the understanding of disease pathways leading to development 
therapeutic interventions 109. 
Two studies 151,152 have previously utilized proteomics approaches to identify 
biomarkers for IUGR by profiling maternal plasma but no SGA patients were included 
as is done in this thesis. In one of the studies 151, an isobaric Tag for Relative and 
Absolute Quantitation (iTRAQ) approach was used to profile maternal plasma in the 
identification of protein markers for IUGR. However, the gestational ages of IUGR 
patients were not harmonized with that of the normal ones and also prior to the 
determination of the relative protein concentration differences, the plasma samples 
from individual patients were pooled together. The other study 152 employed 2-DE 
and image analysis to profile maternal plasma to identify a potential biomarker 
associated with FGR. The spot volumes of individual patients were pooled and the 
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mean spot volume was used prior to quantification of differences in spot volumes. 
The protein markers identified in these studies were antichymotrypsin (SERPINA3) 
and C reactive protein (CRP) 151, and haptoglobin α2 isoform 152 in contrast to our 
proteome signatures which constitutes of Apo CII and Apo CIII (in addition to its 
glycosylated/sialylated isoforms). Typically, 2-DE detect proteins in the mass range of 
10 – 200 kDa 100 and our proteome signatures (Apo CII and Apo CIII) had mass 
range of 8 – 9 kDa hence, 2-DE would not have been able to detected them because 
of their low molecular masses. 
Consequently in both 151,152, individual patient classification was not achievable since 
information on individual sample was not available hence the sensitivity and 
specificity of these approaches were not established. This is contrary to our affinity 
MALDI-ToF-MS proteome profiling method employed in this thesis in that, the 
proteome signatures obtained for each individual was used in the multiparametric 
analysis for stratification of each patient enabling us to differentiate IUGR from CTRL 
/ SGA individuals and also to perform biostatistical analysis to determine the 
sensitivity, specificity and receiver operator characteristics (ROC) / area under curve 
(AUC). So far, there is no other reported literature on differentiating IUGR from SGA 
using a proteomic approach.  
Recently, a study has been published in which was focused on PlGF, placental 
protein 13 (PP13), A-disintegrin, and metalloprotease 12 (ADAM12) from maternal 
serum taken at 11–13 weeks of gestation using antibody-based immunoassays. In 
this study were identified half of pregnancies with SGA neonates 153 but there was no 
comparison with pregnancies affected by IUGR. In contrast, in this thesis the 
gestational age of sampling was ca. 31 weeks for our SGA cohorts and our affinity 
mass spectrometric method was able to distinguished IUGR pregnancies from those 
with SGA fetuses. 
With advancing gestational age, maternal blood protein compositions change in 
complexity and abundance 154-156, therefore gestational age can be an essential 
confounding parameter that needs to be considered in assays involving blood protein 
of pregnant women. Taking into consideration the variety of pregnant women 
recruited in our analysis and their respective relative protein abundances present in 
maternal blood, in this thesis we developed a three value regimes: below – in 
between – above cut-offs for separating IUGR from CTRL / SGA samples / 
individuals, instead of a typical two value regimes analysis with samples below a 
given cut-off which are separated from those above.  
It should be noted that the components of the proteome signature identified in this 
thesis play essential roles in triglyceride metabolism.  
ApoC-II is required for the metabolism of triglyceride-rich lipoproteins by the 
activation of lipoprotein lipase for effective lipolysis of triglyceride-rich lipoproteins 
157,158. Reduction of lipoprotein lipase activity in the presence of either excess or 
deficient apoC-II has been reported to be associated with hypertriglyceridemia 157. 
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ApoC-III occurs in three isoforms, designated as apoC-III0, apoC-III1, and apoC-III2 
depending on the number of sialic acid molecules attached to the protein 159 with 
each isoform contributing to 10, 55 and 35 % respectively of the overall apoCIII levels 
in circulation 160. It has been suggested that ApoC-III affects lipolysis of triglyceride-
rich lipoproteins by lipoprotein lipase based on the amount of sialylation 161. Kinetics 
studies of ApoC-III1 and ApoC-III2 sialylated isoforms revealed that they inhibit the 
activity of lipoprotein lipase, thereby contributing to metabolic syndrome, including 
hypertriglyceridemia. These results give credence to the fact that 
hypertriglyceridemia in humans is associated with the secretion of ApoC-III into the 
circulation 162-165. 
A study by our group on profiling of umbilical cord blood serum form IUGR, SGA and 
healthy neonates identified ApoC-III0, ApoC-III1, and ApoC-III2 as prospective 
proteome signatures 131,132 which correlated with the findings of lipid metabolism 
disorders in newborns with IUGR 166-168. A recent study on profiling of plasma from 
preterm and born term preschool children revealed that ApoC-II and ApoC-III were 
significantly higher in the preterm children than in those born term, indicating 
potential effects of prematurity. Further, high levels of apolipoprotein CIII may be an 
indication of a pro-atherogenic risk factor in early childhood 32. These outcomes 
strengthen the indications that IUGR babies may be at higher risk to develop 
cardiovascular diseases later in life 27,29,33,169. Further studies of the mechanisms on 
our proposed proteome signatures, apoC-II and C-III (and its isoforms) during 
pregnancy may improve one’s comprehension of the pathomechanism in IUGR and 
their lasting effects on neonates. 
IUGR is considered to be a multifactorial condition and placental insufficiency is 
deemed to be one of them 2,21. The placenta is capable of secreting apo B100 170 and 
as observed in our study of quantification of apolipoproteins in maternal blood serum, 
apo B100 levels were lower in pregnancies affected by IUGR as compared to levels 
from individuals with normal pregnancies, which may be an indication that low levels 
of apo B100 may be related to placental insufficiency. 
Blood plasma and serum are the most preferred clinical samples used for the 
identification or discovery of disease biomarkers 171,172. However, preparation of 
plasma or serum requires centrifugation of blood followed by freezing or keeping it on 
dry ice and this advanced procedures can only be accomplished at specialized health 
care centers 130,131,133. Unfortunately, these specialized facilities are not immediately 
available worldwide 173,174. Moreover, individuals living farther away from mass 
spectrometry laboratories might not benefit from mass spectrometric analysis of their 
blood plasma or serum due to the distance between them and the mass spectrometry 
laboratory 175 because transportation of plasma or serum on dry ice is expensive and 
requires the services of specialized couriers 176. These challenges have the 
propensity to hinder the widespread application of a prospective mass spectrometry 
based profiling method for clinical use in the area of disease screening / diagnosis. 
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Currently, blood, plasma, and serum samples can be collected on filter paper cards in 
the form of dried blood spots (DBS), dried plasma spots (DPS) and dried serum spots 
(DSS), respectively, which enable them to function as appropriate storage and 
shipment devices for clinical samples. Mass spectrometry techniques have been 
used to analyze drug metabolites in dried blood spots 177,178, dried plasma spots 179-
181 and dried serum spots 182 and likewise, multiple reaction monitoring mass 
spectrometry (MRM-MS) was used to quantify proteins from dried blood spots by 
analysis of peptides 183-185. But in none of these projects were eluted intact proteins 
from their “dried state” for mass spectrometric analysis. Our novel procedure, 
developed in this thesis, for the resolubilizing and elution of intact proteins from dried 
serum spots followed by analyses of their relative abundances by MALDI-ToF-MS 
enabled us to differentiate healthy donors from patients. 
In conclusion, affinity - MALDI ToF MS allows the identification of proteome 
signatures for screening of pregnancy complications, such as IUGR, using maternal 
blood. This makes affinity - MALDI ToF MS a significant analytical tool for clinical 
research which in future may find valuable application in routine clinical diagnostics in 
combination with clinical examinations such as ultrasound biometry or fundal height 
determination to improve antenatal care. Furthermore, the novel procedure to 
resolubilize and elute intact proteins from dried serum spots will bridge the distance 
between clinics and mass spectrometry laboratories by circumventing the freeze / 
thaw stages which in future is foreseen to pave the way for potential mass 
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Purpose: Intrauterine growth restriction, a major cause of fetal morbidity and
mortality, is defined as a condition in which the fetus does not reach its
genetically given growth potential. Screening for intrauterine growth
restriction biomarkers in the mother’s blood would be of great help for
optimal pregnancy management and timing of delivery as well as for
identifying fetuses requiring further surveillance during their infancies.
Experimental Design: A multiplexing serological assay based on liquid
chromatography–multiple-reaction-monitoring mass spectrometry is applied
for distinguishing serum samples of pregnant women.
Results: Assessment of concentrations of apolipoproteins and of proteins
that belong to the lipid transport system is performed with maternal serum
samples, consuming only 10 μL of serum per multiplex assay from each
patient. Of all investigated proteins the serum concentrations of
apolipoprotein B100 shows the greatest power for discriminating intrauterine
growth restriction from control samples, reaching areas under curves above
0.85 in receiver-operator-characteristics analyses.
Conclusions: These results indicate the potential of liquid
chromatography-multiple-reaction-monitoring mass spectrometry to become
of clinical importance in the future for intrauterine growth restriction risk
assessment based on maternal apolipoprotein B100 serum
levels.
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1. Introduction
Affecting 3–8% of all pregnancies,
intrauterine growth restriction (IUGR)
is defined as a condition in which the
fetus does not reach its genetically
given growth potential. Resulting in low
fetal weight, IUGR is a major cause of
fetal morbidity and mortality.[1,2] The
mother´s metabolic and cardiovascular
conditions, such as obesity, diabetes
mellitus, and hypertension are known
risk factors for IUGR.[3] In accordance,
several epidemiologic studies indicate
that abnormal intrauterine conditions
increase the infant’s risk for cardiovascu-
lar and metabolic diseases, for example,
atherosclerosis, in its later life.[4] One
possible mechanism is an accumulation
of oxidized low density lipoproteins
(oxLDL) leading to fatty streak formation
in the fetal vessels[5] which results in an
increased intima media thickness which
is measurable by ultrasound in the IUGR
fetus.[6] Increased intima media thick-
ness has been shown to (i) persist up
to at least the age of 18 months after birth
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Clinical Relevance
Risk assessment of development impairment in fetuses is of
tremendous importance for (i) optimal pregnancymanage-
ment, (ii) timingof delivery, and (iii) for identifyingpreterm
babieswho require further surveillanceduring their infancies.
Althoughultrasound sonographyhas been accepted as “gold
standard” for determining IUGRby clinicalmeans, its appli-
cation is limited to excellently equipped care centers.Despite
clinical settings, successful screening assayswith pregnant
womenwill only bepracticablewhen they are either noninva-
sive or serological, that is, basedon simple blood tests. Pro-
teomeprofilingofmaternal serumduringpregnancy provides
theprerequisites for risk assessment of development impair-
ment in fetuses, because LiquidChromatography–Multiple
ReactionMonitoringMassSpectrometry enablesmultiplexing
andhence simultaneousdeterminationof biomarker con-
centrations by consuming justminute volumesofmaternal
peripheral blood.
and (ii) correlate with higher blood pressure in affected
infants.[7]
Recently, we analyzed maternal serum samples from 30 preg-
nant Caucasian women, of which subsequently 15 delivered
healthy babies and 15 gave birth to infants that suffered from
IUGR. We identified specific marker proteins that are known to
be involved in the pathomechanisms of atherosclerosis by the
regulation of triglyceride levels.[8] Particularly pro-apolipoprotein
CII and apolipoprotein CIII together with its distinctly differ-
ently glycosylated isoforms enabled us to discriminate pregnan-
cies with IUGR from control individuals ahead of birth, and in-
dependent from other biometrical data.[9]
Incidentally, apolipoproteins have become important screening
biomarkers for predicting cardiovascular risk in the general
population[10] and are considered better predictors than tradi-
tional serum lipid measurements.[11] Hence, since a deranged
lipid metabolism has been observed in both the mother and the
fetus, IUGR may be considered a metabolic disease.[12] Screen-
ing during pregnancy, that is, detecting the presence of IUGR
biomarkers in the mother’s blood, would be of great help in
many aspects. First goals to reach are optimal pregnancymanage-
ment and timing of delivery.[1] Second, early detection of IUGR
fetuses was beneficial for initiating of both, immediate care of af-
fected newborns and further intensive surveillance during their
infancies.
In an effort to potentially widen the spectrum of future screen-
ing biomarkers for detection of pregnancy complications, such
as IUGR, we conducted a retrospective study with the same 30
maternal serum samples that we had investigated previously.[9]
With IUGR in focus and our previous study results in mind, we
focused our interest to evaluate levels of further apolipoproteins
in peripheral blood of pregnant women. Altogether, 15 protiens
(apolipoproteins and proteins that belong to the lipid transport
system) were quantified in all 30 maternal serum samples
by liquid chromatography–multiple-reaction-monitoring
mass spectrometry (LC-MRM/MS). Protein abundance
differences were correlated with clinical IUGR assessment
and were biostatistically evaluated for their suitability to detect
IUGR during pregnancies.
2. Experimental Section
Patient Stratification, Blood Collection, SerumGeneration, and Stor-
age: Blood samples were analyzed from 30 pregnant Caucasian
women who attended the Department of Obstetrics and Gynecol-
ogy, University Hospital of the RWTH Aachen, between March
2008 and August 2010 (Table S1, Supporting Information). IUGR
was defined in accordance to the American College of Obste-
tricians and Gynecologists guidelines[13] as described.[14] Addi-
tional preeclampsia (PE) in some of the mothers with IUGR ba-
bies was defined according to the International Society for the
Study of Hypertension in Pregnancy guideline.[15] Sonographic
examinations were done antenatally on Logiq 5 and Voluson 730
Expert Ultrasound Systems (GE Healthcare Systems, Solingen,
Germany). The regression equation including biparietal diame-
ter, femur length, and head and abdominal circumferences,[16]
was used to estimate fetal weight. Neonatal birth weight cen-
tile was determined according to the population-based newborn
weight charts.[17]
Blood samples (up to 9 mL, each) were taken from each
individual antenatally from the right or left cubital vein us-
ing monovette syringes (Serum Z/9 mL; Monovette, Sarstedt,
Germany). Serum was prepared in the clinic as described.[2,9,18]
Altogether, time between blood sample collection and storage
of frozen serum aliquots averaged around less than 1 h. Frozen
serum aliquots were shipped on dry ice to Proteome Center Ros-
tock (formore information see Experimental Section, Supporting
Information).
Preparation of Peptide Mixtures from Serum Samples and Ad-
dition of Stable Isotope-Labeled Standard Peptides: Peptide mix-
tures (native [NAT] peptides) were prepared for multiple reac-
tion monitoring (MRM) analysis according to previously pub-
lished protocols[19] with the following modifications. Volumes of
90 μL of 37.5 mm ammonium bicarbonate solution and 12.5 μL
of sodium deoxycholate solution (10% w/v in 25 mm ammo-
nium bicarbonate) were added to 10 μL of serum from each pa-
tient. Proteins in these diluted serum solutions were reduced
for 30 min at 60 °C with 50 mm tris(2-carboxyethyl)phosphine
(dissolved in 25 mm ammonium bicarbonate; 3.11 μL). Reduced
plasma proteins were alkylated for 30 min at 37 °C in the dark
with 100 mm iodoacetamide solution (dissolved in 25 mm am-
monium bicarbonate; 3.5 μL). Then, a 100 mm dithiothreitol so-
lution (DTT, dissolved in 25mm ammoniumbicarbonate; 3.5μL)
was added and after 30 min a trypsin solution (Promega, Madi-
son, WI, 0.4 μg μL−1 dissolved in 25 mm ammonium bicarbon-
ate; 2.5 μL) was added. The mixtures were incubated for 16 h at
37 °C. Peptide mixtures were acidified by adding 5 μL of 30%
v/v formic acid to stop digestion. The sodium deoxycholate pre-
cipitate was removed by centrifugation (10 min at 12 000 × g).
Sample supernatants containing the “NAT peptides” were trans-
ferred into fresh tubes.
To 15 μL of the peptide solution (supernatant) were added
10 μL of stable isotope-labeled standard (SIS) peptide solution
(each of the SIS peptides was concentrated to 4 pmol μL−1;
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cf.[19]) and 775 μL of 0.1% v/v formic acid. The SIS peptide panel
was composed of 17 SIS peptides which were quantotypic for
15 plasma proteins. The average post-synthetic purity for the
17 peptides was 92.0%, as was revealed by capillary zone elec-
trophoresis. In this study, an equimolar SIS peptide mixture (at
250 fmol μL−1) was used. This mixture was prepared from
the combination of individual peptide stocks (14 μL, each at
100 pmol μL−1) and 30% acetonitrile/0.1% formic acid (4.9 mL).
The concentrated stock was stored as lyophilized aliquots at
−80 °C until use.
Such prepared peptide mixtures (800 μL each) were desalted
and concentrated prior to MS analysis by solid phase extrac-
tion using Waters Oasis reversed-phase 10-mg HLB cartridges
(Waters, Milford, MA) following the manufacturer’s recom-
mended protocol. Peptides were eluted from the C-18 mate-
rial with 200 μL of 50% v/v acetonitrile, 0.1% v/v formic acid.
The eluted peptide mixtures were either frozen at −80 °C and
lyophilized to dryness for shipping or immediately subjected to
LC-MRM/MS analysis.
LC-MRM/MS Instrumentation and Measurement Conditions:
Prior to LC-MRM/MS analysis, peptides from each patient-
derived sample were either redissolved in 400μL 0.1% v/v formic
acid/2% v/v acetonitrile, or taken directly from sample work-up.
A volume of 10 μL from the peptide mixture solutions was in-
jected for each MRM analysis. Peptide separations and MRM
analyses were performed as described previously.[20] RP-UHPLC
was performed on a Zorbax Eclipse Plus C18 Rapid Resolution
HD column (150 × 2.1 mm, 1.8 μm particles; Agilent Technolo-
gies; Palo Alto, CA, USA). The column and autosampler were
maintained at 50 °C and 4 °C, respectively. The peptide mixtures
were separated using a 43 min ACN gradient from 3 to 90% mo-
bile phase B (composition: 0.1% FA in 90% ACN) at a flow rate
of 0.4 mL min−1. The specific gradient employed was as follows
(time, % B): 0, 3; 1.5, 7; 16, 15; 18, 15.3; 33, 25; 38, 45; 39, 90; 42.9,
90; and 43, 3. Each analysis was followed by a 4min column equi-
libration. To reduce carryover, a blank injection of mobile phase
A (composition: 0.1% FA) was run between each type of sample
(i.e., buffer vs plasma in interference screening), and between dif-
ferent concentration levels of the standard when determining the
calibration curve. The 1290 Infinity LC system was interfaced to
a 6490 triple quadrupole mass spectrometer (both Agilent Tech-
nologies) via a standard-flow ESI source that was operated in the
positive ion mode. The general MS parameters were identical to
those previously published.[21]
MRMData Processing: To generate the “full analysis set” (FAS)
MRM data were processed and visualized with MassHunter
Quantitative and Qualitative Analysis software (version B.05.00;
Agilent Technologies) using the Agilent integrator algorithm
for peak integration, as described previously.[21] Peaks were first
manually inspected to determine the accuracy of peak selection
and integration, before peak (i.e., retention time, peak width,
signal response) and quantitative information (including limits
of quantitation, and dynamic range) were extracted. The “best”
interference-free transition of one “native” (NAT) peptide, that
is, the one with the most intense MRM signal, was used for
protein quantitation. Interference assessment was performed
in serum through signal-intensity ratio measurements on the
NAT and SIS peptide transition. For protein quantitation, seven-
point standard curves were prepared with a 1/x2 weighting. By
substituting the measured relative response (RR) into the
peptide-specific equation and solving for NATconc, the concen-
tration of an endogenous plasma protein (in fmol μL−1) was
calculated: NATconc = (SISconc × m)/(RR−b). Protein concen-
trations in ng mL−1 were calculated using the protein’s molec-
ular mass (in g mol−1; obtained from ExPASy’s “pI/Mw tool”
[http://web.expasy.org/compute_pi/]), the peptide´s relative re-
sponse (NAT/SIS), the corrected SIS peptide concentration (i.e.,
corrected with the purity values as determined by amino acid
analysis and CZE), and a conversion factor (of 1000).[22] In cases
where multiple peptides were quantified for a given protein, that
is, apolipoprotein D, the one that provided the highest protein
concentration was used as the quantifier to finally constellate the
“per protocol set” (PPS).
Biostatistical Analyses: Sensitivity and specificity as well as
receiver operator characteristics (ROC) and Youden indices
(J = sensitivity + specificity − 1)[23] were calculated using the
IBM statistics software SPSS (version 20.0, SPSS Inc., Chicago,
USA) (Table S2, Supporting Information). Linear interpolation[24]
between each pair of two neighboring concentration values
was used to calculate “test cutoff” values. Then, sensitivity and
specificity[25] were calculated for each of the biostatistical estima-
tions at each “test cutoff” point. Logistic regression analysis[26]
was performed using the Origin statistics software (version.
8.1 G; Originlab Corporation, Northampton, MA, USA). Power
analysis was conducted using the G*Power software (version
3.1, University of Düsseldorf).[27] A type I error (α) of 0.05
and a type II error (β) of 0.20 was chosen to compare the
two means. The required power (1−β error probability) was
0.80.
ELISA Assay for Apolipoprotein B100: A commercially avail-
able ELISA test kit (Human Apolipoprotein B, MABTECH AB,
Nacka Strand, Sweden) was used in order to quantitatively an-
alyze apolipoprotein B100 expression in maternal sera. All mea-
surements were performed in duplicate. First, sera samples were
diluted 1:10 000 with dilution buffer. Diluted standard (100 μL),
assay background control, and patient samples were added to
the well plate and incubated at room temperature for 2 h. Af-
ter washing, 100 μL of the 1:1000 diluted solution that contained
the detection antibody “LDL-11-biotin” were added and incubated
at room temperature for 1 h. A subsequent washing step fol-
lowed by adding 100 μL of 1:1000 diluted “SA-HRP”-containing
solution. Incubation was allowed at room temperature for 1 h.
Again, wells were washed and color development was started by
adding 100 μL of “TMB substrate” solution. After 15 min of in-
cubation in the dark, reaction was stopped by adding 100 μL of
“Stop solution.” The absorbance was measured at 450 nm, using
the anthos 2010microplate reader (anthosMikrosystemeGmbH,
Friesoythe, Germany).
3. Results
3.1. Patient Cohorts, Sample Work-Up, and Protein
Concentration Determinations
The study was approved by the Ethics Committee of the RWTH
Aachen (EK 119/08). Written informed consent was obtained
from all 30 participating women. Of those, 15 delivered healthy
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Table 1. Clinical parameters and patient characteristics.
Parameter CTRL IUGR
n Mean 95% CI Min. Max. n Mean 95% CI Min. Max.
Maternal age [year]a) 15 31.7 28.3–33.9 24.2 40.0 15 30.4 26.9–34.0 19.1 41.5
Maternal pre-pregnancy BMI, [kg m−2] 15 23.7 20.8–26.6 17.6 35.7 15 24.2 22.4–26.1 19.9 31.9
Primiparity, [%] 15 27 n.a. n.a. n.a. 15 80 n.a. n.a. n.a.
Actual smoking status, [%] 15 20 n.a. n.a. n.a. 15 27 n.a. n.a. n.a.
Systolic blood pressure, [mmHg] 15 116.2 112.4–119.5 106 129 15 130.8 118.8–141.1 83 162
Diastolic blood pressure, [mmHg] 15 64.9 60.9–69.0 53 81 15 77.2 68.7–85.2 52 101
Gestational age at sampling, [weeks] 15 32.4 29.8–35.0 25 39.3 15 32.1 29.7–34.9 24 40.4
Gestational age at delivery, [weeks] 15 32.8 30.2–35.3 25 39.3 15 33.0 30.5–35.5 26.7 40.4
Mode of delivery, sectio caesarea, [%] 15 86.7 n.a. n.a. n.a. 15 100 n.a. n.a. n.a.
Fetal birth weight, [g] 15 2129 1584–2673 740 3895 15 1383 1005–1761 490 2665
Fetal birth weight percentile 15 50.7 40.8–60.5 25 85 15 4.0 2.5–5.5 1 9
Fetal gender, female, [%] 15 53.3 n.a. n.a. n.a. 15 53.3 n.a. n.a. n.a.
a)At the beginning of hospitalization (time point of sample collection); BMI, body mass index; CI, confidence interval; n.a., not applicable.
infants (control [CTRL]) with adequate for gestational age neona-
tal weight, that is, within the 10th and 90th percentile as com-
pared to the general population. Yet, 11 of them were born
preterm for various reasons (premature rupture of the mem-
brane, spontaneous onset of labor, vaginal bleeding). The other
15 women delivered infants that suffered from IUGR; 12 of them
needed mandatory preterm delivery. Of note, to obtain a homo-
geneous study group, the CTRL group was chosen on the ba-
sis to match for gestational age at blood sampling and infant
gender and to keep the maternal baseline characteristics similar
(Table 1).
Upon quantification of apolipoproteins and other proteins that
belong to the lipid transport system using LC-MRM/MS, the “full
analysis set“ (FAS) comprised in total 3060 protein concentration
data points (i.e., 17 SIS/NAT peptide tandems × 3 relative ratios
per peptide × 30 samples × 2 work-ups). After exclusion of data
that did not fulfill the quality criteria and upon removal of re-
dundancies, quantitation of 15 proteins was accomplished in all
30 serum samples for both independent work-ups. The final PPS
contained 900 protein concentration values (Table S3, Supporting
Information).
Of note, despite the two different sample work-up and trans-
port conditions (see Experimental Section, Supporting Informa-
tion) there were no significant differences in the determined
protein concentrations between first measurement (MS-1) and
second measurement (MS-2) data. The determined protein con-
centrations that were quantified by LC-MRM/MS in this sam-
ple set spanned over four orders of magnitude. The protein con-
centration of the most abundant protein was 7206.13 μg mL−1
for apolipoprotein B100 (in sample 9, MS-2), while that of the
least abundant protein was 4.92 μg mL−1 for apolipoprotein
a (in sample 14, MS-1). Data sets from each sample work-up
(MS-1 and MS-2) were submitted to independent biostatistical
data analysis, but in the following results from MS-1 are re-
ported, whereas data from MS-2 are placed in the Supporting
Information.
Figure 1. Box-and-whisker plots of apolipoprotein B100 concentrations
of LC-MRM/MS measurements (MS-1). The horizontal lines within the
boxes represent the medians; the small squares indicate the means. The
whiskers specify the 5th and 95th percentiles, and the crosses indicate
the 1st and 99th percentiles. IUGR, intrauterine growth restriction; CTRL,
control individuals. Sample sizes (n) and the p-value are given. The dashed
horizontal line marks the “best cutoff” value.
3.2. Biostatistical Data Analysis and Determination of
Apolipoprotein B100 as Best Suitable Marker Protein
Biostatistical evaluation focused on the search for the best dis-
criminating protein, that is, the protein with abundance differ-
ences by which one was able to decide whose mother´s fetus
suffered from IUGR or, alternatively, would fall into the CTRL
group. In a first screen, the respective protein concentration dis-
tributions of a given protein in each of the two groups (IUGR
vs CTRL) were subjected to t-test analysis and were visualized
by box-and-whisker plots, as is exemplified with MS-1 data for
apolipoprotein B100 (Figure 1 and Table S3, Supporting Informa-
tion). While this t-test analysis indicated that only apolipoprotein
B100 was capable to differentiate the two groups, that is, distin-
guish IUGR fromCTRL in a sufficientmanner, this analysis does
not allow to stratify individual patient samples.
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Table 2. Apolipoprotein B100 concentrations in peripheral maternal blood samples and Jmax determination.
Patient IDa) Clinical diagnosis Conc. [μg mL−1] Test cutoff Below cutoff Above cutoff TN FN FP TP Specificity Sensitivity Ja)
Min. 1354.99
18 IUGR 1355.99 1354.49 0 30 15 15 0 0 1.000 0.000 0.000
21 IUGR 1578.30 1467.14 1 29 15 14 0 1 1.000 0.067 0.067
14 CTRL 2144.52 1861.41 2 28 15 13 0 2 1.000 0.133 0.133
29 IUGR 2379.12 2261.82 3 27 14 13 1 2 0.933 0.133 0.067
27 IUGR 2583.01 2481.06 4 26 14 12 1 3 0.933 0.200 0.133
25 IUGR 2614.94 2598.97 5 25 14 11 1 4 0.933 0.267 0.200
30 IUGR 2653.02 2633.98 6 24 14 10 1 5 0.933 0.333 0.267
16 IUGR 2668.98 2661.00 7 23 14 9 1 6 0.933 0.400 0.333
24 IUGR 2727.94 2698.46 8 22 14 8 1 7 0.933 0.467 0.400
19 IUGR 2937.97 2832.95 9 21 14 7 1 8 0.933 0.533 0.467
28 IUGR 3095.18 3016.58 10 20 14 6 1 9 0.933 0.600 0.533
17 IUGR 3165.19 3130.19 11 19 14 5 1 10 0.933 0.667 0.600
10 CTRL 3210.64 3187.92 12 18 14 4 1 11 0.933 0.733 0.667
6 CTRL 3316.27 3263.45 13 17 13 4 2 11 0.867 0.733 0.600
20 IUGR 3416.99 3366.63 14 16 12 4 3 11 0.800 0.733 0.533
5 CTRL 3480.85 3448.92 15 15 12 3 3 12 0.800 0.800 0.600
23 IUGR 3703.17 3592.01 16 14 11 3 4 12 0.733 0.800 0.533
3 CTRL 3829.68 3766.42 17 13 11 2 4 13 0.733 0.867 0.600
2 CTRL 3876.35 3853.01 18 12 10 2 5 13 0.667 0.867 0.533
26 IUGR 3914.43 3895.39 19 11 9 2 6 13 0.600 0.867 0.467
1 CTRL 4001.63 3958.03 20 10 9 1 6 14 0.600 0.933 0.533
15 CTRL 4074.10 4037.86 21 9 8 1 7 14 0.533 0.933 0.467
7 CTRL 4225.17 4149.64 22 8 7 1 8 14 0.467 0.933 0.400
12 CTRL 4332.03 4278.60 23 7 6 1 9 14 0.400 0.933 0.333
22 IUGR 4510.13 4421.08 24 6 5 1 10 14 0.333 0.933 0.267
11 CTRL 5019.85 4764.99 25 5 5 0 10 15 0.333 1.000 0.333
4 CTRL 6574.81 5797.33 26 4 4 0 11 15 0.267 1.000 0.267
8 CTRL 6644.82 6609.82 27 3 3 0 12 15 0.200 1.000 0.200
13 CTRL 6921.18 6783.00 28 2 2 0 13 15 0.133 1.000 0.133
9 CTRL 7159.46 7040.32 29 1 1 0 14 15 0.067 1.000 0.067
Max. 7160.46 7159.96 30 0 0 0 15 15 0.000 1.000 0.000
a)Values from MS-1; b)Ranking according to apolipoprotein B100 protein concentration after adjoining theoretical min. and max. values; c)CTRL, control; FN, false negative;
FP, false positive; IUGR, intrauterine growth restriction; J, Youden index; TN, true negative; TP, true positive.
To determine which protein concentration from the tested
proteins should be used to classify individual patients as either
belonging to the IUGR or the CTRL group, a Youden index anal-
ysis was performed one by one for all 15 proteins (see Exper-
imental Section, Supporting Information). To select the “best
cutoff” value for discriminating IUGR from CTRL samples,[24]
all Jmax values were ranked (Table 2). For apolipoprotein B100, a
Jmax value of 0.67 which was obtained with the “best cutoff” value
at a concentration of 3187.92 μg mL−1 when using the MS-1 data
set (Table 3).
To evaluate the effectiveness of a discrimination test that is
based on maternal apolipoprotein B100 serum concentrations,
we performed logistic regression analysis using the individual
apolipoprotein serum concentrations. With an apolipoprotein
B100 concentration of 3188 μg mL−1 as the “best cutoff” value,
25 of the 30 patient samples were mapped to their correct clini-
cal classifications (Figure 2). Eleven out of the 15 samples from
mothers with fetuses suffering from IUGR were correctly placed
into the IUGR group, leaving just four false negative cases (#20,
#22, #23, #26). Similarly, 14 out of the 15 control cases were cor-
rectly placed in the CTRL group, leaving just one false-positive
case (#14).
Biostatistical evaluation of patient stratification based on
apolipoprotein B100 serum concentrations (Table 4) reached pos-
itive predictive values of 0.92 and 0.91, and negative predictive
values of 0.78 and 0.74 for MS-1 and MS-2, respectively. At the
“best cutoff” value for apolipoprotein B100, theAUCwas 0.86 and
0.88 forMS-1 andMS-2, respectively (Table 4 and Figure 3). Of all
15 proteins, the concentration of apolipoprotein B100 showed the
greatest accuracy in discriminating IUGR from CTRL samples.
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Table 3. Best cutoff values and areas under the curves for 15 proteins from 30 peripheral maternal serum samples.
Ranka) Protein name Optimal cutoff [μg mL−1]a) Sensitivitya) 1−Specificitya) Jmaxa) ROC [AUC]
1 Apolipoprotein B 100 3187.92 0.93 0.27 0.67 0.858
2 Apolipoprotein L1 474.94 0.87 0.53 0.33 0.684
3 Apolipoprotein C-I 172.23 0.47 0.67 0.40 0.667
4 Apolipoprotein F 55.08 0.60 0.13 0.47 0.667
5 Apolipoprotein M 214.90 0.60 0.20 0.40 0.651
6 Apolipoprotein IV 367.81 0.93 0.67 0.27 0.613
7 Apolipoprotein C-II 284.95 0.67 0.33 0.33 0.604
8 PON 1 399.84 0.93 0.73 0.20 0.591
9 Beta-2-glycoprotein I (apo H) 1318.86 0.33 0.07 0.27 0.587
10 Apolipoprotein A-II 786.78 0.47 0.13 0.33 0.573
11 Apolipoprotein E 380.71 0.73 0.47 0.27 0.573
12 Apolipoprotein C-III 107.34 0.80 0.53 0.27 0.569
13 LCAT 56.97 0.47 0.27 0.20 0.538
14 Apolipoprotein (a) 667.94 0.20 0.00 0.20 0.473
15 Apolipoprotein D 222.27 0.80 0.67 0.13 0.471
a)Using data fromMS-1; ranking according to ROC; b)Optimal cutoff concentration at maximum J; c)Calculated from individual concentrations of all 15 proteins with the SPSS
software package; d)J (Youden’s index) defines the maximum potential effectiveness of a biomarker. J = Sensitivity + Specificity − 1.
Figure 2. Logistic regression analysis of serum apolipoprotein B100 con-
centrations of LC-MRM/MSmeasurements. Individual concentrations are
assigned to CTRL (n = 15; top row) and IUGR (n = 15; bottom row) ac-
cording to clinical grouping (gold standard). The gray line marks the dis-
criminating threshold at 3168 μg mL−1. False positive and false negative
samples are labeled with numbers (numbering as in Table 1).
3.3. Safeguarding of Apolipoprotein B100 as Risk Prognosis
Marker
Power analysis indicated that the minimally required total sam-
ple size with all the apolipoprotein B100 protein concentrations
was 16 for the first measurement series (MS-1) and 14 for the
second (MS-2), which both were smaller than the actual number
of 30 serum samples. Additionally, the calculated actual power
of 0.80 suggested that the test was confidently representing sta-
tistical significance in discriminating IUGR cases from controls.
To exclude confounding results, that is, to verify that apolipopro-
tein B100 concentrations were not influenced by potential
biases that were associated with other clinical parameters, we per-
formed statistical comparisons, that is, linear regression analy-
ses. No significant correlations were found between apolipopro-
tein B100 serum concentrations and patient age (R2 = 0.002),
BMI before pregnancy (R2 = 0.015), parity (R2 = 0.053), sys-
tolic (R2 = 0.069) and diastolic blood pressure (R2 = 0.062),
proteinuria (R2 = 0.117) smoking status (R2 = 0.054), ges-
tational age at delivery (R2 = 0.039), and birth weight
(R2 = 0.153).
In ELISA analyses with the same 30 maternal serum
samples, the apolipoprotein B100 concentrations varied
approximately by a factor of six between individuals, ranging
from 432.42 μg mL−1 to 2616.58 μg mL−1 (Table S4, Supporting
Information). Box-and-whisker plots indicate that apolipoprotein
B100 levels are distinctly different between IUGR samples and
controls (p < 0.01) (Figure 4) and confirm the LC-MRM/MS data
which revealed that apolipoprotein B100 levels are decreased in
pregnancies which are complicated by IUGR as compared to
those of pregnant women with healthy fetuses.



















MS-1 11 1 14 4 0.73 0.93 0.07 0.27 0.92 0.78 0.86
MS-2 10 1 15 5 0.67 0.93 0.07 0.33 0.91 0.74 0.88
a)Based on apolipoprotein B100 serum concentrations; AUC, area under curve; ROC, receiver operator characteristics.
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Figure 3. Receiver operator characteristic (ROC) analysis of serum
apolipoprotein B100 concentrations from MS-1. Calculated area under
curve (AUC) is 0.86. The vertical solid line indicates the maximum
Youden’s index (Jmax), the hatched diagonal indicates the 0.5 value.
Figure 4. Box-and-whisker plots of apolipoprotein B100 concentrations of
ELISA measurements. The horizontal lines within the boxes represent the
medians; the small squares indicate the means. The whiskers specify the
5th and 95th percentiles, and the crosses indicate the 1st and 99th per-
centiles. IUGR, intrauterine growth restriction; CTRL, control individuals.
Sample sizes (n) and the p-value are given.
4. Discussion
IUGR is clinically diagnosed by a deceleration (crossing centiles)
of fetal growth velocity in serial antenatal sonographic measure-
ments of fetal biometry data[28] or by an estimated low fetal weight
in addition to signs of compromised fetal well-being (pathologi-
cal fetal cardiogram or resistance indices in Doppler sonographic
measurements, asymmetry, and/ or reduced amniotic fluid in-
dex in ultrasonographic examinations) in the second or third
trimester.[13] While sonography has been accepted as “gold stan-
dard” for determining IUGR by clinical means, its application
is limited to excellently equipped care centers,[1,29] asking for al-
ternative and easy to apply methods by which pregnant women
who are at risk for developing IUGR may be detected. Moreover,
up to 80% of IUGR fetuses remain undetected until delivery.[30]
Equally important, determination of the optimal time of deliv-
ery to avoid still birth on the one hand but to not increase in-
fant prematurity-associated complications on the other hand, is
still challenging. Recently, two seminal studies reported inclu-
sion of maternal placental growth factor (PlGF) measurements
into pregnancy management when IUGR was suspected and
showed beneficial outcome when the obstetrician´s decision was
guided by those results.[31] In another study, low PlGF concen-
trations were associated with lower perinatal mortality and birth
weight <3rd centile but appeared to lead to earlier delivery with
more neonatal respiratory morbidity.[32] These studies underline
the need for biomarkers to better predict adverse pregnancy out-
come as well as to optimize determination of the best time point
for delivery.
The study cohort described here encompassed serum sam-
ples from pregnant women that previously were investigated
in both our primary study on fetal cord blood proteome
profiling[2] and our recently published study of maternal periph-
eral blood apolipoprotein CII and CIII proteoform abundances.[9]
In both studies, differentiation of serum samples into IUGR
and CTRL was achieved with great confidence for which rea-
son this well-studied cohort represented an excellent sample
set for the assessment of novel discriminatory methods per-
formed here that provide great potential for future clinical
application.
MRM tandem-mass spectrometry (MS/MS) enables reliable
and fast quantitation of specific proteins in a given sample by an-
alyzing precursor ions and their fragment ions in a very accurate
way. Instrumentation and software have advanced such that am-
ple transitions (pairs of primary and secondary peptide/fragment
ions) can be measured by well-designed scheduling and selec-
tion of respective m/z windows. Software packages have been
developed for the most important analysis components, such as
project management, assay development, assay validation, data
export, peak integration, quality assessment, and biostatistical
analysis that enable researchers to combine these tools for a com-
prehensive targeted proteomics workflow.[33]
Apolipoprotein B100, which has been identified as best dis-
criminating protein between IUGR and CTRL in this study, is the
main structural protein in atherogenic particles and represents
the total amount of potentially atherogenic circulating lipopro-
teins, including LDL, intermediate density lipoprotein, very low-
density lipoprotein and lipoprotein (a).[34–37] The apolipoprotein
B100 containing chylomicrons can contain large amounts of
cholesterol and triglycerides and also serve as carrier of essential
lipids such as lipophilic vitamins and glycolipids.[38] The impor-
tance of apolipoprotein B containing lipoprotein secretion is evi-
dent in the liver and intestine, where both apo B andmicrosomal
triglyceride transfer protein are needed to export large amounts
of lipids for usage in peripheral tissues.[39,40] Two main isoforms
of apo B exist: apolipoproteins B100 and B48. Apolipoprotein
B100 is synthesized in the liver and represents the circulating apo
B particles.[37,41] Furthermore, the placenta is capable of secreting
apo B particles.[40] Indeed, low apo B levels, as seen in our study
in the majority of IUGR cases, may reflect insufficient placental
function. This means that apo B levels could be directly related
to placental pathology and may be involved in the estimation of
individual pathophysiology.
The potential of apolipoprotein B, togetherwith apolipoprotein
A1, to function as marker of lipoprotein metabolism has been
discussed.[42] Apo A1, the major structural protein component
of high-density lipoprotein (HDL) particles, exhibits pleiotropic
biological functions and also provides anti-inflammatory prop-
erties. These functions include the inhibition of LDL oxidation
and scavenging toxic phospholipids.[37] The apo B100/apo A1
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ratio—in most cases determined by immuno-analytical assays—
has been proposed as a reliable parameter to reflect lipid distur-
bances and was attributed to correlate with the potential to de-
velop atherosclerosis.[34] Moreover, the apo B100/apoA1 ratio was
suggested to predict cardiovascular risk better than any choles-
terol index.[36] In our study, we neither investigated apo A1 values
nor determined apo B100/apo A1 ratios, because apo A1 was not
part of our SIS peptide panel. Nevertheless, our results indicate
that apolipoprotein B100 abundance by itself is good enough to
distinguish between pregnant women whose fetuses suffer from
IUGR and those that are not affected by pregnancy complications
(CTRL).
We previously had outlined the fact that (apo B-containing)
LDL particles reflected by LDL-cholesterol measurements were
not altered in PE, unless there was substantial placental dys-
function, the latter of which was reflected by the presence
of IUGR.[14,43] This finding is in agreement with a recent
study in which apo B levels in PE were found to be un-
changed but apo A1 levels were low.[37] As a result, apo
B/apo A1 ratios were increased in PE. Yet, other studies,
however, showed contradicting results when they focused on
cases in which most fetuses born to mothers with PE were
small for gestational age, and hence, with great certainty suf-
fered from IUGR.[44] While this has not been taken into
account by the authors, the need of excellent clinical character-
ization of the study collective and sufficient subgroup analyses
in heterogeneous diseases is obvious. A recent meta-analysis of
74 studies found that PEwas additionally associated with elevated
total cholesterol and non-HDL-cholesterol in the third trimester,
suggesting that pure PE is rather associated with increased apo
B-containing LDL-particles.[45] Noteworthy, plasma cholesterol
concentrations in the newborns from our cohorts (IUGR and
CTRL) are markedly reduced compared to those of the mothers
(Table S5, Supporting Information), which is in agreement with
previously reviewed results.[46]
The results described here fromMS-1 andMS-2 are nearly the
same and they also demonstrate that sample shipment of serum
proteins can be done on both the processed peptide level (results
fromMS-1) and the intact protein level (results fromMS-2). Since
serumprotein compositionsmay artificially be altered depending
on sample handling and storage conditions,[47] this is not a trivial
result. Yet, due to its gentleness on protein integrity, lyophyliza-
tion has been assumed as a useful method to prepare long lasting
samples[48] that do not require freezing temperatures and expen-
sive maintenance of an uninterrupted cold chain.
We found in this study that apolipoprotein B100 is de-
creased in women whose pregnancies are complicated by IUGR
as compared to pregnant women with healthy fetuses. Other
studies[14,43,44,49] confirmed that there are lower maternal serum
LDL-C and TC concentrations in IUGR pregnancies. These data
contribute to the hypothesis of a decreased cholesterol supply to
the fetus in IUGR. One possible explanation for a diminished
apolipoprotein B100 level in maternal serum is that the reduced
maternal LDL cholesterol concentration in IUGR pregnancies
is attributed to increased accumulation of oxidized LDL parti-
cles within the placenta.[50] With this causal connection of mater-
nal apolipoprotein B100 serum levels to IUGR, the assessment
performed here underlines the potential of LC-MRM/MS to be-
come of clinical importance in the future.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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Supplemental Table 1: Demographic data. Individual clinical and laboratory parameters for all patients and control individuals. 


















































1 24 20 2 27+0 109 / 53 0
f
 20 27+4  sectio caesarea 1355 85 m 
2 37 23 2 27+1 108 / 65 0
f
 0 27+4  sectio caesarea 1095 40 m 
3 30 22 0 25+0 114 / 61 0
f
 0 25+0  vaginal 740 30 m 
4 30 20 1 31+2 124 / 69 0
f
 0 33+6  sectio caesarea 1960 25 f 
5 29 21 0 32+0 114 / 71 150 0 32+1  sectio caesarea  1920 50 m 
6 24 35 0 31+6 129 /73 0
f
 10 31+6  vaginal 1750 50 f 
7 32 22 0 37+4 126 / 63 0
f
 0 37+4  sectio caesarea  3130 50 f 
8 31 25 1 37+5 121 / 75 0
f
 0 37+5  sectio caesarea 3465 70 m 
9 35 21 1 33+6 122 / 58 0
f
 0 34+6  sectio caesarea 2420 40 f 
10 37 19 1 38+6 120 / 60 0
f
 0 39+0  sectio caesarea 3150 30 f 
11 39 20 1 36+0 110 / 60 0
f
 0 36+0  sectio caesarea 2920 60 m 
12 32 25 2 32+3 110 / 70 0
f
 0 32+3  sectio caesarea 1850 50 f 
13 29 24 1 27+5 106 / 61 0
f
 0 28+4  sectio caesarea 1250 60 f 
14 24 17 1 28+0 110 / 54 0
f
 5 28+0  sectio caesarea 1030 40 f 
15 24 35 1 39+2 120 / 81 0
f
 0 39+2  sectio caesarea 3895 80 m 
16 31 22 0 31+0 129 / 76 90 0 32+1  sectio caesarea 1255 9 f 
17 23 23 0 30+5 125 / 71 101 10 30+5  sectio caesarea 940 4 f 
18 33 31 0 24+0 155 / 100 2324 10 26+5  sectio caesarea 650 4 m 
19 25 26 0 37+3 83 / 52 0
f
 0 37+5  sectio caesarea 2550 5 m 
20 39 27 0 28+2 148 / 92 300 0 28+2  sectio caesarea 850 8 m 
21 34 19 0 32+0 136 / 71 0
f
 0 32+1  sectio caesarea 1310 8 m 
22 23 21 0 35+5 162 / 100 500 0 35+5  sectio caesarea 1330 1 f 
23 27 22 0 32+6 130 / 68 150 0 33+2  sectio caesarea 1405 6 f 
24 19 23 0 35+5 116 / 64 0
f
 10 36+1  sectio caesarea 1870 2 m 
25 27 28 3 27+0 112 / 55 0
f
 0 27+0  sectio caesarea 580 3 f 
26 31 20 1 38+6 100 / 60 0
f
 0 39+0  sectio caesarea 1970 1 f 
27 34 23 2 26+4 140 / 90 1725 0 26+6  sectio caesarea 490 1 m 
28 25 22 0 33+6 122 / 79 0
f
 3 36+4  sectio caesarea 1905 3 f 
29 37 22 0 40+3 150 / 80 0
f
 0 40+3  sectio caesarea 2665 2 m 
30 41 28 0 30+2 155 /101 200 0 32+0  sectio caesarea 975 3 f 
a) at beginning of hospitalization (time point of sample collection)    b) systolic/diastolic blood pressure 
c) immunoturbidimetric assay (Tina-quant albumin; Roche Diagnostics. Mannheim. Germany); proteinuria is defined as urinary protein excretion >300 mg/L. 
d) dip stick assay; significant proteinuria is present with readings of more than +1 (max: +3). e) cigarettes per day  f)   gestational weeks at time point of delivery. 
Supplemental Table 2: Best cutoff values and areas under the curves for 15 proteins from 30 peripheral maternal serum samples of 
second measurement a). 
 
rank protein name optimal cutoff (µg/mL) b) sensitivity c) 1-specificity c) J max. d) ROC (AUC) 
1 apolipoprotein B 100 3256.09 0.93 0.20 0.73 0.876 
2 apolipoprotein L1 533.83 0.60 0.13 0.47 0.702 
3 apolipoprotein C-I 177.71 0.40 0.07 0.33 0.622 
4 apolipoprotein F  37.48 0.80 0.53 0.27 0.658 
5 apolipoprotein M 195.36 0.73 0.27 0.47 0.662 
6 apolipoprotein IV 418.12 0.87 0.60 0.27 0.629 
7 apolipoprotein C-II 324.41 0.40 0.13 0.27 0.604 
8 PON 1 552.07 0.60 0.33 0.27 0.591 
9 beta-2-glycoprotein I (Apo H) 1134.54 0.53 0.20 0.33 0.604 
10 apolipoprotein A-II 817.01 0.40 0.20 0.20 0.556 
11 apolipoprotein E 386.98 0.67 0.40 0.27 0.604 
12 apolipoprotein C-III 102.67 0.80 0.60 0.20 0.547 
13 LCAT 66.43 0.20 0.13 0.07 0.447 
14 apolipoprotein (a) 362.26 0.27 0.13 0.13 0.440 
15 apolipoprotein D 185.71 0.87 0.73 0.13 0.460 
a) ranking according to ROC. 
b) optimal cut-off concentration at maximum J. 
c) calculated from individual concentrations of all 15 proteins with the SPSS software package. 
d) J (Youden’s index) defines the maximum potential effectiveness of a biomarker. J = Sensitivity + Specificity - 1. 
 
Supplemental Table 3: Per Protocol Set: Concentrations of 15 proteins in 30 maternal serum samples determined by LC-MRM/MS analysis.
protein UniProt Acc. No. protein MW (Da) 
apolipoprotein (a) P08519 498944.46
apolipoprotein AII P02652 8706.91
apolipoprotein AIV P06727 43376.26
apolipoprotein B100 P04114 512834.66
apolipoprotein CI P02654 6630.58
apolipoprotein CII P02655 8914.93
apolipoprotein CIII P02656 8764.68
apolipoprotein D P05090 19298.08
apolipoprotein E P02649 34235.72
apolipoprotein F
 b) Q13790 31495.72
apolipoprotein L1 O14791 41128.72
apolipoprotein M O95445 21247.32
LCAT P04180 47077.93
PON 1 P27169 39597.14
beta-2-glycoprotein I P02749 36232.58
(apo H)
a)     Vertical line indicates position of bond breakage
b)     Values mentioned belong to apolipoprotein with propeptide
c)     Numbering according to Supplemental Table 1.
Supplemental Table 3: Per Protocol Set: Concentrations of 15 proteins in 30 maternal serum samples determined by LC-MRM/MS analysis.
selected peptide 
a) transition [m/z] run
(precursor -> fragment) avg. (μg/ml)
LFLE|PTQADIALLK (2+) 786.46 -> 1069.63 (y10) MS-1 195.75
MS-2 190.34
S|PELQAEAK (2+) 486.75 -> 443.24 (y8) MS-1 735.81
MS-2 738.76
SLA|PYAQDTQEK (2+) 675.83 -> 540.25 (y9) MS-1 516.46
MS-2 509.46
FP|EVDVLTK (2+) 524.29 -> 803.45 (y7) MS-1 4587.42
MS-2 4643.1
T|PDVSSALDK (2+) 516.76 -> 466.24 (y9) MS-1 158.69
MS-2 157.51
TA|AQNLYEK (2+) 519.27 -> 865.44 (y7) MS-1 326.55
MS-2 329.05
GWV|TDGFSSLK (2+) 598.80 -> 854.43 (y8) MS-1 131.05
MS-2 130.45
VL|NQELR (2+) 436.25 -> 659.35 (y5) MS-1 275.94
MS-2 276.01
LG|PLVEQGR (2+) 484.78 -> 399.73 (y7) MS-1 423.68
MS-2 437.37
SGVQQL|IQYYQDQK (3+) 566.62 -> 613.33 (b6) MS-1 108.2
MS-2 98.51
VTE|PISAESGEQVER (2+) 815.90 -> 651.32 (y12) MS-1 582.95
MS-2 582.15
AF|LLTPR (2+) 409.25 -> 599.39 (y5) MS-1 216.81
MS-2 216.03
SSGLVSNA|PGVQIR (2+) 692.88 -> 669.40 (y6) MS-1 53.23
MS-2 50.99
IQ|NILTEEPK (2+) 592.83 -> 943.51 (y8) MS-1 534.34
MS-2 533.44




std. dev. avg. (μg/ml) std. dev. p value 1 2
181.33 485.64 908.53 0.24 54.12 257.09
172.55 618.9 1423.86 0.26 40.59 281.69
180.55 681.52 161.57 0.39 798.15 835.75
184.19 673.11 175.1 0.33 793.49 908.05
180.28 592.79 168.78 0.24 677.70 585.71
176.26 598.57 178.63 0.18 731.90 502.55
1535.71 2886.96 818.06 <0,01 4001.63 3876.35
1544.14 2863.86 795.69 <0,01 4133.05 4050.76
46.89 134.77 37.23 0.13 159.27 196.79
46.08 137.5 35 0.19 151.34 200.66
165.96 277.72 70.36 0.30 206.59 416.28
172.14 276.56 72.78 0.29 224.53 371.86
39.33 124.04 50.68 0.68 112.60 156.96
38.04 124.51 50.65 0.72 119.66 153.11
87.88 284.46 101.77 0.81 286.23 372.97
91.16 284.3 106.49 0.82 289.12 381.97
129.5 393.83 127.77 0.53 261.52 426.98
129.39 392.73 133.28 0.48 259.34 466.94
43.31 85.17 22.28 0.08 134.81 176.81
39.46 78.88 25.36 0.12 105.31 149.35
141.24 491.78 99.05 0.05 531.50 441.08
123.26 484.18 101.85 0.02 466.10 413.96
54.91 190.74 35.69 0.13 147.97 228.72
58.17 189.29 36.13 0.14 145.51 231.67
10 52.49 12.12 0.86 57.01 49.67
12.51 55.43 14.45 0.38 38.93 73.26
153.15 596.58 197.02 0.34 558.72 525.31
156.8 591.86 194.3 0.37 545.15 542.29
250.96 1078.65 355.99 0.56 1225.66 1151.52
200.91 1081.62 338.55 0.60 1138.29 1098.37
controls (n=15) IUGR (n=15)
3 4 5 6 7 8 9
98.41 239.87 541.24 95.95 632.26 243.56 11.07
107.02 239.87 532.63 95.95 579.37 220.19 19.68
885.20 843.84 533.18 731.61 564.68 849.20 1129.18
898.40 840.04 536.24 631.73 584.73 917.02 1131.47
367.65 563.67 454.00 711.24 472.21 499.25 336.88
329.22 513.31 442.50 774.49 405.98 544.61 333.37
3829.68 6574.81 3480.85 3316.27 4225.17 6644.82 7159.46
3824.76 6319.33 3364.17 3302.76 4300.10 6961.71 7206.13
177.63 179.51 119.86 176.62 148.15 198.14 268.83
184.58 183.47 122.89 181.17 138.21 205.57 261.72
299.76 305.94 162.10 289.26 334.96 448.54 810.59
320.83 278.57 157.80 303.44 346.82 465.54 836.25
117.75 178.47 85.87 191.59 110.63 149.81 161.48
127.91 175.58 84.93 196.09 111.30 144.90 161.92
322.47 176.62 217.34 374.52 98.84 391.41 314.07
326.91 161.45 211.99 353.71 107.20 386.15 298.47
430.70 396.55 186.64 582.21 416.18 554.65 623.85
440.58 359.04 184.95 599.95 425.23 562.51 603.66
206.52 116.01 117.39 99.92 52.15 132.81 80.90
169.62 122.19 112.20 78.27 47.64 160.34 74.18
479.11 746.45 614.07 684.86 542.66 743.39 801.54
493.96 641.92 644.62 743.51 558.12 769.52 697.01
217.21 254.47 139.13 223.18 143.55 268.22 356.55
212.23 258.54 134.78 221.07 135.69 258.33 363.28
62.89 51.69 47.00 53.06 31.86 66.56 61.69
50.68 50.59 39.11 49.76 37.64 63.90 69.68
809.74 396.38 493.75 621.94 318.58 855.15 604.03
852.94 383.55 467.17 617.04 333.62 829.40 620.46
1475.41 1220.74 798.50 1419.32 827.36 1168.11 1016.96
1254.79 1015.58 819.59 1427.62 943.59 1191.27 1135.87
(μg/ml)
10 11 12 13 14 15 16
199.27 105.79 201.73 210.34 4.92 40.59 36.90
174.67 98.41 206.65 221.42 8.61 28.29 27.06
591.90 651.99 473.11 920.27 686.45 542.62 744.68
573.73 616.86 466.69 855.86 709.38 617.67 793.98
829.75 597.53 211.03 350.08 764.37 325.81 636.50
744.57 585.82 210.39 374.79 747.02 408.75 616.27
3210.64 5019.85 4332.03 6921.18 2144.52 4074.10 2668.98
3393.65 4926.50 4386.07 7037.86 2146.98 4292.73 2715.66
130.42 101.01 79.32 144.72 117.33 182.79 156.25
125.89 99.96 85.54 135.54 123.97 162.14 156.22
329.52 356.68 117.23 267.85 151.72 401.24 259.52
320.81 371.26 111.84 262.17 149.04 414.96 266.16
122.83 127.91 61.73 174.21 68.78 145.14 177.70
120.96 125.74 64.16 169.01 70.08 131.47 170.48
335.91 337.51 195.88 161.36 264.13 289.85 358.19
361.12 365.95 184.20 163.17 247.41 301.36 361.38
436.94 510.76 568.75 386.32 261.38 311.72 502.14
415.76 498.56 581.23 390.03 263.06 359.74 447.45
52.74 114.54 81.11 113.00 71.50 72.80 97.58
41.45 95.82 84.29 108.65 60.59 67.78 83.83
767.68 478.50 487.45 478.50 326.11 621.31 416.66
735.17 468.07 534.32 474.08 428.07 663.76 396.29
231.03 225.56 184.52 200.16 197.15 234.68 170.35
239.52 231.88 174.00 197.29 197.78 238.82 176.24
58.48 43.15 48.20 66.56 40.76 59.86 38.01
66.47 38.65 39.02 58.11 39.94 49.12 47.65
556.41 373.49 456.28 383.00 448.16 614.18 592.96
529.46 388.63 443.45 377.65 436.44 634.40 613.08
1424.16 818.98 894.42 1487.85 1330.05 925.19 665.24
1500.56 935.82 959.58 1248.13 1391.84 969.52 737.06
17 18 19 20 21 22 23
98.41 113.17 121.78 24.60 78.73 2231.38 45.51
78.73 5350.87 97.18 27.06 81.19 2210.46 51.66
840.64 411.87 345.19 654.15 775.41 677.04 972.05
879.63 400.45 338.53 619.49 738.79 634.52 954.52
596.14 788.22 442.93 367.97 690.48 490.63 717.21
597.85 786.52 427.49 396.19 657.15 484.88 744.57
3165.19 1355.99 2937.97 3416.99 1578.30 4510.13 3703.17
3209.41 1470.21 2939.20 3209.41 1456.70 4271.85 3563.15
222.28 77.58 103.61 128.21 151.25 165.84 167.84
217.04 81.01 106.90 134.13 132.56 174.25 163.59
336.18 280.64 275.03 272.82 245.56 413.70 258.04
337.99 285.08 258.11 318.07 275.54 336.16 290.36
236.62 126.44 104.04 129.50 99.08 156.09 177.53
234.81 141.56 114.79 123.84 94.03 151.40 183.29
269.73 285.46 182.18 278.69 269.39 330.91 566.69
260.47 298.47 187.22 269.13 273.44 328.89 593.41
541.19 375.10 356.59 331.77 354.06 339.62 437.29
593.43 360.86 341.44 330.44 372.29 341.58 424.11
75.35 135.31 85.67 99.21 114.04 93.11 66.32
67.61 119.06 84.87 102.26 107.86 93.48 44.51
568.80 560.58 447.58 529.54 491.01 471.38 490.89
533.34 524.26 474.94 488.80 477.64 399.97 484.39
267.59 235.03 187.11 178.13 184.59 155.47 124.32
275.73 239.45 183.89 173.92 183.75 152.18 124.81
56.92 71.98 32.87 62.34 40.03 44.16 54.07
59.86 56.74 44.99 77.85 38.93 58.30 46.55
594.80 671.03 403.30 918.74 555.21 420.93 500.02
565.27 688.75 396.75 894.00 558.99 416.50 502.98
1307.67 2080.68 975.05 1284.51 524.90 1037.53 1078.92
1141.75 2052.16 847.41 1118.42 559.38 1073.22 1108.48
24 25 26 27 28 29 30
17.22 3051.84 703.61 46.74 455.13 216.50 43.05
20.91 9.84 578.14 47.97 442.83 223.88 35.67
708.00 761.42 755.91 495.34 769.32 657.35 654.38
727.38 859.99 736.38 448.37 605.85 659.06 699.73
954.75 578.90 514.05 312.93 449.11 672.70 679.30
1037.16 569.31 495.00 344.12 459.01 656.52 706.56
2727.94 2614.94 3914.43 2583.01 3095.18 2379.12 2653.02
2600.20 2602.66 4147.79 2686.18 3079.22 2304.19 2702.15
103.38 137.23 94.27 122.82 137.07 97.25 156.72
102.53 141.52 112.53 130.54 145.92 98.47 165.35
196.68 205.61 136.97 315.85 353.05 257.80 358.33
180.93 198.95 127.40 268.66 410.86 233.60 360.48
46.64 92.65 66.76 75.69 141.89 80.50 149.50
48.20 85.31 69.09 76.10 150.65 77.52 146.51
165.93 227.20 246.98 344.79 237.24 351.94 151.63
153.09 220.39 261.24 321.09 238.62 340.91 156.75
208.44 189.09 437.50 405.67 524.08 251.28 653.58
212.23 191.76 415.90 383.93 549.11 255.98 670.48
80.19 95.86 77.73 46.59 78.65 54.24 77.73
66.70 119.56 68.45 38.57 59.30 59.47 67.70
459.11 642.53 347.46 497.15 704.13 385.25 364.64
496.90 655.91 304.64 521.07 703.02 425.00 376.54
176.24 234.75 178.06 162.28 212.58 197.15 197.43
177.64 223.18 180.52 163.89 205.22 193.43 185.50
43.98 76.47 51.78 52.70 60.04 47.28 54.81
57.10 87.68 38.47 64.45 48.01 38.56 66.38
611.78 1025.52 455.54 292.93 487.84 605.60 812.51
602.83 1016.29 464.86 292.65 466.98 588.44 809.56
1058.53 1233.44 942.73 714.07 1169.49 1047.64 1059.31
1133.20 1422.09 967.96 827.54 1122.74 980.32 1132.59










1 1304.50 5.30 0.41 
2 1224.08 18.86 1.54 
3 1147.42 60.10 5.24 
4 1980.33 19.45 0.98 
5 2292.00 10.02 0.44 
6 1292.83 7.66 0.59 
7 1308.67 18.27 1.40 
8 2051.17 77.19 3.76 
9 2616.58 4.71 0.18 
10 1306.58 45.96 3.52 
11 1702.00 8.84 0.52 
12 1885.33 66.59 3.53 
13 2349.92 4.71 0.20 
14 715.75 30.64 4.28 
15 2365.75 2.36 0.10 
16 1404.92 60.10 4.28 
17 1224.08 10.61 0.87 
18 819.50 46.55 5.68 
19 1501.58 68.35 4.55 
20 1555.75 57.75 3.71 
21 614.92 31.82 5.17 
22 1909.92 27.11 1.42 
23 1230.33 35.94 2.92 
24 953.67 71.30 7.48 
25 2164.08 3.02 0.14 
26 764.08 2.76 0.36 
27 1347.83 8.84 0.66 
28 922.00 37.12 4.03 
29 668.67 44.19 6.61 
30 432.42 15.32 3.54 
a) duplicate measurements 
b) n.d.: not determined 
 
























1 122 55 222 180 
 
40 29 91 30 
2 141 95 261 144 
 
56 50 113 25 
3 124 85 252 175 
 
30 33 70 26 
4 171 64 294 419 
 
17 21 47 14 
5 150 74 248 100 
 
29 26 63 1 
6 131 86 233 126 
 
44 33 81 9 
7 169 80 293 296 
 
27 39 75 19 
8 232 95 397 298 
 
18 30 59 10 
9 206 88 375 433 
 
26 41 78 21 
10 130 83 254 128 
 
17 47 77 14 
11 178 67 292 275 
 
21 29 59 15 
12 162 56 254 235 
 
21 43 60 15 
13 162 44 249 296 
 
26 29 62 12 
14 65 57 151 120 
 
60 26 95 24 
15 157 63 257 193 
 
14 19 41 15 
16 91 108 236 157 
 
29 11 62 49 
17 89 108 231 302 
 
37 26 68 24 
18 70 49 151 271 
 
8 27 37 7 
19 155 51 248 191 
 
13 11 36 45 
20 112 77 272 144 
 
2 4 19 49 
21 50 90 154 107 
 
20 23 53 26 
22 198 65 330 223 
 
7 9 42 70 
23 119 56 214 245 
 
7 7 62 192 
24 84 77 175 107 
 
19 9 38 29 
25 110 109 245 148 
 
38 13 62 48 
26 102 56 203 256 
 
20 23 54 17 
27 142 74 236 112 
 
36 12 72 64 
28 111 54 211 278 
 
20 17 52 44 
29 105 71 231 187 
 
10 13 45 149 
30 82 67 216 262 
 
18 13 39 34 
a) Blinded analysis of serum triglycerides, cholesterol, LDL-C and HDL-C was performed by colorimetric enzymatic methods using an automated photometric measuring unit 
(Roche/Hitachi Modular P800, Roche Diagnostics, Basel, Switzerland; triglycerides GPO-PAP reagent, cholesterol CHOD-PAP reagent, LDL-C plus 2nd generation reagent, HDL-C plus 
3rd generation reagent, Cobas®, Roche/Hitachi, Mannheim, Germany). Measurement ranges were: TG=4–1000 mg/dL, cholesterol=3–800 mg/dL, LDL-C=3–550 mg/dL, and HDL-C=3– 
120 mg/dL. 
Supplemental Materials and Methods 
 
Patient cohorts and sample work-up 
In addition to an estimated fetal weight below the 10th percentile, one of the following criteria 
had to be fulfilled to be classified IUGR: (1) deceleration of fetal growth velocity during the last 4 
weeks, (2) elevated resistance index in umbilical artery Doppler sonography above the 95th 
percentile or absent or reversed end-diastolic blood flow, (3) fetal asymmetry (head to 
abdominal circumference ratio above the 95th percentile), or (4) oligohydramnions (Amniotic 
Fluid Index < 5 cm). Gestational age was established on the basis of the last menstrual period 
and was confirmed by ultrasonic examination between the 10th and the 14th week of gestation. 
Patients with one of the following criteria were excluded from the trial: multiple gestation, fetal 
anomalies, abnormal fetal karyotype, patients with clinical or biochemical sighs of infection, 
positive TORCH screening results, maternal diabetes mellitus/gestational diabetes, or other 
severe maternal metabolic disorders, and patient’s withdrawal from the study. Peripheral blood 
was antenatally collected on average 3.7 days ahead of birth (Supplemental Table 1). It needs 
to be mentioned that the first serum sample work-up for MRM analysis was done at the 
Proteome Center Rostock, Germany. SIS peptide mixtures were prepared at the UVic Genome 
BC Proteomics Centre, Canada, and sent by post to the Proteome Center Rostock, Germany. 
The lyophilized peptide mixtures (containing NAT and SIS peptides) were transported at room 
temperature to the UVic Genome BC Proteomics Centre, Canada, for re-solubilization and 
subsequent LC-MRM/MS analysis (MS-1). By contrast, the second serum sample work-up was 
performed at the UVic Genome BC Proteomics Centre, Canada. For this, 10 µl of each serum 
sample were lyophilized at the Proteome Center Rostock, Germany, and dried proteins were 
transported at room temperature to the UVic Genome BC Proteomics Centre, Canada, where 
they were then re-solubilized and worked-up on site, and immediately subjected to LC-MRM/MS 
analysis (MS-2). 
 
Youden Index Analysis 
The procedure is explained using apolipoprotein B100 as example. First, all 30 patient samples 
were ranked according to their experimentally determined apolipoprotein B100 concentrations 
(Table 2). Then two theoretical concentration values were added. The first theoretical 
concentration was determined by subtracting the value “1” from the lowest concentration and 
the second by adding the value “1” to the highest concentration. These two additional 
concentration values were added at the top and at the bottom of the protein concentration list, 
respectively. Then, “test cut-off” values were determined and with each “test cut-off” value it was 
assessed how many of the samples had protein concentration values below this “test cut-off” 
value and how many had protein concentration values above that value. Next, it was 
determined which of the samples were true positives (TP) and which were false positives (FP) 
by labeling the samples according to clinical assessment data (the "gold standard"). At each 
“test cut-off” value the Youden index was determined. The highest J value (J max) in the list of 
samples determined the best discrimination threshold concentration, i.e., the “best cut-off” value 
within the samples within this data set. This procedure was repeated for all 15 proteins for both, 
MS-1 and MS-2 data. Ultimately, this process generated 30 tables, in each of which the J max 
value for the respective protein was indicated (Table 3, Supplemental Table 2). 
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Abstract: Fetal growth restriction (FGR) affects about 3% to 8% of pregnancies, leading to higher 
perinatal mortality and morbidity. Current strategies for detecting fetal growth impairment are 
based on ultrasound inspections. However, antenatal detection rates are insufficient and critical in 
countries with substandard care. To overcome difficulties with detection and to better discriminate 
between high risk FGR and low risk small for gestational age (SGA) fetuses, we investigated the 
suitability of risk assessment based on the analysis of a recently developed proteome profile 
derived from maternal serum in different study groups. Maternal serum, collected at around 31 
weeks of gestation, was analyzed in 30 FGR, 15 SGA, and 30 control (CTRL) pregnant women who 
delivered between 31 and 40 weeks of gestation. From the 75 pregnant women of this study, 2 were 
excluded because of deficient raw data and 2 patients could not be grouped due to indeterminate 
results. Consistency between proteome profile and sonography results was obtained for 59 patients 
(26 true positive and 33 true negative). Of the proteome profiling 12 contrarious grouped 
individuals, 3 were false negative and 9 were false positive cases with respect to ultrasound data. 
Both true positive and false positive grouping transfer the respective patients to closer surveillance 
and thorough pregnancy management. Accuracy of the test is considered high with an 
area-under-curve value of 0.88 in receiver-operator-characteristics analysis. Proteome profiling by 
affinity—mass spectrometry during pregnancy provides a reliable method for risk assessment of 
impaired development in fetuses and consumes just minute volumes of maternal peripheral blood. 
In addition to clinical testing proteome profiling by affinity-mass spectrometry may improve risk 
assessment, referring pregnant women to specialists early, thereby improving perinatal outcomes. 
Keywords: FGR; SGA; Proteome profiling; Affinity-MS; Pregnancy complications; Apolipoproteins 
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1. Introduction 
Fetal Growth Restriction (FGR) is a pregnancy condition in which the fetus does not reach its 
genetically given growth potential. It is a major cause of fetal and neonatal morbidity and mortality, 
affecting about 3% to 8% of all pregnancies [1–3]. Clinically, FGR needs to be distinguished from 
constitutionally small for gestational age (SGA) fetuses, which represent “physiological smallness” 
and hence, are not of the same clinical concern. The current standard of detection of FGR and 
differentiation from SGA is based on ultrasound examinations [1,3,4]. Once identified, FGR 
pregnancies need intense observation and should be transferred to perinatal specialists to enhance 
surveillance and if necessary, induce labor to avoid intra-uterine death while balancing against the 
risk of prematurity. 
Antenatal diagnosis has proven to reduce adverse perinatal outcomes and allows for proper 
and timely referral of the neonate to intensive care [5–7]. However, antenatal detection rates still are 
sparse and range at about 20–50%, even in high-income countries [8,9]. FGR diagnosis is often made 
by observation of fetal growth velocity, which can only be confirmed with significant delay in serial 
ultrasound measurements which are usually timed at least two weeks apart. Most important, the 
need for ultrasound equipment and highly trained ultrasound specialists limits routine screening for 
FGR/SGA in pregnant women in many countries, especially in low-income countries [2]. In recent 
studies, maternal serological biomarkers have been suggested to improve FGR detection rates. 
Among other biomarkers, soluble Fms-like thyrosinkinase-1 (sFlt-1) and placental growth factor 
(PlGF) were applied in concert with ultrasound biometry and maternal risk factor estimations to 
predict FGR outcome [10], indicating that molecular diagnosis improved clinical screening results. 
In our recently published proteome profiling studies, using affinity—mass spectrometry with 
serum from cord blood as well as from maternal peripheral venous blood, we identified 
apolipoprotein C-II and apolipoprotein CIII protein species as potential candidates from neonates 
and from pregnant women to differentiate between FGR and CTRL. By use of five candidate 
proteins, we developed a proteome-based scoring system for the detection of FGR with high 
confidence [7,11]. However, owing to the aim of our former study to analyze changes in maternal 
and fetal blood in parallel, the control (CTRL) cohort contained individuals who gave birth 
prematurely for other reasons than FGR to match the FGR cohort for gestational age. This cohort 
matching limited interpretation and generalization of the data.  
In the present study, we aim at validating in different clinical scenarios the FGR-specific 
affinity—mass spectrometry-based serum proteome profiling procedure, which we developed [7,11–
14]. For this purpose, we challenged the FGR proteome profile by supplementation of our previous 
cohorts (FGR II and CTRL II) with three further cohorts: 15 patients with severe early onset FGR 
requiring early delivery before 34 weeks of gestation (FGR I), 15 individuals with uncomplicated 
pregnancies who gave birth near term (CTRL I) but blood was sampled at similar gestational ages as 
with cohort FGR I, and 15 donors with otherwise uncomplicated pregnancies, i.e., without features 
of FGR, classified as SGA by antenatal sonography (SGA I). 
2. Materials and Methods 
2.1. Patient and Control Individual Cohorts 
The study was approved by the Ethics Committee of the Rheinisch-Westfälisch Technische 
Hochschule (RWTH) Aachen, Germany (EK 138/06, EK 119/08, EK 154/11). Written informed 
consent was obtained from all participating women. At time of inclusion in the study, sonographic 
examinations were done to classify patients into study cohorts using Logiq 5 or Voluson 730 Expert 
Ultrasound Systems (GE Healthcare Systems, Solingen, Germany). The regression equation 
including biparietal diameter, femur length, as well as head and abdominal circumferences, 
proposed by Hadlock et al. [15], was used to estimate fetal weight. Fetal and neonatal birth weight 
percentiles were determined according to the population-based newborn weight charts, as described 
previously [16]. FGR was defined in accordance with national and international guidelines [3], as 
described earlier [7,11–13,16]. In addition to having an estimated fetal weight below the 10th 
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percentile, one of the following criteria had to be fulfilled: (i) deceleration of fetal growth velocity 
during the last 4 weeks, (ii) elevated resistance index in umbilical artery Doppler sonography above 
the 95th percentile or absent or reversed end-diastolic blood flow (ARED), (iii) fetal asymmetry 
(head to abdominal circumference ratio above the 95th percentile), or (iv) oligohydramnios 
(amniotic fluid index <5 cm). Neonatal weight was assessed post-partum to verify the diagnosis 
(<10th percentile). Healthy pregnant women with estimated antenatal fetal weight below the 10th 
percentile and confirmed fetal growth along their percentiles for more than 4 weeks and otherwise 
normal sonographic findings were classified into the SGA group. Patients with one of the following 
criteria were excluded from the trial: multiple gestation, fetal anomalies, abnormal fetal karyotype, 
patients with clinical or biochemical signs of infection, positive TORCH (Toxoplasmosis, Other 
(syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus, and Herpes) screening 
results, maternal diabetes mellitus/gestational diabetes, other severe maternal metabolic disorders, 
and patients’ withdrawal from the study, as was done previously [7,11–13,17]. The CTRL groups 
were chosen to best match to the FGR groups for clinical parameters, such as gestational age at blood 
sampling, BMI, parity, smoking status, and fetal sex. A part of the CTRL group, cohort CTRL II 
(patient numbers 151–165), n = 15, and a part of the FGR group, cohort FGR II (patient numbers 351–
365), n = 15), have already been analyzed previously [7] and were included again for further 
developing the method. Then, 45 serum samples from other individuals were added to validate the 
established FGR proteome profile. Of those, 15 were from individuals with uncomplicated 
pregnancies with an estimated fetal weight adequate for gestational age; these were referred to as 
the CTRL I cohort (patient numbers 101–115). Another 15 blood samples were from patients with 
otherwise uncomplicated pregnancies carrying SGA fetuses; these were referred to as the SGA I 
cohort (patient numbers 201–215). The third group of 15 individuals with pregnancies with 
confirmed FGR fetus are referred to as the FGR I cohort (patient numbers 301–315) (Table 1 and 
Supplemental Table S1).  
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Table 1. Summarized or averaged demographic data as well as clinical and laboratory parameters for all patients and control individuals. 
Parameter 
CTRL I (101–115) i CTRL II (151–165) j FGR I (301–315) i FGR II (351–365) j SGA I (201–215) i 
n Mean 95% CI Min. Max. n Mean 95% CI Min. Max. n Mean 95% CI Min. Max. n Mean 95% CI Min. Max. n Mean 95% CI Min. Max. 
Mat. Age (years) a 15 29.4 26.5–32.3 21.5 39.2 15 30.5 27.7–33.3 24.2 39.0 15 28.1 25.1-31.1 22.0 41.8 15 30.4 26.8-34.0 19.1 41.5 15 28.9 24.9–32.8 17.6 40.2 
Mat. BMI, (kg/m2) b 15 22.8 21.7–23.9 19.5 26.9 15 23.3 20.4–26.2 17.6 35.7 15 22.2 20.6–23.9 18.0 28.9 15 24.2 22.4–26.1 19.9 31.9 15 22.4 20.6–24.3 16.2 28.1 
Primiparity, (%) 15 100.0 n.a. n.a. n.a. 15 80.0 n.a. n.a. n.a. 15 93.3 n.a. n.a. n.a. 15 86.7 n.a. n.a. n.a. 15 86.7 n.a. n.a. n.a. 
Smoking Status, (%) 15 20.0 n.a. n.a. n.a. 15 20.0 n.a. n.a. n.a. 15 46.7 n.a. n.a. n.a. 15 26.7 n.a. n.a. n.a. 15 26.7 n.a. n.a. n.a. 
Systolic bp, (mmHg) c 15 115.6 
109.2–
122.0 
99 135 15 116.2 
121.1–
120.3 
106 129 15 120.4 
113.6–
127.2 
96 139 15 130.9 
118.6–
143.1 




Diastolic bp, (mmHg) c 15 68.9 63.1–74.6 54 87 15 64.9 60.5–69.4 53 81 15 69.1 63.6–74.5 52 82 15 77.3 68.2–86.3 52 101 15 66.3 60.2–72.3 45 84 
ga at sample, (weeks) d 15 29.4 28.3–30.5 25.7 32.6 15 32.4 29.8–35.0 25 39.3 15 29.6 28.3–30.9 25.4 33.9 15 32.3 29.7–34.9 24 40.4 15 31.0 29.3–32.7 22.9 34.6 
ga at delivery, (weeks) d 15 39.6 38.9–40.3 37.4 41.6 15 32.8 30.2–35.3 25 39.3 15 30.5 29.2–31.8 25.9 34.1 15 33.0 30.5–35.5 26.7 40.4 15 38.1 37.4–38.8 36.1 40.7 
Δt (days) e 15 71.3 62.7–79.8 50 105 15 2.7 0.01–5.3 0 18 15 6.3 2.1–10.6 0 31 15 4.7 0.95–8.4 0 19 15 49.9 37.1–62.8 22 105 
C-section, (%) f 15 20.0 n.a. n.a. n.a. 15 86.7 n.a. n.a. n.a. 15 100.0 n.a. n.a. n.a. 15 100.0 n.a. n.a. n.a. 15 66.7 n.a. n.a. n.a. 
Fetal Birth Weight, (g) 15 3399 
3232–
3565 
2960 3765 15 2129 
1584–
2673 
740 3895 15 1015 845–1185 495 1525 15 1383 
1005–
1761 




fbw Percentile g 15 47.1 37.5–56.8 14 70 15 50.7 40.8–60.5 25 85 15 5.2 3.8–6.6 2 9 15 4.0 2.5–5.5 1 9 15 4.5 3.2–5.7 1 9 
Female, (%) h 15 60.0 n.a. n.a. n.a. 15 53.3 n.a. n.a. n.a. 15 40.0 n.a. n.a. n.a. 15 53.3 n.a. n.a. n.a. 15 46.7 n.a. n.a. n.a. 
(a) mat: maternal age in years determined at the beginning of hospitalization (time point of blood sampling); n.a.: not applicable; (b) pre pregnancy BMI; (c) blood 
pressure; (d) gestational age; (e) time interval between sample collection and delivery; (f) c: caesarea, mode of delivery; (g) fbw: fetal birth weight; (h) fetal gender; (i) this 
study; (j) from [7]. 
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2.2. Blood Collection, Generation, and Storage of Peripheral Blood Serum 
Blood was taken at admission to Hospital without considering special fasting status. 
Gestational age was calculated from the time point of the last menstrual period and was verified by 
first trimester ultrasound scan documentation, which is offered routinely in the German Health 
System between the 10th and the 14th week of gestation (Table 1). Blood samples (up to 9 mL each) 
were taken antenatally from each individual from the right or left cubital vein using monovette 
syringes (Serum Z/9 mL; Monovette®, Sarstedt, Germany). After incubation at room temperature for 
15–30 min, samples were subjected to sedimentation of blood cells by centrifugation (Labofuge 400R, 
Fa. Heraeus Instruments, Waltham, MA, USA) at 2000 × g and at room temperature for 15 min [7,11–
14,17]. Serum was aspirated, divided into aliquots (100 µL each), and stored at −80 °C. Altogether, 
time between blood sample collection and storage of frozen serum aliquots averaged around less 
than 1 h. Frozen serum aliquots were shipped on dry ice to the Proteome Center Rostock. 
2.3. Protein Extract Preparation from Peripheral Blood Serum 
Serum protein solutions were prepared from frozen serum samples according to established 
protocols [7,11–14]. In brief, from each thawed serum aliquot, 5 µL were incubated with 10 µL 
MB-HIC8 “binding buffer” and 5 µL of MB-HIC8 bead slurry for 1 min (Profiling Kit 100 MB-HIC8; 
Bruker Daltonik, Bremen, Germany). After washing the beads three times with 100 µL of “wash 
buffer” each, proteins were eluted with 10 µL of “elution buffer”, consisting of a 50% ACN solution. 
The magnetic MB-HIC8 beads with their hydrophobic surfaces enriched apolipoproteins and 
depleted the most abundant serum proteins, albumin and IgG [7,11–13]. 
2.4. MALDI-ToF MS Profiling of Serum Proteins and Internal Calibration of Mass Spectra 
After extraction from the beads, serum protein-containing solutions (0.5 µL each) were spotted 
directly onto stainless steel MTP 384 target plates (Bruker Daltonik, Bremen, Germany) together 
with 0.5 µL ferulic acid solution (10 mg ferulic acid, SigmaAldrich, München, Germany) dissolved in 
330 µL ACN/0.1% aqueous TFA (33/67, v/v) as matrix. After drying, 0.5 µL ferulic acid solution was 
added to each sample spot again and was allowed to dry, as was done previously [7,11–13]. Protein 
solutions were spotted in duplicate for each patient/donor for recording the first independent set of 
measurement series MS1 and the second independent set of measurement series MS2 of the same 
protein extract preparation (Supplemental Table S2). Protein mixtures embedded in the crystallized 
matrix were analyzed with a Reflex III MALDI TOF mass spectrometer (Bruker Daltonik, Bremen, 
Germany), which was equipped with a SCOUT source for delayed extraction and was operated in 
linear positive ion mode using an acceleration voltage of 20 kV. Spectra were recorded in a mass 
range from 4 to 20 kDa, respectively, accumulating 900 shots per spectrum. Spectra were externally 
calibrated using a commercially available Protein Calibration Standard (Bruker Daltonik, Bremen, 
Germany). All mass spectra were internally recalibrated using average masses of ion signals at m/z 
6631.6 (singly charged and unmodified apolipoprotein C-I, Uniprot accession number P02654) and 
m/z 13762.4 (singly charged and unmodified transthyretin, Uniprot accession number P02766). Ion 
signal areas were determined with the ClinProTools™ 3.0 software (Bruker Daltronik, Bremen, 
Germany) using the parameters as described previously [7,11–14,18]. Independent measurement 
series MS1 and MS2 were recorded for protein samples from individuals belonging to cohorts CTRL 
I, SGA I, and FGR I (in total, 90 mass spectra (Supplemental Table S2)). From individuals belonging 
to cohorts CTRL II and FGR II, we recorded four measurement series, MS1, MS2, MS3, and MS4, as 
described previously [7]. In total, from 75 individuals, 210 mass spectra were recorded, to which is 
referred to as the “full analysis set (FAS)” (Scheme 1 and Supplemental Scheme S1). 
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Scheme 1. The use of individual samples and respective mass spectra. Mass spectra which were 
applied for training sets were not applied in test set analyses. FAS: full analysis set, PPS: per 
protocol set, “O“: training set “O”, “W“: training set “W”, out: individuals or mass spectra that were 
excluded, test: test set. 
The mass spectra of the serum proteins from patient 115 contained very strong ion signals at 
m/z 11527.0 and m/z 11683.5, corresponding to the protein serum amyloid A1 minus the N-terminal 
arginyl residue and to full-length serum amyloid A1, respectively [19–21]. These ion signals were 
absent in all other mass spectra, indicating that this individual’s blood protein composition was 
different from all the others, which was the reason for exclusion. On the other hand, the mass spectra 
of the serum proteins from patient 315 could not be mass calibrated by the analysis software, 
although they resembled those of the other patients quite well with respect to ion signal abundances 
and rough locations of ion signal groups (data not shown). Nevertheless, the mass spectra were 
excluded as well (Scheme 1 and Supplemental Scheme 1), leaving a “per protocol set (PPS)” of 73 
individuals (206 mass spectra). 
2.5. Raw Data Processing and Formation of Quotients from Ion Signal Areas 
After having determined the areas under each ion signal for each mass spectrum, we applied 
our established multi-parametric analysis procedure [7,11,18] in which the signal areas of five ion 
signals, those at m/z 8205, m/z 8766, m/z 8916, m/z 9422, and m/z 9713 (Supplemental Table S2), 
within each spectrum were brought into context to each other by forming quotients of ion signal 
areas. The signal area of the ion at m/z 8916 was divided by the signal area of the ion at m/z 8205 
from one and the same spectrum to produce a value for spectra assessment (quotient A) as the first 
assessment value. The signal area of the ion at m/z 8766 over the sum of the signal areas of the ions at 
m/z 9422 plus m/z 9713 were determined (quotient B) as the second assessment value. The signal 
area of the ion at m/z 8916 over the sum of the signal areas of the ions at m/z 8766 plus m/z 9422 plus 
m/z 9713 were determined (quotient C) as the third assessment value. This data processing 
procedure was applied individually for each of the spectra. 
2.6. Youden Index Analyses for Determining Cut-Off Values 
To determine “best cut-off” values for quotients A, B, and C (see Raw Data Processing) that 
can be used to classify an individual spectrum (patient) as either belonging to the FGR I or the 
CTRL I group, a Youden index analysis was performed [17,22,23]. The first independent 
measurement series MS1 from both the per protocol set (PPS) for CTRL I (n = 14) and FGR I (n = 14) 
were chosen as training set “O” (Scheme 1 and Supplemental Scheme S1). The procedure is 
explained with quotient A as an example. First, all 28 patient spectra from the PPS were ranked 
according to their quotient values (Supplemental Table S3). Then, two theoretical quotient A values 
were added. The first theoretical quotient A value was determined by subtracting the value “1” 
from the lowest quotient A value and the second by adding the value “1” to the highest quotient A 
value. These two additional quotient A values were added at the top and the bottom of the quotient 
A list, respectively. Next, linear interpolation [24] between each pair of two neighboring 
concentration values was used to determine the “test cut-off” values and with each “test cut-off” 
value, it was assessed how many of the samples had quotient A values below this “test cut-off” 
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value and how many had quotient A values above that value. Next, it was determined which of the 
samples were true positives (TP) and which were false positives (FP) by labeling spectra according 
to ultrasound assessment data (the "gold standard"). The sensitivity and specificity [25] were 
calculated for each “test cut-off” point. In addition, at each “test cut-off” value, the Youden index (J = 
sensitivity + specificity − 1) was determined [17,22,23]. The highest J value (Jmax) in the list of 
samples determined the best discrimination threshold for the quotient A values, i.e., the “best 
cut-off” value within the samples within this data set. This procedure was repeated for quotient B 
and quotient C values accordingly using data from the training set “O” (Supplemental Tables S4 
and S5). 
2.7. Cumulative Score Assignment 
The “cut-off” values of 4.2, 5.0, and 4.0 for quotients A, B, and C, respectively, obtained from 
training set “O” were combined with the “cut-off” values of 3.4, 7.0, and 5.1 for quotients A, B, and 
C, respectively, from our previous study (training set “W”) [7]. These combined “cut-off” values 
were then applied to the “validation” test set, which consisted of a second independent 
measurement series MS2 of the same CTRL I and FGR I sera plus the third and fourth measurement 
series, MS3 and MS4, of CTRL II and FGR II sera [7]. The following scoring rules were applied: when 
the quotient value of a specific spectrum (sample) was below or equal to the lower of the two 
“cut-off” values, a score of “0.0” was assigned. When the quotient value was above the lower of the 
two “cut-off” values but below or equal to the upper of the two “cut-off” values, a score of “0.5” 
was assigned. When the quotient value was above the upper of the two “cut-off” values, a score of 
“1.0” was assigned. This weighting procedure was applied independently to each of the three ion 
signal ratios A, B, and C for test set “development”. Then, the score values of each spectrum from all 
three ion signal ratios were summed up so that each spectrum (each sample) reached a cumulative 
score between “0.0” and “3.0”. 
2.8. Bioinformatic and Biostatistical Analysis 
Clinical and biometric data analysis was carried out using the “statistical analysis software, 
SAS”, version 9.1 (SAS Institute, Cary, NC, USA). Clinical data were evaluated by two-way ANOVA 
analysis of variance and expressed as mean and 95% confidence interval. Differences of serum 
parameters were tested for significance using the Mann-Whitney U test association analyses and 
Spearman's rank correlation (rho). Graphical representations, such as box-and-whisker plots [26], 
sensitivity, specificity, and area under the curve from the receiver operator characteristic (ROC) 
analysis, [27,28] were done using the Origin software (version. 8.1 G; OriginLab Corporation, 
Northampton, MA; USA). Quotient values A, B, and C of protein ion signal areas were graphically 
represented in heat maps. Hierarchical clustering was performed based on the complete linkage 
method and Spearman’s correlation coefficient as a measure of similarity. Signal intensities were 
centered and scaled row-wise for visualization purposes [7,13,29]. Unsupervised principle 
components analysis (PCA) was performed with quotient values A, B, and C of protein ion signal 
areas using MATLAB ver. 9.5.0 (R2018b), The MathWorks®, Inc., Natick, MA, USA [29,30]. The first 
two PCs were selected to project the data into a subspace, which is useful for visualization using the 
Origin software, and as input for a support vector machine algorithm (SVM). SVM was used to 
calculate the separation line for the classifier based on PCA projection. 
2.9. Power Analysis 
A power analysis was carried out [7,12–14] to evaluate the minimally required sample sizes that 
are needed to discriminate FGR from the CTRL and/or SGA individuals on the basis of the obtained 
data with the help of the G*Power statistical software (version 3.1.9.2, University of Düsseldorf) [31]. 
A type I error (α) of 0.05 and a type II error (β) of 0.20 were chosen in a comparison of two means. 
The minimally required power (1-β error probability) was 0.80. 
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3. Results 
3.1. Patient Cohorts and MALDI Mass Spectrometric Profiling 
The University Hospital Aachen is a tertiary care center with a high percentage of high-risk 
pregnancies. Between August 2006 and November 2011, women with singleton pregnancies 
attending the Department of Obstetrics and Gynecology for any reason between 24 and 40 weeks of 
gestation were asked to participate in a prospective observational study for biomarker development 
for the detection of FGR and preeclampsia. No specific situation was considered, however most of 
the patients were admitted to the outpatient clinic for routine checks or planning of birth or because 
of suspected preterm birth, suspected FGR, or suspected preeclampsia. Of the approximately 5000 
women who delivered at the University Hospital Aachen during the recruitment period, ca. 10% 
(531 individuals) agreed to participate in the study. Of those, 167 patients fell into the group of 
suspected pregnancies with fetal weight below the 10th percentile. In 95 patients, gestational age 
was 34 weeks and below. Finally, peripheral venous blood samples from 75 Caucasian singleton 
pregnancies were chosen from the biobank to be subjected to blood serum proteome analysis by 
affinity—mass spectrometry. 
Women with normal pregnancies (cohort CTRL I) delivered healthy infants with adequate for 
gestational age neonatal weight, i.e., within the 10th and 90th percentile at the expected gestational 
age of ca. 40 weeks, and hence, represented the general population. The mean time difference 
between blood sampling and delivery was 71 days. Eleven of the 15 women from cohort CTRL II 
delivered preterm for various reasons (premature rupture of the membrane, spontaneous onset of 
labor, vaginal bleeding). The mean time difference between blood sampling and delivery was 3 
days. From the FGR I cohort all 15 women and from the FGR II cohort, 13 out of 15 women needed 
mandatory preterm delivery for non-reassuring fetal well-being. The mean time difference between 
blood sampling and delivery was 5 and 6 days, respectively. The mean days SGA babies (cohort 
SGA I) were born after blood sampling was 50 days. Maternal age, BMI, and blood pressure did not 
differ significantly between groups, as indicated by the overlap of 95% CI. Most of the women in all 
groups were primiparous. Women within the newly added FGR I cohort were more likely to smoke. 
As per definition, birth-weight percentiles differed significantly between the FGR/SGA and CTRL 
groups, as indicated by the non-overlap of the 95% confidence interval (Table 1 and Supplemental 
Table S1). 
Following our standardized protocol for producing protein solutions out of blood samples, on 
average, about 60 protein ion signals were reproducibly recorded in each mass spectrum within a 
mass range of m/z 4000 to m/z 20000 (Figure 1). The most prominent ion signals were observed in 
the mass range between m/z 8000 and m/z 10000 (Figure 1, insert), correlating to singly charged 
(protonated) ion signals of small proteins. The ion signals of which their areas were used for 
bio-statistical analysis were, as in our previous study [7,11], from apolipoprotein CII (m/z 8205), 
pro-apolipoprotein CII (m/z 8916), apolipoprotein CIII0 (m/z 8766), apolipoprotein CIII1 (m/z 9422), 
and apolipoprotein CIII2 (m/z 9713).  
 
Figure 1. Affinity—MALDI-ToF mass spectrum of intact protein ions. Proteins are from maternal 
peripheral venous blood serum upon work-up with ClinProt® beads. Ion signals that are selected for 
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multi-parametric analysis are labeled with “*” (see insert). Ion signals that are used for internal 
re-calibration are marked with “#”. Ferulic acid is used as the matrix. 
The MALDI-ToF mass spectra from proteins of FGR, CTRL, and SGA serum samples displayed 
high similarities to each other, indicating that relative quantitative differential analysis of ion signal 
intensities, and of quotients thereof, was feasible. Exceptions were mass spectra from patients 115 
and 315, respectively. These were excluded from further analysis to leave a PPS with 206 mass 
spectra from 73 individuals (Scheme 1). 
3.2. Determination of “Best Cut-Off” Values for Quotients A, B, and C to Separate FGR from CTRL 
Areas of the five selected ion signals were determined and brought into context with each other 
following the previously introduced rules, thereby generating quotients A, B, and C. Then, “best 
cut-off” values for quotients A, B, and C were to be applied in our assay to assign a given mass 
spectrum (patient sample) to one of the clinical groups, i.e., FGR, SGA, or CTRL. However, because 
the serum protein composition of the CTRL I cohort was not yet investigated, we decided not to use 
the “best cut-off” values from our previous study [7], although quotients A, B, and C were 
determined in the same way as before, using the areas of the same ion signals as was done 
previously. Instead, we generated a training set “O”, which contained 14 mass spectra for CTRL I 
(series MS1) and 14 mass spectra for FGR I (series MS1) (Supplemental Table S2 and Supplemental 
Scheme S1). Jmax values indicated the “best cut-off” values of 4.2, 5.0, and 4.0 for quotients A, B, 
and C, respectively (Supplemental Tables 3–5). Next, the cumulative score for each mass spectrum 
was calculated according to previously established rules: a score of “1” was assigned to this 
respective spectrum (sample) when the quotient value of this specific spectrum (sample) was higher 
than the respective “best cut-off” value. In the contrary case, the score for this spectrum (sample) 
was set to “0”. These assessments were again independently carried out for each of the three ion 
signal ratios and for each spectrum. In sum, each sample reached a cumulative score between “0” 
and “3”, as was the case in our previous study [7]. 
Of note, the cumulative score discriminator was kept at 1.0, meaning a cumulative score below 
or equal to 1.0 assigned a given mass spectrum to the CTRL group and a cumulative score above 1.0 
to the FGR group. For training set “O”, the distribution of cumulative scores (Figure 2) revealed that 
one of the 14 FGR spectra were wrongly assigned to the CTRL group and one of the 14 CTRL spectra 
were wrongly placed in the FGR group. 
 
Figure 2. Distribution pattern of cumulative scores with training set “O”. Cumulative score values 
range between “0.0” and “3.0”. Spectra of training set “O” (first measurement series, MS1, of CTRL I 
and FGR I serum samples; n = 28) are represented. Green bars represent spectra of CTRL I (patients 
101–114) and red bars represent spectra of FGR I (patients 301–314, see Supplemental Table S2). 
Numbers in parentheses indicate numbers of spectra with the respective cumulative score. The 
vertical dashed line marks the cumulative score cut-off value which sorts the spectra, which is the 
respective samples, into either the FGR group (right) or the CTRL group (left). 
Accordingly, excellent bio-statistical results were obtained, i.e., sensitivity was 0.93 and 
specificity was 0.93. Hence, an area under curve (AUC) in the receiver-operator characteristics 
(ROC) analysis of 0.95 was reached (Table 2). The cumulative score distribution was applied for 
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power analysis investigations, which showed that the required minimal sample size was 3 FGR and 
3 CTRL mass spectra to reach a statistically meaningful separation of the two groups (Supplemental 
Table S6). 
Table 2. Summary of biostatistic evaluation of individual patients a. 




training “O”/CTRL I vs. FGR I 
(CTRL I, n = 14; FGR I, n = 14) b 
13 1 13 1 0.93 0.93 0.07 0.07 0.93 0.93 0.95 
2 
“development” test/CTRL I + II vs. 
FGR I + II 
(CTRL, I + II, n = 28; FGR I + II, n = 29) 
c 
26 6 22 3 0.90 0.79 0.21 0.10 0.81 0.88 0.88 
3 
“valid” test/CTRL I + II and SGA I 
vs. FGR I + II 
(CTRL I + II, n = 28; SGA I, n = 14; 
FGR I + II, n = 29) c 
26 9 33 3 0.90 0.79 0.21 0.10 0.74 0.92 0.88 
(a) cumulative score separator: > 1 = FGR; ≤ 1 = CTRL; (b) no. of mass spectra; Jmax determined 
cut-off values; c) no. of patients; combined cut-off values; TP: true positive; FP: false positive; TN: 
true negative; FN: false negative; sens: sensitivity; spec: specificity; FPR: false positive rate; FNR: 
false negative rate; PPV: positive predictive value; NPV: negative predictive value; ROC: receiver 
operating characteristic; AUC: area under the curve. 
3.3. Combination of “Best Cut-Off” Values and Weighting of Cumulative Scores for Separating FGR from 
CTRL 
Since the “best cut-off” values of 4.2, 5.0, and 4.0 for quotients A, B, and C, respectively, which 
were obtained in this study with training set “O”, were somewhat different from those “best 
cut-off” values of 3.4, 7.0, and 5.1 for quotients A, B, and C, respectively, from our previous study 
(training set “W”) [7], we decided to apply both sets of “best cut-off” values in combination when 
analyzing the test sets. The “development” test set (Supplemental Scheme S1) contained mass 
spectra from CTRL I (series MS2) and from FGR I (series MS2) as well as spectra from CTRL II (series 
MS3 and MS4) and from FGR II (series MS3 and MS4), summing up to 42 mass spectra for CTRL (28 
women) and 44 mass spectra for FGR (29 patients). The quotient value distributions were found to 
be distinctive, such that the values for quotients A, B, and C were generally higher in the FGR group 
as compared to those of the CTRL group (Figure 3). 
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Figure 3. Distribution of quotient values for selected ion intensity differences of the “development” 
test set. Quotient values distributions are shown as box and whisker plots (second measurement 
series, MS2, of CTRL I and FGR I plus third and fourth measurement series, MS3 and MS4, of CTRL 
II and FGR II serum samples, n = 86). (A) Signal area of the ion at m/z 8916 over the signal area of the 
ion at m/z 8205. (B) Signal area of the ion at m/z 8766 over the sum of the signal areas of ions at m/z 
9422 plus m/z 9713. (C) Signal area of the ion at m/z 8916 over the sum of signal areas of ions at m/z 
8766 plus m/z 9422 plus m/z 9713. The boxes represent the 25th–75th percentiles. The horizontal lines 
within the boxes represent the medians; the small squares indicate the means. The whiskers specify 
the 5th and 95th percentiles and the crosses indicate the 1st and 99th percentiles. Dashed lines mark 
selected cut-off values. Cut-off values for the quotients are (A) 3.4 and 4.2, (B) 5.0 and 7.0, (C) 4.0 and 
5.1. FGR, fetal growth restriction; CTRL, control individuals. 
Since the application of two “best cut-off” values per quotient generated three value regimes 
(below—in between—above), the score of a mass spectrum was assigned “0.0” when falling into the 
regime “below”, “0.5” when “in between”, and “1.0” when “above”. Accordingly, the cumulative 
score values of each spectrum, summed up from all three ion signal ratios, ranged between “0.0” 
and “3.0” with steps of 0.5. Keeping the cumulative score discriminator at 1.0, as was done above 
and in our previous studies, decided whether a given mass spectrum was assigned to the CTRL 
group or to the FGR group.  
Using quotient values A, B, and C from the “development” test set separated the FGR group (n 
= 44) from the CTRL group (n = 42) quite satisfactorily by hierarchical clustering (Figure 4), 
confirming that the ion signal abundances of five proteins were carrying the requested information 
for differentiating FGR from CTRL with good confidence. Duplicate measurements from FGR 
samples are clearly sorted to the FGR group (right) and control samples to the CTRL group (left), 
except for FGR samples 302, 304, 310, 312, and 364 (one measurement each), which are allocated to 
the CTRL group, and CTRL samples 151 (both measurements) and 164 (one measurement) are 
grouped to the FGR group. 
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Figure 4. Hierarchical clustering analysis with quotient values A, B, and C of protein ion signal areas 
of the “development” test set. This set contains the second measurement series, MS2, of CTRL I and 
FGR I plus the third and fourth measurement series, MS3 and MS4, of CTRL II and FGR II serum 
samples (n = 86). Quotients A to C are arranged from top to bottom. Color code for the quotient 
values; red: high values; brown: medium high; grey: medium low; green: low. Patient numbering is 
as in Supplemental Tables S1 and S2. 
Bio-statistic evaluation of the “development” test set performance revealed a false positive rate 
of 0.21 and a false negative rate of 0.10. Hence, an area under curve (AUC) in the receiver-operator 
characteristics (ROC) analysis of 0.88 was reached (Table 2). The cumulative score distribution was 
applied for power analysis investigations, which showed that the required minimal sample size was 
9 FGR and 9 CTRL mass spectra to reach a statistically meaningful separation of the two groups 
(Supplemental Table S6). 
3.4. Application of “Weighted Cumulative Scores” for Separating FGR from CTRL and from SGA 
Encouraged by the separation power with which pregnant women whose fetuses suffered from 
FGR could be distinguished from CTRL individuals whose pregnancies were unaffected, solely 
based on ion signal abundances of serum proteins as recorded in MALDI mass spectra, we 
generated a “validation” test set (Scheme 1 and Supplemental Scheme S1) which contained 118 mass 
spectra from three different patient/donor groups (73 individuals). Because of indeterminate results, 
4 mass spectra (patients 155 and 213) were excluded, leaving 114 mass spectra (71 individuals) for 
the biostatistics analysis. The FGR group contained 44 mass spectra (29 patients), 14 from cohort 
FGR I (series MS2) and 30 from cohort FGR II (series MS3 and MS4). The CTRL group contained 42 
mass spectra (28 individuals), 14 from cohort CTRL I (series MS2) and 28 from cohort CTRL II (series 
MS3 and MS4). The SGA group contained 28 mass spectra (series MS 1 and MS2) from cohort SGA I 
(14 patients). The analysis procedure followed what was described above for the “development” test 
set and started with determining the quotient values A, B, and C, respectively. 
Subjecting the quotient values (in total, 342 values) to Principal Component Analysis (PCA) 
afforded two well separated clusters. The first and second centered PCs of the quotient data yielded 
48.6% (PC1) and 27.5% (PC2) of the total variances, respectively. The decision boundary, which was 
obtained from the SVM classifier, separated both clusters with the exceptions of FGR samples 301 
and 302, which were placed on the CTRL side. Likewise, CTRL sample 164 was placed on the FGR 
side. It should be mentioned that SGA individuals clustered with the CTRL donors and, hence, were 
separated from FGR patients with good confidence (Figure 5). 
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Figure 5. Principle component analysis with quotient values A, B, and C of protein ion signal areas of 
the “validation” test set. This set contains measurement series MS2 of cohorts CTRL I and FGR I plus 
measurement series MS3 and MS4 of cohorts CTRL II and FGR II, in addition to measurement series 
MS1 and MS2 of cohort SGA I serum samples (n = 114) which represent 71 individuals. Locations of 
mass spectra derived positioning from FGR samples are shown as red triangles, locations of CTRL 
samples as green squares, and SGA patients as blue circles (filled symbols). The curved line indicates 
the decision boundary obtained from the support vector machine (SVM) algorithm classifier. 
In agreement with the obtained PCA results, good separation was achieved with the 
cumulative score discriminator of 1.0 as well. From the 71 individuals (114 mass spectra) of the 
“validation” test set, 59 were assigned correctly (26 TP and 33 TN), i.e., their grouping stood in 
agreement with the clinical assignment which served as the “gold standard”. The positive predictive 
value was 0.74 and the negative predictive value 0.92, hence an area under curve (AUC) in the 
receiver-operator characteristics (ROC) analysis of 0.88 was reached (Table 2). The cumulative score 
distribution was applied for power analysis investigations, which showed that the required minimal 
sample size was 5 FGR and 5 CTRL/SGA mass spectra to reach a statistically meaningful separation 
of the two groups (Supplemental Table S6). 
4. Discussion 
The aim of the present study was to establish a blood-based biomarker test to detect FGR and to 
distinguish from constitutional SGA that is robust, simple, and easily available and may be added to 
current clinical practice to improve detection rates. The study took advantage of an existing biobank 
in which patients with suspected SGA/FGR and CTRL were included and well characterized by 
antenatal ultrasound inspection. Maternal serum proteins were analyzed by affinity mass 
spectrometry at the time point of admission to hospital. Our test discriminated between FGR and 
SGA as well as pregnancies unaffected by FGR, i.e., CTRL, with good confidence. The use of two 
cut-off values for each quotient of ion signal areas opened three value regimes: below—in 
between—above cut-offs. Despite differing from rather routinely used two value regimes 
(below—above cut-offs) for separation of samples/individuals, separation of FGR from CTRL/SGA 
was successfully employed. Examples of other clinical studies in which it was found that a three 
value regime was suitable for fulfilling the task to separate two conditions are “early risk prognosis 
of free-flap transplant failure”, “MGMT promoter methylation for selecting glioblastoma patients 
into trials omitting Temozolomide”, and “diagnostic criteria for high-dimensional metabolic data in 
newborn screening for medium-chain acyl-CoA dehydrogenase deficiency” [22,32,33], but also with 
sFlt-1/PlGF ratio (<38 and >85) [34,35] and PlGF measurements alone to predict still-birth FGR (<12 
and >100) [36]. 
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Our study is limited by the small sample size. Moreover, a selection bias of samples taken from 
the biobank cannot be excluded. Selection of suitable control groups for “case-control” clinical 
studies is very important and sometimes critical for the distinguishing ability of the assay [37,38]. 
Since it is known that maternal blood protein compositions change in complexity and abundance 
with advancing gestational age [39–41], such reasoning becomes critical with any blood 
protein-based assay that shall find application in pregnant women. Adaptation of cut-off values 
depending on gestational age has already found application in point-of-care diagnostics, which is 
based on abundance ratios of molecular markers found in maternal blood [42]. 
Strengths of our study are the well characterized patient cohorts and the application of 
multiparametric mass spectrometry measurements. A combination of marker proteins, i.e., 
angionenic factors and acute-phase proteins in serum samples, was found to yield in good 
discrimination of HELLP and preeclampsia from control [43]. The need for accumulating markers 
for screening purposes sooner or later may request to move away from immunoanalytical assays, 
such as ELISAs, and orient towards screening systems with inherent multiplexing capabilities. 
Affinity—mass spectrometry, as performed here, enables parallel analysis of dozens of proteins and 
accurate determination of relative protein abundances as well as ratios of, for example, differently 
modified protein species, which allow to differentiate varying glycosylation and other 
post-translational modifications simply by mass, but which may be difficult to detect and/or to 
differentiate by conventional antibody assays [18].  
Current state of the art FGR detection is based on ultrasound assessment. However, even in 
high-income countries, like Germany, in which antenatal ultrasound is offered most frequently and 
usually routinely more than 3 times during pregnancy, FGR detection rate ranges between about 20–
50% [8,9]. A high percentage of undetected cases lead to sub-standard care, stillbirth, and increased 
risk of perinatal mortality and morbidity. Moreover, diagnosis is often delayed because estimating 
fetal growth velocity needs to be performed at two different time points during pregnancy, which 
take place at least 14 days apart [44]. Diagnosis requires both availability of ultrasound equipment 
and ultrasound trained specialists [1,2,45]. Although stillbirth remains an important clinical issue for 
high-income countries, the majority of cases occur in low- and middle-income countries where 
ultrasound inspection is hardly available. Currently used clinical tests in these countries, such as 
measurement of symphysis-fundal height, may have even lower sensitivity and specificity for the 
identification of SGA infants—the primary step in diagnosing FGR—than ultrasound assessments 
[46]. Since ultrasound-based investigations obviously lack power, effort has been given to improve 
diagnosis, for example, by adding single marker proteins, such as PlGF-measurements, to standard 
care. The PELICAN trial aimed at evaluating the diagnostic accuracy of PlGF in women with 
suspected preeclampsia. They also challenged PlGF measurements for detecting SGA with birth 
weight below the 1st percentile. Using a PlGF cut-off below the 5th percentile for gestational age 
sensitivity ranged between 0.91 to 0.93, and specificity between 0.51 and 0.53 (before or after 35 
weeks of gestation, respectively), resulting in a high degree of false positive classified patients [47]. 
Similarly, Benton et al. challenged PlGF measurements in 219 patients with antenatally suspected 
FGR defined as a fetal abdominal circumference (AC) <10th percentile for gestational age on 
ultrasound. In their cohorts from Canada, New Zealand, and the United Kingdom, which also 
included samples of the PELICAN trial, they found a sensitivity of 0.98 and a specificity of 0.75 for 
the antenatal identification of FGR using the 5th percentile of PlGF as a cut-off. They also 
highlighted that PlGF levels correlate with the degree of placental pathology in these patients [48]. 
Likewise, the addition of sFlt-1 to PlGF measurement has been suggested for the detection of 
high-risk pregnancies. An sFlt-1/PlGF ratio below 38 has been proven to be capable for ruling out 
pathologic pregnancies like preeclampsia [34,35]. In FGR pregnancies, sFlt-1/PlGF ratios are 
increased [34] and in a recent observational trial, Quezada et al. reported sFlt-1/PlGF ratios above 85 
in 75% of patients with diagnosed FGR [49]. In the study of Visan et al., the combination of 
sFLT1/PIGF ratio at a cut-off of 38 to ultrasound-based estimation of fetal weight <10th percentile led 
to an increase in sensitivity for the detection of FGR from 44.4% to 84.2%, with a change in specificity 
from 89% to 84.3%, with a false-positive rate of 10% [10]. 
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Similar to others, with our assay, we found a relatively higher rate (9 out of 71) of false positive 
classified patients with respect to ultrasound data (“gold standard”). A high false positive rate 
causes unnecessary anxiety of pregnant women and increases rates of intervention. Yet, time of 
uncertainty can be considered rather short (approximately 3–4 days) as in true positive cases, 
delivery is expected to take place rather soon after testing. Hence, if pregnancy continues for more 
than 5 days after testing, a repeated test may be scheduled to confirm or falsify the primary test 
result.  
Obviously, earlier confirmation of placental dysfunction in suspected fetal growth restriction 
has the potential to improve risk stratification and earlier access to targeted surveillance. More 
studies combining ultrasound and blood-borne biomarkers are needed to determine whether this 
approach improves diagnostic accuracy over the use of ultrasound estimation of fetal size or 
biochemical markers of placental dysfunction alone [50]. Our multiparametric affinity—mass 
spectrometry test may aid in screening and in decision-making processes, e.g., to refer patients to 
ultrasound specialists, especially in rural areas with sub-standard care.  
5. Conclusions 
In conclusion, we have developed an affinity—mass spectrometry-based biomarker test for the 
detection of FGR in pregnant women, which was challenged against the actual gold standard of 
antenatal ultrasound-based diagnosis. Our approach allows for a multi-marker-based screening in a 
single blood test, which has been proven to be robust and easy to perform and allows FGR risk 
assessment with high confidence. The combination of this blood test with clinical examination offers 
a promising means for better antenatal care, which shall be further evaluated in follow-up 
multi-centric studies. 
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Supplemental Scheme 1: The three disease / control groups are represented by five 
patient cohorts. Individuals for cohorts CTRL I, FGR I, and SGA I have been recruited 
for this study, whereas cohorts CTRL II and FGR II consisted of individuals which were 
included in a previous study as well  . The training sets “O” (this study) and “W” 
(from  ) were both used for determining cut-off values and the “development” test 
set for estimating assay performance. With the “validation” test set was investigated 
the assay´s capability to separate SGA from FGR in the presence of CTRL samples. 
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101 35.0 20.4 0 108 / 60 0 0 / 29 + 4 39 + 2 68 s.c. 3210 40 f
102 23.6 22.0 0 102 / 54 0 0 / 30 + 6 41 + 2 73 vaginal 3765 50 m
103 28.9 20.3 0 120 / 60 0 0 / 32 + 4 41 + 4 63 vaginal 3580 50 f
104 21.5 23.9 1 115 / 60 0 20 / 30 + 4 37 + 6 51 s.c. 3200 43 m
105 31.7 23.9 1 110 / 70 0 0 / 28 + 5 40 + 0 79 vaginal 3690 60 m
106 28.9 22.2 0 122 / 68 0 0 / 31 + 6 39 + 0 50 vaginal 3420 60 f
107 39.2 21.1 1 127 / 61 0 0 / 31 + 3 39 + 0 53 vaginal 3440 60 f
108 32.0 24.1 0 130 / 80 0 0 / 30 + 4 39 + 3 62 vaginal 3050 20 f
109 25.1 26.9 0 99 / 87 0 0 / 27 + 6 37 + 3 67 vaginal 2960 30 m
110 29.3 23.5 0 135 / 70 0 0 / 28 + 4 39 + 1 74 s.c. 3450 50 m
111 31.2 23.2 1 116 / 81 0 0 / 28 + 0 41 + 0 91 vaginal 3750 70 f
112 26.6 19.5 0 100 / 80 0 0 / 30 + 2 39 + 4 65 vaginal 3660 60 m
113 24.5 22.4 1 115 / 59 0 2 / 26 + 2 38 + 2 84 vaginal 2970 30 f
114 38.2 25.5 1 130 / 80 0 0 / 25 + 5 40 + 5 105 vaginal 3765 70 f
115 
j) 25.7 23.1 1 105 / 63 0 25 / 28 + 4 40 + 4 84 vaginal 3070 14 f
151 24.9 20.3 2 109 / 53 0
f 20 / 27+0 27+4 4 s.c. 1355 85 m
152 37.9 23.1 2 108 / 65 0
f 0 / 27+1 27+4 3 s.c. 1095 40 m
153 30.5 22.1 0 114 / 61 0
f 0 / 25+0 25+0 0 vaginal 740 30 m
154 30.3 20.8 1 124 / 69 0
f 0 / 31+2 33+6 18 s.c. 1960 25 f
155 29.9 21.4 0 114 / 71 150 0 / 32+0 32+1 1 s.c. 1920 50 m
156 24.2 35.7 0 129 /73 0
f 10 / 31+6 31+6 0 vaginal 1750 50 f
157 32.1 22.4 0 126 / 63 0
f 0 / 37+4 37+4 0 s.c. 3130 50 f
158 31.8 25.8 1 121 / 75 0
f 0 / 37+5 37+5 0 s.c. 3465 70 m
159 35.7 21.8 1 122 / 58 0
f 0 / 33+6 34+6 7 s.c. 2420 40 f
160 37.1 19.1 1 120 / 60 0
f 0 / 38+6 39+0 1 s.c. 3150 30 f
161 40.0 20.8 1 110 / 60 0
f 0 / 36+0 36+0 0 s.c. 2920 60 m
162 32.7 25.1 2 110 / 70 0
f 0 / 32+3 32+3 0 s.c. 1850 50 f
163 29.6 24.1 1 106 / 61 0
f 0 / 27+5 28+4 6 s.c. 1250 60 f
164 24.6 17.6 1 110 / 54 0
f 5 / 28+0 28+0 0 s.c. 1030 40 f
165 24.7 35.4 1 120 / 81 0
f 0 / 39+2 39+2 0 s.c. 3895 80 m
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301 41.8 23.7 3 134 / 78 0 0 / 33 + 6 34 + 1 2 s.c. 1525 3 m
302 34.9 19.9 0 130 / 82 0 0 / 29 + 3 30 + 0 4 s.c. 755 2 m
303 31.9 22.5 0 129 / 76 90 0 / 31 + 0 32 + 1 8 s.c. 1255 9 f
304 24.5 19.7 0 122 / 53 0 40 / 26 + 1 26 + 4 3 s.c. 590 3 m
305 28.8 26.0 1 120 / 80 0 15 / 30 + 5 31 + 5 7 s.c. 1190 6 m
306 27.5 22.1 0 130 / 68 0 0 / 32 + 6 33 + 2 3 s.c. 1405 6 f
307 30.7 24.0 0 120 / 75 0 10 / 28 + 1 28 + 5 4 s.c. 730 4 f
308 29.4 20.1 0 103 / 59 0 0 / 29 + 6 31 + 4 12 s.c. 1240 9 m
309 23.6 23.7 0 125 / 71 101 10 / 30 + 5 30 + 5 0 s.c. 940 4 f
310 27.8 18.0 1 111 / 64 0 3 / 27 + 1 28 + 6 12 s.c. 900 8 m
311 22.0 19.4 0 110 / 60 0 0 / 25 + 3 25 + 6 3 s.c. 495 3 m
312 28.7 19.2 0 128 / 76 0 0 / 28 + 4 33 + 0 31 s.c. 1245 4 f
313 23.4 23.5 0 96 / 52 0 5 / 29 + 3 29 + 5 2 s.c. 855 4 m
314 23.1 29.0 0 109 / 77 0 5 / 29 + 4 29 + 6 2 s.c. 860 4 f
315 
j) 23.4 22.7 1 139 / 65 0 0 / 31 + 2 31 + 4 2 s.c. 1240 9 m
351 31.9 22.5 0 129 / 76 90 0 / 31+0 32+1 8 s.c. 1255 9 f
352 23.6 23.7 0 125 / 71 101 10 / 30+5 30+5 0 s.c. 940 4 f
353 33.1 31.9 0 155 / 100 2324 10 PE 24+0 26+5 19 s.c. 650 4 m
354 25.6 26.2 0 83 / 52 0
f 0 / 37+3 37+5 2 s.c. 2550 5 m
355 39.6 27.1 0 148 / 92 300 0 PE 28+2 28+2 0 s.c. 850 8 m
356 34.3 19.9 0 136 / 71 0
f 0 / 32+0 32+1 1 s.c. 1310 8 m
357 23.8 21.5 0 162 / 100 500 0 PE 35+5 35+5 0 s.c. 1330 1 f
358 27.5 22.1 0 130 / 68 150 0 / 32+6 33+2 3 s.c. 1405 6 f
359 19.1 23.5 0 116 / 64 0
f 10 / 35+5 36+1 3 s.c. 1870 2 m
360 27.8 28.3 3 112 / 55 0
f 0 / 27+0 27+0 0 s.c. 580 3 f
361 31.7 20.2 1 100 / 60 0
f 0 / 38+6 39+0 1 s.c. 1970 1 f
362 34.0 23.8 2 140 / 90 1725 0 PE 26+4 26+6 2 s.c. 490 1 m
363 25.1 22.6 0 122 / 79 0
f 3 / 33+6 36+4 19 s.c. 1905 3 f
364 37.9 22.1 0 150 / 80 0
f 0 / 40+3 40+3 0 s.c. 2665 2 m
365 41.5 28.0 0 155/101 200 0 PE 30+2 32+0 12 s.c. 975 3 f
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201 17.7 21.8 0 109 / 64 69 0 / 34 + 4 37 + 5 22 vaginal 2300 3 m
202 31.8 20.0 2 120 / 80 84 0 / 32 + 3 38 + 3 42 s.c. 2545 4 f
203 27.2 28.1 0 114 / 60 0 0 / 29 + 5 36 + 1 45 s.c. 2000 3 m
204 25.6 16.2 0 138 / 48 0 0 / 32 + 3 38 + 4 43 s.c. 2740 6 m
205 31.0 25.8 0 146 / 84 0 15 / 31 + 4 37 + 5 43 s.c. 2455 5 f
206 30.5 24.5 1 132 / 62 0 0 / 29 + 5 36 + 1 45 s.c. 2040 4 f
207 21.4 25.0 0 104 / 59 70 5 / 32 + 1 40 + 5 60 vaginal 2780 3 f
208 40.2 26.0 1 120 / 75 0 0 / 32 + 2 38 + 2 42 s.c. 2590 7 f
209 36.6 21.9 1 84 / 45 0 0 / 33 + 6 37 + 3 25 s.c. 1950 1 m
210 19.7 18.4 0 104 / 73 0 30 / 31 + 4 38 + 1 46 vaginal 2750 8 m
211 36.1 25.5 5 121 / 73 0 0 / 32 + 6 38 + 3 39 vaginal 2560 3 m
212 40.2 20.6 1 117 / 70 0 0 / 30 + 1 37 + 2 50 s.c. 2560 9 m
213 27.0 21.1 0 110 / 70 0 0 / 22 + 6 37 + 6 105 s.c. 2170 2 f
214 22.9 18.2 0 110 / 60 0 15 / 33 + 0 39 + 0 42 vaginal 2780 5 m
215 25.0 23.6 0 134 / 71 0 0 / 25 + 6 40 + 1 100 s.c. 2750 4 f
a)     determined at begining of hospitalization (time point of blood collection)
b)     systolic/diastolic pressure
c)     immunoturbidimetric assay (Tina-quant albumin; Roche Diagnostics. Mannheim, Germany); proteinuria is defined as urinary protein excretion >300 mg/L
d)     dip stick assay; significant protein is present with readings of more than +1 (max: +3)
e)     amount of cigarettes per day
f)      preeclampsia
g)     w: week, d: day
h)     Δd: time difference between blood sample collection and delivery in days
i)      s.c.: sectio caesarea
j)     spectra not used for biostatistical analyses
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CTRL 101 MS1 414.30 200.24 883.56 2074.71 539.74
CTRL 101 MS2 400.35 206.89 841.79 2383.00 622.14
CTRL 102 MS1 698.00 150.34 1247.64 1569.02 681.66
CTRL 102 MS2 705.71 133.29 1264.78 1534.71 652.39
CTRL 103 MS1 421.90 107.80 921.31 1840.63 402.83
CTRL 103 MS2 457.38 105.68 1019.10 1990.28 489.84
CTRL 104 MS1 264.59 116.04 961.72 2034.77 467.03
CTRL 104 MS2 178.14 106.47 658.71 1933.72 420.97
CTRL 105 MS1 500.00 156.60 977.96 2285.33 593.77
CTRL 105 MS2 464.62 141.43 920.55 2197.40 587.02
CTRL 106 MS1 222.37 126.91 791.88 1778.87 394.30
CTRL 106 MS2 213.55 143.11 763.30 1885.79 430.03
CTRL 107 MS1 438.96 159.81 970.72 2400.46 409.66
CTRL 107 MS2 475.35 127.37 939.19 2109.18 364.65
CTRL 108 MS1 377.30 232.00 727.85 2564.50 554.57
CTRL 108 MS2 383.90 203.30 684.85 2141.79 398.44
CTRL 109 MS1 329.15 106.16 911.18 1942.23 492.75
CTRL 109 MS2 325.66 108.23 917.82 1948.87 509.50
CTRL 110 MS1 390.37 281.28 982.85 1860.78 523.74
CTRL 110 MS2 380.13 265.66 907.92 1739.45 446.88
CTRL 111 MS1 238.20 102.48 886.59 1953.43 479.76
CTRL 111 MS2 251.44 101.71 936.77 2040.18 482.76
CTRL 112 MS1 312.80 238.63 967.43 2128.26 439.25
CTRL 112 MS2 324.25 234.88 974.10 2150.88 464.01
CTRL 113 MS1 254.58 278.50 1027.06 2026.04 427.75
CTRL 113 MS2 281.71 292.17 1106.54 2132.15 461.05
CTRL 114 MS1 144.47 182.59 589.61 1461.07 320.83
CTRL 114 MS2 152.05 178.65 584.65 1455.51 327.33
CTRL 115 
e)
MS1 281.34 14.20 1167.01 1110.15 413.78
CTRL 115 
e)
MS2 231.69 18.74 937.52 977.23 402.52
SGA 201 MS1 215.62 270.94 789.79 1330.84 339.23
SGA 201 MS2 263.98 460.72 1037.82 2435.07 655.13
SGA 202 MS1 732.59 93.49 876.16 2469.79 564.72
SGA 202 MS2 654.59 91.84 769.69 2215.84 510.94
SGA 203 MS1 233.77 141.40 1082.29 2776.67 526.12
SGA 203 MS2 233.77 141.40 1082.29 2776.67 526.12
SGA 204 MS1 306.25 262.94 937.48 2267.95 442.92
SGA 204 MS2 273.12 283.39 844.56 2332.37 435.84
SGA 205 MS1 292.18 456.29 907.95 2217.01 629.64
SGA 205 MS2 217.11 399.58 691.47 1921.16 582.48
SGA 206 MS1 411.65 128.55 977.60 1703.53 552.24
SGA 206 MS2 433.39 131.13 1017.58 1770.33 649.78
SGA 207 MS1 520.37 184.78 1227.13 2247.78 404.80
SGA 207 MS2 523.52 165.27 1260.87 2034.50 375.76
SGA 208 MS1 120.34 99.83 679.65 1608.17 595.25
SGA 208 MS2 118.43 99.81 704.81 1762.08 614.28
SGA 209 MS1 483.31 80.24 908.62 1778.71 437.86






areas of ion signals (m/z)


















SGA 210 MS1 197.06 132.67 787.89 2419.87 418.73
SGA 210 MS2 168.81 124.32 679.19 2021.89 317.82
SGA 211 MS1 201.32 157.10 892.48 1903.22 420.12
SGA 211 MS2 170.87 130.35 781.20 1517.58 330.60
SGA 212 MS1 239.09 225.91 637.04 1840.71 497.30
SGA 212 MS2 293.11 217.61 766.70 1913.29 524.41
SGA 213 MS1 319.36 281.63 1057.62 2544.11 496.54
SGA 213 MS2 243.79 227.11 829.42 2215.08 422.14
SGA 214 MS1 464.05 152.31 979.33 2000.95 519.80
SGA 214 MS2 540.68 150.61 1129.53 2173.92 608.80
SGA 215 MS1 107.24 122.08 636.23 1336.81 363.48
SGA 215 MS2 157.04 130.62 883.08 1777.3 520.11
IUGR 301 MS1 192.37 235.80 825.99 2279.91 404.18
IUGR 301 MS2 194.27 245.49 853.32 2481.24 441.21
IUGR 302 MS1 567.62 81.83 1174.89 2088.35 639.09
IUGR 302 MS2 659.08 102.29 1320.98 2364.86 635.10
IUGR 303 MS1 364.36 220.96 1245.24 2128.28 554.69
IUGR 303 MS2 352.85 225.31 1252.01 2323.04 618.43
IUGR 304 MS1 304.41 132.04 1112.63 1861.06 375.89
IUGR 304 MS2 263.48 123.54 940.25 1765.63 404.76
IUGR 305 MS1 217.45 163.06 1083.87 1687.21 452.45
IUGR 305 MS2 236.67 147.27 1180.20 1695.96 457.25
IUGR 306 MS1 220.31 122.83 1070.73 1806.31 430.47
IUGR 306 MS2 232.44 126.49 1215.18 1946.77 444.06
IUGR 307 MS1 213.23 399.97 1071.57 2112.83 424.41
IUGR 307 MS2 139.88 343.33 671.93 1850.29 389.32
IUGR 308 MS1 212.31 130.90 929.72 1175.19 592.87
IUGR 308 MS2 201.66 129.91 856.22 1109.21 598.61
IUGR 309 MS1 239.50 166.24 1135.39 1948.42 395.73
IUGR 309 MS2 233.65 134.17 1094.62 1505.65 308.34
IUGR 310 MS1 418.20 97.19 934.46 1417.34 383.97
IUGR 310 MS2 484.28 88.89 1051.94 1347.04 307.99
IUGR 311 MS1 262.66 99.87 937.06 1606.35 339.85
IUGR 311 MS2 263.28 99.37 958.19 1638.39 353.77
IUGR 312 MS1 477.13 145.12 1254.09 1709.73 469.29
IUGR 312 MS2 480.48 142.78 1233.48 1666.21 433.14
IUGR 313 MS1 180.27 183.17 1029.00 1663.82 331.00
IUGR 313 MS2 191.68 186.87 1156.24 1830.70 396.27
IUGR 314 MS1 293.84 105.08 924.29 1241.76 235.34
IUGR 314 MS2 434.38 124.61 1449.40 1512.45 269.20
IUGR 315 
e)
MS1 n.d. n.d. n.d. n.d. n.d.
IUGR 315
 e)
MS2 n.d. n.d. n.d. n.d. n.d.
a) MS1: first measurement of ClinProt work-up, (“training set”).
b) MS2: second measurement of ClinProt work-up, (“test set”).
c) abbreviated protein name
d) m/z value in MALDI mass spectrum
e) n.d.: ion signal areas not determined
clinical 
diagnosis
patient ID measurement 
a,b)
areas of ion signals (m/z)
Supplemental Table 3: Determination of Youden Index (Jmax) for Quotient A. 
patient ID clinical diagnosis quotient A 
a)













          102 CTRL 1.8 1.3 0 28 14 14 0 0 1.00 0.00 0.00 
108 CTRL 1.9 1.9 1 27 14 13 1 0 1.00 0.07 0.07 
105 CTRL 2.0 1.9 2 26 14 12 2 0 1.00 0.14 0.14 
302 IUGR 2.1 2.0 3 25 14 11 3 0 1.00 0.21 0.21 
101 CTRL 2.1 2.1 4 24 13 11 3 1 0.93 0.21 0.14 
103 CTRL 2.2 2.2 5 23 13 10 4 1 0.93 0.29 0.21 
107 CTRL 2.2 2.2 6 22 13 9 5 1 0.93 0.36 0.29 
310 IUGR 2.2 2.2 7 21 13 8 6 1 0.93 0.43 0.36 
110 CTRL 2.5 2.4 8 20 12 8 6 2 0.86 0.43 0.29 
312 IUGR 2.6 2.6 9 19 12 7 7 2 0.86 0.50 0.36 
109 CTRL 2.8 2.7 10 18 11 7 7 3 0.79 0.50 0.29 
112 CTRL 3.1 2.9 11 17 11 6 8 3 0.79 0.57 0.36 
314 IUGR 3.1 3.1 12 16 11 5 9 3 0.79 0.64 0.43 
303 IUGR 3.4 3.3 13 15 10 5 9 4 0.71 0.64 0.36 
106 CTRL 3.6 3.5 14 14 9 5 9 5 0.64 0.64 0.29 
311 IUGR 3.6 3.6 15 13 9 4 10 5 0.64 0.71 0.36 
104 CTRL 3.6 3.6 16 12 8 4 10 6 0.57 0.71 0.29 
304 IUGR 3.7 3.6 17 11 8 3 11 6 0.57 0.79 0.36 
111 CTRL 3.7 3.7 18 10 7 3 11 7 0.50 0.79 0.29 
113 CTRL 4.0 3.9 19 9 7 2 12 7 0.50 0.86 0.36 
114 CTRL 4.1 4.1 20 8 7 1 13 7 0.50 0.93 0.43 
301 IUGR 4.3 4.2 21 7 7 0 14 7 0.50 1.00 0.50 
308 IUGR 4.4 4.3 22 6 6 0 14 8 0.43 1.00 0.43 
309 IUGR 4.7 4.6 23 5 5 0 14 9 0.36 1.00 0.36 
306 IUGR 4.9 4.8 24 4 4 0 14 10 0.29 1.00 0.29 
305 IUGR 5.0 4.9 25 3 3 0 14 11 0.21 1.00 0.21 
307 IUGR 5.0 5.0 26 2 2 0 14 12 0.14 1.00 0.14 
313 IUGR 5.7 5.4 27 1 1 0 14 13 0.07 1.00 0.07 
  max 6.7 6.2 28 0 0 0 14 14 0.00 1.00 0.00 
a) ranking according to the values of quotients A after adjoining theoretical minimum and maximum values 
b) FN = false negative, FP = false positive, TN = true negative, TP = true positive. 
c) J=Youden index; bold print: Jmax 
Supplemental Table 4: Determination of Youden Index (Jmax) for Quotient B. 
patient ID clinical diagnosis quotient B 
a) 













          302 IUGR 3.0 2.5 0 28 14 14 0 0 1.00 0.00 0.00 
111 CTRL 4.2 3.6 1 27 13 14 0 1 0.93 0.00 -0.07 
109 CTRL 4.4 4.3 2 26 13 13 1 1 0.93 0.07 0.00 
104 CTRL 4.6 4.5 3 25 13 12 2 1 0.93 0.14 0.07 
103 CTRL 4.8 4.7 4 24 13 11 3 1 0.93 0.21 0.14 
311 IUGR 5.1 5.0 5 23 13 10 4 1 0.93 0.29 0.21 
310 IUGR 5.4 5.3 6 22 12 10 4 2 0.86 0.29 0.14 
105 CTRL 5.4 5.4 7 21 11 10 4 3 0.79 0.29 0.07 
306 IUGR 5.5 5.5 8 20 11 9 5 3 0.79 0.36 0.14 
107 CTRL 5.7 5.6 9 19 10 9 5 4 0.71 0.36 0.07 
106 CTRL 5.8 5.8 10 18 10 8 6 4 0.71 0.43 0.14 
304 IUGR 5.9 5.9 11 17 10 7 7 4 0.71 0.50 0.21 
312 IUGR 6.7 6.3 12 16 9 7 7 5 0.64 0.50 0.14 
102 CTRL 6.7 6.7 13 15 8 7 7 6 0.57 0.50 0.07 
309 IUGR 7.1 6.9 14 14 8 6 8 6 0.57 0.57 0.14 
314 IUGR 7.1 7.1 15 13 7 6 8 7 0.50 0.57 0.07 
308 IUGR 7.4 7.3 16 12 6 6 8 8 0.43 0.57 0.00 
108 CTRL 7.4 7.4 17 11 5 6 8 9 0.36 0.57 -0.07 
305 IUGR 7.6 7.5 18 10 5 5 9 9 0.36 0.64 0.00 
101 CTRL 7.7 7.6 19 9 4 5 9 10 0.29 0.64 -0.07 
303 IUGR 8.2 7.9 20 8 4 4 10 10 0.29 0.71 0.00 
301 IUGR 8.8 8.5 21 7 3 4 10 11 0.21 0.71 -0.07 
313 IUGR 9.2 9.0 22 6 2 4 10 12 0.14 0.71 -0.14 
112 CTRL 9.3 9.2 23 5 1 4 10 13 0.07 0.71 -0.21 
114 CTRL 10.2 9.8 24 4 1 3 11 13 0.07 0.79 -0.14 
113 CTRL 11.3 10.8 25 3 1 2 12 13 0.07 0.86 -0.07 
110 CTRL 11.8 11.6 26 2 1 1 13 13 0.07 0.93 0.00 
307 IUGR 15.8 13.8 27 1 1 0 14 13 0.07 1.00 0.07 
  max 16.8 16.3 28 0 0 0 14 14 0.00 1.00 0.00 
a) ranking according to the values of quotients A after adjoining theoretical minimum and maximum values 
b) FN = false negative, FP = false positive, TN = true negative, TP = true positive. 
c) J=Youden index; bold print: Jmax 
 
Supplemental Table 5: Determination of Youden Index (Jmax) for Quotient C. 
patient ID clinical diagnosis quotient C 
a)













          108 CTRL 2.2 1.7 0 28 14 14 0 0 1.00 0.00 0.00 
301 IUGR 2.8 2.5 1 27 14 13 1 0 1.00 0.07 0.07 
114 CTRL 3.0 2.9 2 26 13 13 1 1 0.93 0.07 0.00 
101 CTRL 3.1 3.1 3 25 13 12 2 1 0.93 0.14 0.07 
105 CTRL 3.2 3.2 4 24 13 11 3 1 0.93 0.21 0.14 
107 CTRL 3.3 3.3 5 23 13 10 4 1 0.93 0.29 0.21 
106 CTRL 3.4 3.4 6 22 13 9 5 1 0.93 0.36 0.29 
112 CTRL 3.4 3.5 7 21 13 8 6 1 0.93 0.43 0.36 
111 CTRL 3.5 3.5 8 20 13 7 7 1 0.93 0.50 0.43 
109 CTRL 3.6 3.5 9 19 13 6 8 1 0.93 0.57 0.50 
307 IUGR 3.6 3.6 10 18 13 5 9 1 0.93 0.64 0.57 
104 CTRL 3.7 3.7 11 17 12 5 9 2 0.86 0.64 0.50 
110 CTRL 3.7 3.7 12 16 12 4 10 2 0.86 0.71 0.57 
113 CTRL 3.8 3.7 13 15 12 3 11 2 0.86 0.79 0.64 
103 CTRL 3.9 3.8 14 14 12 2 12 2 0.86 0.86 0.71 
302 IUGR 4.2 4.0 15 13 12 1 13 2 0.86 0.93 0.79 
303 IUGR 4.3 4.2 16 12 11 1 13 3 0.79 0.93 0.71 
309 IUGR 4.5 4.4 17 11 10 1 13 4 0.71 0.93 0.64 
306 IUGR 4.5 4.5 18 10 9 1 13 5 0.64 0.93 0.57 
311 IUGR 4.6 4.6 19 9 8 1 13 6 0.57 0.93 0.50 
304 IUGR 4.7 4.6 20 8 7 1 13 7 0.50 0.93 0.43 
305 IUGR 4.7 4.7 21 7 6 1 13 8 0.43 0.93 0.36 
313 IUGR 4.7 4.7 22 6 5 1 13 9 0.36 0.93 0.29 
308 IUGR 4.9 4.8 23 5 4 1 13 10 0.29 0.93 0.21 
310 IUGR 4.9 4.9 24 4 3 1 13 11 0.21 0.93 0.14 
102 CTRL 5.2 5.1 25 3 2 1 13 12 0.14 0.93 0.07 
312 IUGR 5.4 5.3 26 2 2 0 14 12 0.14 1.00 0.14 
314 IUGR 5.8 5.6 27 1 1 0 14 13 0.07 1.00 0.07 
  max 6.8 6.3 28 0 0 0 14 14 0.00 1.00 0.00 
a) ranking according to the values of quotients A after adjoining theoretical minimum and maximum values 
b) FN = false negative, FP = false positive, TN = true negative, TP = true positive. 
c) J=Youden index; bold print: Jmax 
 
Supplemental Table 6: Power analysis of mass spectrometric ion signal-derived proteome profile series a). 
 















1 training “O”: CTRL I vs FGR I CTRL 0.79 0.58 3 14 0.05 0.20 0.81 
 (CTRL I, n=14; FGR I, n=14) b) FGR 2.29 0.61 3 14 
2 “development” test: CTRL I+II vs FGR I+II CTRL 0.91 0.75 9 28 0.05 0.20 0.83 
 (CTRL I+II, n=28; FGR I+II, n=29) c) FGR 1.82 0.67 9 44 
3 “validation” test: CTRL I+II and SGA I vs FGR I+II CTRL+SGA 0.93 0.65 5 42 0.05 0.20 0.81 
 (CTRL I+II, n=28; SGA I, n=14; FGR I+II, n=29) c) FGR 2.15 0.63 5 29 
 
a) cumulative score separator: >1 = FGR; ≤ 1 = CTRL. 
b) number of individuals 
c) only via Jmax determined cut-off values: quotient A = 4.2; quotient B = 5.0; quotient C = 4.0. 




2.3 Comparison of blood serum protein analysis by MALDI-MS from either 
conventional frozen samples or storage disc-deposited samples: A study with 





Comparison of blood serum protein analysis
by MALDI-MS from either conventional frozen
samples or storage disc-deposited samples:
A study with human serum from pregnant
donors and from patients with intrauterine
growth restriction
Manja Wölter1, Manuela Russ1, Charles A Okai1, Werner Rath2,
Ulrich Pecks2 and Michael O Glocker1
Abstract
Mass spectrometric profiling of intact serum proteins, i.e. determination of relative protein abundance differences, was
performed using two different serum sample preparation methods: one with frozen and thawed serum, the other with at
room temperature deposited and dried serum. Since in a typical clinical setting freezing of serum is difficult to achieve,
sampling at room temperature is preferred and can be met when using the NoviplexTM card system. Once deposited and
dried, serum proteins can be stored and shipped at room temperature. After resolubilization of serum proteins from ‘‘dried
serum spots’’, mass spectra of high quality have been recorded comparable to those that were obtained using fresh-frozen
and subsequently thawed serum samples. Differentiation between patients with intrauterine growth restriction and control
individuals was achievable, independent from the sample work-up procedure. Having at hand a reliable and robust method
for serum storage and shipment which works at room temperature bridges the gap between the clinics and the protein
analysis laboratory. Our novel serum handling protocol reduces costs for both, storage and shipping, and ultimately enables
clinical risk assessment based on mass spectrometric determination of intact protein abundance profiles.
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Introduction
Intrauterine growth restriction (IUGR) is a pathological
pregnancy condition in which the fetus does not reach its
genetically given growth potential and, in addition, is a
risk factor for cardiovascular and metabolic diseases
later in life.1–3 About 3–8% of all pregnancies are
affected.4,5 Of note, other preterm babies, categorized
as ‘‘small for gestational age (SGA)’’, are not associated
with developmental risks. The majority of SGA neonates
is born small by genetic constitution and grows in utero
in accordance with their percentiles.6,7 Differentiating
these two pregnancy conditions is important to (i)
improve pregnancy management and (ii) to start close
surveillance and treatment during early weeks of
infancy.8 As even at time of birth, SGA is difficult to
distinguish from IUGR by clinical means, a robust
molecular assay with only minimal invasive procedures
prior to or at time of delivery was highly desired.
Mass spectrometry-based proteome profiling provides
a powerful approach to diagnose polygenic diseases like
IUGR due to its ability to characterize individual serum
samples based on complex proteome signatures from
both, newborns and pregnant women.9,10 However,
one of the remaining challenges for making a mass spec-
trometry-based profiling assay of delicate samples
attractive for clinical use is to bridge the distance
between the delivery room and the mass spectrometry
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laboratory. Both, cord blood serum and maternal per-
ipheral blood serum have to be prepared directly in the
clinics immediately after blood withdrawal. Current
state-of-the-art preparation of serum requests centrifu-
gation followed by freezing, i.e. placing freshly prepared
serum in a freezer or keep it on dry ice.7,9–11 However,
storing serum at freezing temperatures is in many cases
too demanding for regular birth clinics and can only be
guaranteed by specialized obstetric care centers. In add-
ition, serum shipment on dry ice is costly and requires
access to advanced mail carriers. In the serum-receiving
laboratory, samples have to be kept frozen until time of
analysis, which typically is initiated by thawing.12
As of yet, most hospitals are not prepared to store and
ship frozen serum. Instead, keeping blood and other spe-
cimen and transporting such samples at room tempera-
ture is preferred routine.13 Dried blood spots have been
prepared on filter paper cards which provide a suitable
storage and shipment device for clinical samples13 and
analysis of small molecules, such as phospholipids, cre-
atinine, and drug metabolites by mass spectrometry has
been successful upon resolubilization.14–16 While quanti-
tation of blood proteins from dried blood spots can be
done by multiple reaction monitoring mass spectrometry
(MRM MS) analysis of enzymatically generated partial
peptides,17–19 elution of intact proteins and subsequent
analysis by mass spectrometry to generate a proteome
profile has not yet been reported. A suitable means to
avoid demanding and costly serum freezing was storing
and shipping of serum as so-called ‘‘dried serum spots’’.20
Dried blood spots have found wide-spread application
for sampling of specimen in the clinics21 and analysis of
small molecules by mass spectrometry from these sources
has become routine even for screening of larger popula-
tions.14–16 Dried blood spot sampling as well as dried
serum spot sampling was preferred, particularly because
freeze/thaw cycles22 can be avoided.
In this study, we are comparing the linear mode
MALDI-ToF mass spectra obtained from intact
blood serum proteins either stored on a membrane
disc which functions as serum storage device and onto
which serum can be deposited and kept at room tem-
perature with mass spectra obtained from fresh frozen
serum after conventional work-up.9,10,23 Key step for
successful relative abundance analysis of intact serum
proteins derived from dried serum spots by mass spec-
trometry is the resolubilization procedure by which
deposited proteins can be prepared and analyzed in a
reliable and robust fashion.
Patients, materials and methods
Patient stratification
Blood samples were from eight pregnant Caucasian
women who attended the Department of Obstetrics
and Gynecology, University Hospital of the RWTH
Aachen (Supplemental Table 1). The study was
approved by the Ethics Committee of the RWTH
Aachen (EK 119/08). Written informed consent was
obtained from all participating women. Gestational
age was established on the basis of the last menstrual
period and was confirmed by ultrasonic examination
between the 10th and the 14th week of gestation.
Sonographic examinations were done antenatally on
Logiq 5 and Voluson 730 Expert Ultrasound
Systems (GE Healthcare Systems, Solingen, Germany).
The regression equation including biparietal diameter,
femur length, and head and abdominal circumferences,24
was used to estimate fetal weight. Neonatal birth weight
centile was determined according to the population-
based newborn weight charts.25 IUGR was defined in
accordance to the ACOG guidelines26 as described.27
Blood sample collection and generation of serum
aliquots
In the clinic, blood samples (up to 9ml, each) were
taken from each individual antenatally from the right
or left cubital vein using monovette syringes (Serum
Z/9mL; Monovette, Sarstedt, Germany). After incu-
bation at room temperature for 15–30 minutes, samples
were subjected to sedimentation of blood cells by cen-
trifugation (Labofuge 400R; Fa. Heraeus Instruments,
Waltham, USA) at 2000 g at room temperature for
15 minutes. Serum was aspirated and divided into ali-
quots (100ml each).
Serum storage and transport
Conventional blood serum sample treatment was
applied, i.e. serum was shock frozen and stored at
80C.9,10,23 Altogether, time between blood sample
collection and storage of frozen serum aliquots aver-
aged around less than 1 hour. Frozen serum aliquots
were shipped on dry ice to the Proteome Center
Rostock to maintain the cold-chain.
For developing an alternative serum sample storage
and shipment procedure, a tiny volume of just 2 ml of
serum was deposited on the ‘‘serum storage disc’’ that is
mounted on the base sheet of a NoviplexTM card
(Shimadzu Europe, Duisburg, Germany).28 Serum
deposits were let to dry at ambient temperature in a
clean box and deposited serum proteins were stored
dry at room temperature for up to three days. Dried
serum spots were shipped to the Proteome Center
Rostock by courier at room temperature.
Re-solubilization of serum proteins
A serum protein-containing serum storage disc was put
with tweezers into the cap of a 1.5ml Eppendorf tube
(Eppendorf, Hamburg, Germany). To each serum stor-
age disc were added 10ml of 0.1% RapiGest solution
(dissolved in 50mMNH4HCO3) and the cavity was cov-
ered with fabric (Gaze, Holzhaus Medical Remscheid,
Germany). Tubes were closed and kept upside-down
during shaking for 1 hour at room temperature.
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Afterwards, tubes were turned upright, placed into a
centrifuge (Hettich, Tuttlingen, Germany) and samples
were centrifuged at 10,000 r/min at room temperature
for 5 minutes to collect the solvent at the bottom of
the tube while the ‘‘emptied’’ serum storage disc was
kept behind on the fabric. Fabric and serum storage
disc were removed and protein solutions were immedi-
ately subjected to further work-up.
For double-extraction of serum storage discs, one
serum storage disc (from patient 8), from which pro-
teins had been eluted with 0.1% RapiGest solution (see
above), was transferred into an 1.5ml Eppendorf tube.
After adding 200 ml of extraction buffer (1% sodium
deoxycholate (SDC), 20mM dithiothreitol (DTT) in
50mM NH4HCO3), shaking was maintained for 1
hour at room temperature. Thereafter, 200 ml of
50mM NH4HCO3 were added (end concentration:
0.5% SDC, 10mM DTT in 50mM NH4HCO3) and
incubated for 5 minutes at 95C. Next, tubes were
placed into an ultrasonic bath (Bandelin, Berlin,
Germany) for 15–30 seconds and then shaken for 10
minutes. This procedure was repeated three times.
Finally, centrifugation for 10 minutes at 20C and at
16,000 g sedimented the serum storage disc. The
supernatant (400ml) with re-solubilized serum proteins
was transferred into a new tube for further use.
Preparation of compatible protein extracts for
MALDI-MS analysis
To prepare MALDI-MS compatible serum protein solu-
tions from frozen serum, serum aliquots were thawed
and 5ml were incubated with 10ml MB-HIC8 ‘‘binding
buffer’’ and 5ml of MB-HIC8 bead slurry for 1min
(Profiling Kit 100 MB-HIC8; Bruker Daltonik,
Bremen, Germany). After washing the beads three
times with 100ml of ‘‘wash buffer’’, each, proteins were
eluted with 10ml of ‘‘elution buffer’’, consisting of a 50%
ACN solution; according to established protocols.7,9–11
Protein-containing solutions were immediately subjected
to mass spectrometric analysis in duplicate.
To record protein profiles by MALDI-MS from
serum proteins that had been stored and re-solubilized
from serum storage discs, 2ml of each protein resolubili-
zation solution was incubated with 5ml MB-HIC8 ‘‘bind-
ing buffer’’ and 2ml of MB-HIC8 bead slurry for 1min.
After washing the beads three times (40ml of ‘‘wash
buffer’’, each), proteins were eluted with 4ml of ‘‘elution
buffer’’. Protein-containing solutions were immediately
subjected to mass spectrometric analysis in duplicate.
MALDI-MS analysis of serum proteins
After extraction from beads, serum protein-containing
solutions (0.5 ml each) were spotted in duplicate directly
onto a stainless steel MTP 384 target plate (Bruker
Daltonik, Bremen, Germany) together with 0.5ml feru-
lic acid solution (10mg ferulic acid, Sigma-Aldrich,
München, Germany) dissolved in ACN/0.1% aqueous
TFA (33/67, v/v) as matrix. After drying, 0.5 ml ferulic
acid solution was added to each sample spot again.
Since protein samples were prepared in duplicate for
each patient/donor was recorded a first and a second
measurement (MS1 and MS2).7,9,10
Matrix-embedded protein mixtures were analyzed
with a Reflex III MALDI TOF mass spectrometer
(Bruker Daltonik, Bremen, Germany) which was
equipped with a SCOUT source for delayed extraction
and was operated in linear positive ion mode using an
acceleration voltage of 20kV. Spectra were recorded in
a mass range from 4 to 20kDa, respectively, accumulat-
ing 900 shots per spectrum. Spectra were externally cali-
brated using a commercially available Protein
Calibration Standard (Bruker Daltonik, Bremen,
Germany). All mass spectra were internally recalibrated
using average masses of ion signals at m/z 13762.4 (singly
charged and unmodified transthyretin); uniprot accession
number P02766; at m/z 14040.2 (doubly charged and
unmodified Apo A-I, uniprot P02647); and at m/z
6631.6 (singly charged and unmodified apolipoprotein
C, uniprot P02654). Ion signal areas were determined
with the ClinProTools 2.2 software (Bruker Daltronik,
Bremen, Germany) as described previously.23,29
Raw data processing and bio-statistical analysis
Our recently established multiparametric analysis9,10,23 in
which the signal areas of five ion signals within each spec-
trum were brought into context to each other by forming
quotients of ion signal areas was applied. First, the signal
area of the ion at m/z 8916 was divided by the signal area
of the ion at m/z 8205 from one and the same spectrum to
produce a value for spectra assessment (quotient A).
Second was calculated the value of the signal area of the
ion at m/z 8766 over the sum of the signal areas of the ions
at m/z 9422 plus m/z 9713 (quotient B). Third, the signal
area of the ion atm/z 8916 over the sum of the signal areas
of the ions at m/z 8766 plus m/z 9422 plus m/z 9713 were
determined (quotient C) as third assessment value. This
data processing was applied for each of the spectra. Cut-
off values for the quotients had been defined at 3.4 (quo-
tient A), 7.0 (quotient B), and 5.1 (quotient C), respect-
ively.10 When the value of the quotient of the specific
spectrum was higher than the respective cut-off value, a
score of ‘‘1’’ was given to this respective spectrum. In the
contrary case, the score for this spectrum was set to ‘‘0’’.
Next, it was determined that a cumulative score of above
‘‘1’’ sorted the respective spectrum into the IUGR group.
Sensitivity and specificity as well as receiver operating
characteristic (ROC) curve30,31 were calculated using the
Origin statistics software (version 8.1G; Originlab
Corporation, Northampton, MA, USA).
In-solution digestion of re-solubilized serum
proteins
To 400 ml of the protein mixture that was obtained after
double-extraction of a serum storage disc (see above),
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5 ml of trypsin solution (0.1 mg/ml; dissolved in 50mM
NH4HCO3) was added and the mixture was incubated
for 16 hours at 37C. First, 350 ml of digested solution
were removed. Then, 350 ml ethyl acetate and 7ml tri-
fluoroacetic (TFA) were added and mixed immediately.
After removing the aqueous phase (lower phase, about
300 ml) with a gel loader tip, the peptide solution was
concentrated by using the SpeedVac (SpeedVac RVC 2-
25CDplus, Martin Christ GmbH, Osterode am Harz,
Germany). End volume of the peptide mixture was
about 10 ml.
Desalination of peptides
Following previously published protocols,32 two layers
of C18 filter paper (Empore C18 Extraction Disc,
Model 2215 3M, Singapore) were placed into a 200 ml
pipette tip (Greiner, Frickenhausen, Germany). The
C18 filter was conditioned first with 50 ml methanol
and then with 50 ml 80% acetonitrile (ACN), 0.5%
acetic acid by centrifugation (1200 r/min; Eppendorf,
Hamburg, Germany) for a few seconds, respectively.
Solvents were discarded after each step. Then, 10 ml of
peptide-containing solution and 40 ml of 0.5% acetic
acid were added and tips were again centrifuged
(1200 r/min; Eppendorf, Hamburg, Germany) for
about 30 seconds. After washing the C18 filters with
50 ml 0.5% acetic acid, solvent was removed. Then, pep-
tides were eluted with 20 ml 80% ACN, 0.5% acetic
acid. Subsequently, solvent was removed by lyophiliza-
tion (SpeedVac RVC 2-25CDplus, Martin Christ
GmbH, Osterode am Harz, Germany). Thereafter, lyo-
philized peptides were dissolved in 20 ml of aqueous
0.1% formic acid (FA) that contained ACN (2%, v/
v). Peptide concentration was determined using the
Qubit assay kit (Invitrogen, Carlsbad, CA).33
NanoLC-ESI-MS configuration
Nanoscale LC separation of tryptic peptides was per-
formed with a nanoACQUITY UPLC system (Waters
Corporation, Manchester, UK), equipped with a C18
nanoACQUITY trap column: 100 Å 5 mm,
180 mm 20mm (Waters Corporation) and a nano
ACQUITY UPLC HSS T3, 10K lbf/in2, 100 Å,
1.8 mm, 75 mm 200mm analytical reversed phase
column (Waters Corporation), following previously
published procedures.34,35 The tryptic peptide solution
was diluted to 5 ng/ml with solvent mixture A (H2O/
0.1% FA) plus 2% B (ACN/0.1% FA). The peptide
mixture, 2 ml partial loop injection, was initially trans-
ferred with an aqueous 0.1% FA/0.1% ACN solution
to the pre-column at a flow rate of 10 ml/min for 6min.
Mobile phase A was 0.1% FA in water whereas mobile
phase B was 0.1% FA in ACN. After desalting and pre-
concentration, the peptides were eluted from the pre-
column to the analytical column and separated with a
gradient of 3–40% mobile phase B within 90min at a
flow rate of 0.3ml/min, followed by a 9minute rinse
with 85% of mobile phase B. The column was re-equi-
librated for 31 min to achieve initial conditions. The
column temperature was maintained at 35C. The
lock mass compound, [Glu1]-fibrinopeptide B, was
delivered by the auxiliary pump of the LC system at
0.5 ml/min at a concentration of 100 fmol/ml to the ref-
erence sprayer of the NanoLockSpray source of the
mass spectrometer. The precursor ion masses and asso-
ciated fragment ion spectra of the tryptic peptides were
measured with a SYNAPT G2S HDMS mass spec-
trometer (Waters Corporation, Manchester, UK) dir-
ectly coupled to the chromatographic system and
operated in positive ion mode. The time-of-flight ana-
lyzer of the mass spectrometer was externally calibrated
with fragment ions of [Glu1]-fibrinopeptide B from m/z
50 to 2000, with the data post-acquisition lock mass
corrected using the monoisotopic mass of the doubly
charged precursor of [Glu1]-fibrinopeptide B. The ref-
erence sprayer was sampled every 30 s. Accurate mass
data were collected in data independent mode of acqui-
sition by alternating the energy applied to the collision
cell between a low energy and elevated energy state as
described previously.36,37 The spectral acquisition time
in each mode was 0.5 s.
NanoLC-ESI-MS data processing and protein
identification
LC–MS data were processed according to published
protocols,34 using ProteinLynx GlobalSERVER ver-
sion 3.0 (Waters Corporation, Manchester, UK).
Protein identifications were obtained by comparing
the mass spectrometric peptide ion data with the
human protein-derived in-silico digested entries of a
UniProt/Swiss-Prot database (UniProt release 1
November 2013). Search criteria used for protein iden-
tification included automatic peptide and fragment ion
tolerance settings, one allowed missed cleavage, and
variable methionine oxidation. Details on the principle
of the search algorithm for data independently acquired
LC–MS data have been previously presented.38 Protein
identifications were accepted if at least three fragment
ions per peptide, seven fragment ions per protein and
two peptides per protein were matched.
Results
Comparison of work-up procedures and resulting
MALDI-MS profiles
The newly developed work-flow (Figure 1) replaced
freezing and thawing of serum by depositing serum
(2 ml) onto the ‘‘serum storage disc’’ on the
NoviplexTM card at room temperature. After drying,
serum proteins were stored, also at room temperature,
for several days. Then, loaded ‘‘serum storage discs’’
on the NoviplexTM cards were shipped to the labora-
tory in a clean dry envelope. Here, serum proteins
were re-solubilized using RapiGestTM as detergent.
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The re-solubilized serum protein solutions were then
worked-up for MALDI-MS analysis by desalting,
target preparation, and matrix addition.
To investigate whether the sample work-up protocol
had had an impact on the mass spectrometrically deter-
mined serum protein signature, eight previously ana-
lyzed and grouped blood serum samples were
investigated. Four were from control individuals
(CTRL), i.e. from pregnant women who delivered
healthy infants adequate for gestational age, all
being born preterm for various reasons. And four
blood samples were from patients which belonged
to the IUGR group, i.e. from pregnant women who
delivered infants that suffered from IUGR, three of
them needed mandatory preterm delivery
(Supplemental Table 1).
The conventional procedure for preparing serum
proteins followed established protocols which included
freezing of serum, shipping of samples in the frozen
state, and thawing of serum in the laboratory
(Figure 1). Thawed sera were subjected to subsequent
work-up steps in duplicate. Each serum sample was
worked-up in parallel, including desalting, target prep-
aration, and addition of matrix. MALDI MS analysis
of protein profiles was done in linear mode
(Figure 2(A)).
The resulting MALDI MS profiles upon preparing
serum proteins from a ‘‘serum storage disc’’
(Figure 2(B)) were almost identical to the ones that
were obtained from the same blood serum when using
conventional work-up procedures. Again, the mass
spectra from all work-ups from all eight blood samples
that were done with the novel serum depositing and
resolubilization protocol looked nearly identical
(Supplemental Figures 1 to 8).
Typically, MALDI mass spectra of conventionally
prepared and/or of alternatively prepared serum pro-
tein samples showed ca. 50–70 strong ion signals in the
mass range between m/z 4000 and m/z 20,000
(Figure 2), reflecting serum proteins of moderate abun-
dance. High abundant serum proteins, such as serum
albumin and immunoglobulins, were depleted during
work-up, most likely during the desalting step. In all
spectra, the two most prominent ion signals were found
at m/z 8916 and at m/z 9422. Since mass spectra for all
serum protein mixtures from all four patients and from
all four control individuals looked very similar to each
other (Supplemental Figures 1 to 8), they were sub-
jected to biostatistical analysis.
Biostatistical data analysis of MALDI MS protein
profiles
From all MALDI mass spectra (cf. Supplemental
Figures 1 to 8) were extracted the areas under the ion
signals of the pre-defined signature ion signals (Table 1);
at m/z 8205 (apolipoprotein C2), m/z 8766 (apolipo-
protein C30), m/z 8916 (pro-apolipoprotein C2), m/z
Figure 2. Linear MALDI-ToF mass spectra of intact proteins from
patient 6 upon conventional (a) and novel (b) work-up of maternal
peripheral venous blood. Ion signals which were selected for
multiparametric analysis are labeled with ‘‘#’’. Ion signals which
were used for internal re-calibration are marked with *. Ferulic
acid was used as matrix.
Figure 1. Work-flow for conventional (left fork) and novel (right
fork) work-up protocol that is suitable for generating MALDI-ToF-
MS proteome profiles of intact proteins and for recording nanoESI
MSE spectra of peptides after tryptic digestion of blood serum
proteins. Serum is prepared in the clinics (top) and protein ana-
lysis in the mass spectrometry laboratory (bottom).
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9422 (apolipoprotein C31), and m/z 9713 (apolipo-
protein C32). As in our previous analyses, the
lowest area values for an ion signal of interest were
around 70 a.u. for ion signals at m/z 8766 and the
highest values were about 2000 a.u. for ion signals at
m/z 9422.
Areas under the ion signals of a given MALDI mass
spectrum were then used to form ion signal ratios: quo-
tients A, B, and C. The previously defined inclusion/
exclusion criteria, i.e. cut-off values for quotient
A (3.4), quotient B (7.0), and quotient C (5.1) were
applied for each of the work-up series and showed
that the quotient values were about the same in each
case (Figure 3). The individual cumulative score for
each mass spectrum characterized a mass spectrum,
i.e. the respective serum sample, to belong either to
the group of IUGR or to the group of control individ-
uals, respectively.
The IUGR serum samples of both, the conventional
work-up series and of the alternative work-up series
with use of NoviplexTM cards, clearly differentiated
from the control serum samples, such that cumulative
score values were higher in the IUGR groups as com-
pared to the control groups. Particularly, quotients
A and B from the IUGR groups were in most cases
above their respective threshold values and quotients
from the control groups were below. Values for quo-
tient C did not differentiate the two groups,






Areas of ion signals (m/z)b
8205 8766 8916 9422 9713
1 1 No 912.63 88.57 1654.79 1753.41 244.10
1 2 No 692.45 50.04 1248.52 1270.10 148.99
2 1 No 280.39 97.90 771.32 1731.44 409.70
2 2 No 228.99 83.87 636.99 1185.37 235.78
3 1 No 442.47 68.32 1005.80 1605.37 267.76
3 2 No 519.65 62.73 1130.90 1633.43 273.89
4 1 No 263.78 140.97 976.65 2165.50 400.03
4 2 No 189.89 117.18 816.82 2201.06 354.85
5 1 No 295.67 158.35 1100.91 1091.85 176.76
5 2 No 279.03 172.91 1055.31 1186.35 237.48
6 1 No 130.21 193.54 931.66 1198.36 201.42
6 2 No 137.98 195.25 942.13 1172.94 202.48
7 1 No 144.88 152.06 712.42 1397.50 183.95
7 2 No 171.77 161.66 845.94 1686.70 275.35
8 1 No 212.85 112.33 1087.08 1997.76 232.32
8 2 No 330.53 162.66 1295.84 1949.12 253.85
1 3 Yes 333.19 70.68 549.64 761.98 76.03
1 4 Yes 506.10 81.92 871.49 1476.36 192.45
2 3 Yes 187.11 69.60 514.49 1230.78 222.15
2 4 Yes 217.04 64.49 555.39 1450.04 353.32
3 3 Yes 265.96 65.37 599.87 811.38 118.34
3 4 Yes 290.02 59.52 617.51 840.91 117.21
4 3 Yes 330.56 109.35 784.84 1267.69 247.46
4 4 Yes 239.03 92.97 553.09 1021.92 238.04
5 3 Yes 175.67 150.44 597.64 714.73 114.86
5 4 Yes 183.51 171.40 650.76 835.65 125.70
6 3 Yes 75.91 137.79 391.13 802.60 164.15
6 4 Yes 76.46 114.74 348.52 651.10 112.05
7 3 Yes 104.57 97.01 422.48 739.52 102.89
7 4 Yes 159.35 122.00 705.41 1474.42 241.08
8 3 Yes 335.00 108.85 894.12 1065.99 173.45
8 4 Yes 286.67 87.43 744.41 940.61 174.28
IUGR: intrauterine growth restriction.
aFor numbering see Supplemental Table 1.
bArbitrary units.
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independent of the work-up protocol, but contributed
to the cumulative score of each individual serum
sample. Results from the duplicate measurements con-
firmed each other.
Statistical evaluation of the mass spectrometry sig-
nature and comparison with clinical data that were
used as ‘‘gold standard’’ provided with both work-up
procedures good results, i.e. the number of true positive
assignments of spectra was 7 out of 8 when serum was
conventionally worked-up and 8 out of 8 when serum
was worked up using our novel protocol where no
freeze/thaw cycles were necessary (Table 2).
Likewise, the number of true negative spectra assign-
ments was 8 out of 8 when serum was conventionally
worked-up and 6 out of 8 when serum was worked up
with our novel protocol, i.e. without freezing serum for
storage and during shipping (Table 2). As in both cases,
the area under the curve (AUC) was greater than 0.9 in
ROC curve analyses, high confidence was reached with
the newly developed experimental approach.
Estimation of protein re-solubilization efficiency
To guarantee satisfactory mass spectrometric profiling
data with our here developed protocol that included
NoviplexTM cards, the proteins had to be present in
the resolubilization solution in high enough protein
amounts to saturate the beads which were requested
for desalting. To test whether serum storage discs
from the NoviplexTM cards that were applied for
MALDI MS profiling contained more than enough
protein material, we subjected an already eluted
serum storage disc from patient 8 to an additional elu-
tion of residual proteins, using somewhat harsher con-
ditions. Instead of using RapiGestTM as detergent, for
this second elution an SDC-containing buffer was
applied at elevated temperatures. The second eluted
protein mixture was then tryptically digested in total
and the resulting peptide mixture was analyzed by
nanoLC-ESI-MSE (Figure 4).
NanoLC-ESI-MSE analysis of the resulting peptide
mixture provided a total ion current chromatogram
that contained 5997 ion signals from the low energy
regime of which 764 peptide ion signals were matched
to protein entries of the Uniprot database. Applying
the chosen quality criteria for protein assignments
resulted in the identification of 73 non-redundant pro-
teins (Supplemental Table 2).
As an example, the doubly charged precursor ion
signal at m/z 519.27 was recorded in the total ion cur-
rent time segment of around 27.02min together with
about a dozen other peptide ion signals (Figure 4).
Some of the 688,747 high energy ions of the total data-
set were fragment ions from this precursor ion and
could be assigned to Y00 ions of a peptide whose
sequence was ‘‘TAAQNLYEK’’. This amino acid
sequence represents the partial amino acid sequence
25–33 of apolipoprotein C2 and the partial amino
acid sequence 31–39 of pro-apolipoprotein C2.
Confidence of identification of the mentioned amino
acid sequence was high and yielded a score of 1369.9
which, thus, proved the presence of the peptide and,
therefore, the presence of at least one of the two origi-
nating proteins.
In sum, the fact that so many proteins were identi-
fied in the second elution of this serum storage disc
convinced us that the first elution was already contain-
ing enough protein material to saturate the beads which
were used for desalting during sample work-up. Elution
Figure 3. Distributions of quotient values derived from protein ion
intensities in all MALDI mass spectra after conventional work-up
(a) and after novel work-up (b) of maternal peripheral venous
blood samples. Box and whisker plots show value distributions
from the ion signal area quotients A, B, and C. The boxes represent
the 25th to the 75th percentiles. The horizontal lines within the
boxes represent the medians; the small squares indicate the
means. The whiskers specify the 5th and 95th percentiles. Dashed
horizontal lines mark cut-off values.
IUGR: intrauterine growth restriction; CTRL: control individuals.


























No 7 0 8 1 0.88 1.00 0.11 0.00 1.00 0.89 0.95
Yes 8 2 6 0 1.00 0.75 0.00 0.20 0.80 1.00 0.91
aROC: receiver operating characteristic; AUC: area under the curve of two measurement series.
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of proteins from the beads and preparing of matrix
enabled to generate MALDI-ToF-MS profiles of the
patients’ serum samples in a reliable fashion.
Discussion
Patient samples from dried blood spots and from dried
serum spots have been subjected to global proteome
analyses39 and to targeted proteome analyses,40 respect-
ively. Strikingly, analysis of intact proteins either from
dried blood spots or from dried serum spots has as of
yet not been reported. The closest to analyzing intact
proteins from filter paper sources possibly is ‘‘paper
spray’’ of protein complexes.41 Yet, because ‘‘paper
spray’’ produces multiply charged ions supplied by
wetted paper, the comparison may be skewed. Also,
as multiply charged ions are produced, profiling of
complex bio-fluids may perhaps not become the prime
application of this method. NoviplexTM cards were
developed for generating plasma out of full blood,28
and hence, they provide a suitable storage disc, similar
to filter paper, but with the potential to resolubilize
proteins under fairly mild elution conditions.
RapigestTM was chosen by us to be added to the elution
solution, because of its detergent properties which are
desired for resolubilization of deposited serum proteins.
But, because RapigestTM can be destroyed by simple
acidification,42 this detergent enables to employ mass
Figure 4. NanoLC-ESI-MSE analysis of re-solubilized and tryptically digested proteins from patient 8 using the novel work-up protocol of
maternal peripheral venous blood. Total ion current chromatogram after in-solution digest and nanoLC separation (a). The arrow points to
the time segment for which the mass spectrum is shown in (b). Precursor ion ESI mass spectrum of peptides eluting at 27.02min (b). The
arrow points to the doubly charged precursor ion for which the fragment mass spectrum is shown in (c). Fragment ion mass spectrum of
doubly charged precursor ion at m/z 519.27 (c). Y00 fragment ions are marked and partial amino acid sequence is given in single letter
code. Selected ion signals are labeled with m/z values.
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spectrometry as detection assay of intact proteins. The
desalting procedure of choice as part of our work-flow
has turned out to be the ClinProtTM bead system for
mainly two reasons. First, the ClinProtTM bead system
provides a large surface onto which proteins may attach
to after removal of detergent; thereby sample losses are
minimized. Second, the ClinProtTM bead system has
already been found suitable to generate serum protein
profiles that, when analyzed by linear MALDI-ToF-
MS, have enabled us previously to distinguish between
IUGR and control individuals.7,9–11
Despite the fact that the number of patient samples
that were investigated in this study was too small for
clinical and/or biostatistical disease evaluation, the
point to be made was reached. Instead of demonstrat-
ing whether the analyzed mass spectra belonged to
either the IUGR group or to the control group, the
goal of this project was to prove that the serum protein
profiles were of comparable quality independent of the
chosen work-up protocol. The conclusion from our
analyses is that our novel procedure that avoids
freeze/thaw steps and prepares serum proteins at
room temperature is well suitable for recording prote-
ome profiles by MALDI-ToF-MS. The robustness of
all involved steps makes this assay attractive to clinics
world-wide, paving the way for future mass spectromet-
ric assessments of other diseases.
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Supplemental Figure 1: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 1 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 1-1 and 1-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 1-3 and 1-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 







Supplemental Figure 2: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 2 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 2-1 and 2-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 2-3 and 2-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 








Supplemental Figure 3: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 3 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 3-1 and 3-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 3-3 and 3-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 










Supplemental Figure 4: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 4 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 4-1 and 4-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 4-3 and 4-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 






Supplemental Figure 5: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 5 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 5-1 and 5-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 5-3 and 5-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 








Supplemental Figure 6: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 6 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 6-1 and 6-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 6-3 and 6-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 






Supplemental Figure 7: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 7 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 7-1 and 7-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 7-3 and 7-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 






Supplemental Figure 8: 
 
MALDI-ToF mass spectra of 
intact peripheral blood proteins 
from mother 8 upon conventional 
serum work-up including freeze / 
thaw steps (spectra 8-1 and 8-2), 
and following our novel work flow 
with depositing serum on serum 
storage discs at room tempera-
ture (spectra 8-3 and 8-4).  
Ion signals labeled: „#“ indicate 
mass peaks whose area under 
signals were used for multipara-
metric analysis; „*“ indicates ion 
signals which were chosen for 
mass calibration. Mass range m/z 
4000 – 20000. Ferulic acid was 
used as matrix.  
 










systolic BP a) 
[mmHg] 

















1  35.7 21.8 1 0 122 58 0 c) 34 6/7 c-section f 2420 40 
2  29.6 24.1 1 0 106 61 0 c) 28 4/7 c-section f 1250 60 
3  24.7 35.4 1 0 120 81 0 c) 39 2/7 c-section m 3895 80 
4  24.6 23.0 0 0 110 70 0 c) 34 3/7 c-section m 2450 50 
5  31.9 22.5 0 0 129 76 77 b) 32 1/7 c-section f 1255 9 
6  23.6 23.7 0 10 125 71 182 b) 30 5/7 c-section f 940 4 
7  27.8 28.3 3 0 112 55 0 c) 27 0/7 c-section f 580 3 
8  21.6 17.0 0 5 110 70 0 c) 29 6/7 c-section m 1000 10 
a) at beginning of hospitalization 
b) immunoturbidimetric assay (Tina-quant albumin; Roche Diagnostics. Mannheim. Germany); proteinuria is defined as urinary protein excretion >300 mg/d. 
c) dip stick assay; significant proteinuria is present with readings of more than + (max: +++). 




















1 IGKC_HUMAN P01834 11,780 3 41.51 
2 ALBU_HUMAN P02768 71,363 32 45.48 
3 APOA1_HUMAN P02647 30,778 15 42.32 
4 HPT_HUMAN P00738 45,890 11 24.88 
5 IGHM_HUMAN P01871 49,991 12 26.99 
6 TRFE_HUMAN P02787 79,345 18 25.70 
7 IGHA1_HUMAN P01876 38,510 7 19.55 
8 APOC2_HUMAN P02655 11,284 3 28.71 
9 APOA2_HUMAN P02652 11,289 5 26.00 
10 IGLL5_HUMAN B9A064 23,405 3 14.49 
11 LAC3_HUMAN P0CG06 11,409 2 21.70 
12 LAC2_HUMAN P0CG05 11,465 2 21.70 
13 LAC1_HUMAN P0CG04 11,519 2 21.70 
14 APOA4_HUMAN P06727 45,399 13 28.28 
15 IGJ_HUMAN P01591 18,555 4 28.30 
16 IGHG3_HUMAN P01860 42,313 5 13.53 
17 IGHG1_HUMAN P01857 36,619 5 15.45 
18 IGHG2_HUMAN P01859 36,528 5 15.64 
19 HPTR_HUMAN P00739 39,543 7 15.52 
20 IGHG4_HUMAN P01861 36,454 4 13.15 
21 CLUS_HUMAN P10909 53,065 6 13.36 
22 A1AT_HUMAN P01009 46,908 10 20.57 
23 APOE_HUMAN P02649 36,268 7 23.03 
24 HBB_HUMAN P68871 16,112 3 23.13 
25 A2MG_HUMAN P01023 164,717 17 11.26 
26 CO3_HUMAN P01024 188,688 35 18.46 
27 MUCB_HUMAN P04220 43,571 8 20.20 
28 IGHA2_HUMAN P01877 37,325 4 9.71 
29 SAMP_HUMAN P02743 25,501 6 26.91 
30 AACT_HUMAN P01011 47,822 5 10.41 
31 FETUA_HUMAN P02765 40,123 2 3.81 
32 HEMO_HUMAN P02790 52,418 7 13.64 
33 CO4A_HUMAN P0C0L4 194,383 24 11.81 
34 CO4B_HUMAN P0C0L5 194,291 23 11.35 
35 CFAB_HUMAN P00751 86,902 9 11.91 
36 CXCL7_HUMAN P02775 14,179 2 14.84 
37 PZP_HUMAN P20742 165,346 10 6.48 
38 CERU_HUMAN P00450 123,061 7 7.51 
39 CFAH_HUMAN P08603 143,773 11 8.20 
40 APOL1_HUMAN O14791 44,031 4 8.04 
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41 HEP2_HUMAN P05546 57,242 6 9.62 
42 THRB_HUMAN P00734 71,520 6 6.75 
43 VTNC_HUMAN P04004 55,104 5 8.16 
44 ITIH4_HUMAN Q14624 103,586 7 6.24 
45 AMBP_HUMAN P02760 39,912 4 7.39 
46 APOH_HUMAN P02749 39,610 2 5.22 
47 CD5L_HUMAN O43866 39,628 3 7.20 
48 A1BG_HUMAN P04217 54,824 4 8.08 
49 VTDB_HUMAN P02774 54,560 4 6.96 
50 ITIH2_HUMAN P19823 106,920 7 6.66 
51 K2C1_HUMAN P04264 66,210 6 8.54 
52 K1C10_HUMAN P13645 59,055 5 7.53 
53 C1QC_HUMAN P02747 26,002 2 12.24 
54 PON1_HUMAN P27169 39,902 3 8.73 
55 ZA2G_HUMAN P25311 34,487 2 7.38 
56 ANGT_HUMAN P01019 53,439 3 6.60 
57 KNG1_HUMAN P01042 73,041 5 6.06 
58 AFAM_HUMAN P43652 71,008 3 5.34 
59 ITIH1_HUMAN P19827 101,846 4 3.18 
60 FHR1_HUMAN Q03591 38,791 3 10.91 
61 K22E_HUMAN P35908 65,718 2 3.13 
62 C1S_HUMAN P09871 78,224 4 5.67 
63 K1C16_HUMAN P08779 51,610 3 3.38 
64 K1C14_HUMAN P02533 51,904 3 3.39 
65 PLMN_HUMAN P00747 93,306 4 4.32 
66 PSG1_HUMAN P11464 47,622 3 7.40 
67 FIBA_HUMAN P02671 95,715 2 2.42 
68 K1C28_HUMAN Q7Z3Y7 51,195 3 5.39 
69 PEDF_HUMAN P36955 46,483 2 5.02 
70 C1R_HUMAN P00736 81,658 3 3.26 
71 PSG8_HUMAN Q9UQ74 48,171 2 4.69 
72 K1C27_HUMAN Q7Z3Y8 50,450 2 3.92 
73 K1C25_HUMAN Q7Z3Z0 49,888 2 4.00 
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